Conditions: Uremic Pruritus
Keywords: Hemodialysis difelikefalin CR845 Pruritus Chronic Itch Itch Itching Uremic Pruritus Dialysis CKD CKD-associated pruritus CKD-aP ESRD (end stage renal disease) KALM Chronic Kidney Disease Kidney failure, chronic Kidney dysfunction Generalized pruritus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 473
Healthy volunteers: no

Brief summary:
This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week randomized, double-blind, placebo-controlled Phase and a 52-week Open-label Extension Phase.

Detailed description:
Double-blind Phase: The Double-blind Phase of the study will consist of a Screening Visit, a 7-day Run-in Period, and a 12-week Double-blind Treatment Period. Informed consent will be obtained prior to performing any study-specific procedures. The Screening Visit will occur within 7 to 28 days prior to randomization to assess eligibility.

Open-label Extension Phase: Patients who received at least 30 doses of study drug (either active or placebo) during the 12-week Double-blind Treatment Period and continue to meet other eligibility criteria will have the option to receive open label CR845 for an additional 52 weeks.

The last dose of open-label study drug will be administered at the last dialysis visit on Week 52, or Early Termination.

Follow-up Period: A final safety Follow up Visit will be conducted 7-10 days after the End of Treatment/Early Termination Visit.

Arms:
arm 1: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week) arm 2: IV Placebo administered after each dialysis session (3 times/week)

Interventions: intervention 1: CR845 0.5 mcg/kg intervention 2: Placebo
Intervention descriptions: intervention 1: IV CR845 0.5 mcg/kg administered three times/week intervention 2: IV placebo administered three times/week

Protocol document:
Prot_000.pdf: 
Cara Therapeutics, Inc. 
Confidential 
Page 1 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
 
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 
PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND 
EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS 
WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK 
OPEN-LABEL EXTENSION 
 
Protocol number:   
CR845-CLIN3103 
Phase: 
3 
IND number: 
123140 
EUDRACT number:  
2018-001930-17 
Investigational Product: 
CR845 solution (for clinical trial use only) 
Protocol version: 
Version 2.2  
Date: 
10 September 2019 
Sponsor: 
 
 
Cara Therapeutics, Inc. 
4 Stamford Plaza 
Stamford, CT  06902 
(203) 406-3700 
 
Information contained in this document is proprietary and confidential information of Cara Therapeutics, 
Inc.  Any distribution, copying, or disclosure is strictly prohibited unless such disclosure is required by 
federal regulations or state law.  Persons receiving the information in this document are hereby given notice 
that the information is confidential and may not be further copied, distributed, disseminated or otherwise 
disclosed to any other person without the express written authorization of Cara Therapeutics, Inc.   
 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072




Cara Therapeutics, Inc. 
Confidential 
Page 3 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
INVESTIGATOR APPROVAL STATEMENT 
I have read and understand the protocol (CR845-CLIN3103) and I agree that this 
document contains all ethical, legal, and scientific information necessary to conduct this 
study.  I will oversee the conduct of the study as described in the protocol and any 
amendment(s) made to the protocol.  
I agree to conduct the study as detailed herein and in compliance with the current 
International Council for Harmonisation Harmonised Tripartite Guideline for Good 
Clinical Practice and all applicable regulatory requirements. 
Principal Investigator (Refer to Investigator Site File [ISF]) 
 
 
Printed Name: 
 
 
 
 
 
 
 
 
Signature: 
 
 
 
 
 
 
Date: 
 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 4 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
1.0 
Protocol Synopsis 
STUDY TITLE 
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to 
Evaluate the Safety and Efficacy of Intravenous CR845 in 
Hemodialysis Patients with Moderate-to-Severe Pruritus, with a 
52-Week Open-label Extension 
PROTOCOL 
NUMBER 
CR845-CLIN3103 
EUDRACT 
NUMBER 
2018-001930-17 
PHASE OF 
DEVELOPMENT 
3 
INVESTIGATIONAL 
PRODUCT 
CR845 Solution (for clinical trial use only) 
NAME OF ACTIVE 
INGREDIENT 
CR845 
ROUTE OF 
ADMINISTRATION 
Intravenous (IV) 
STUDY CENTERS 
Approximately 95 US and non-US sites 
OBJECTIVES 
 
Primary Objective 
• 
To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg 
compared to placebo in reducing the intensity of itch in 
hemodialysis patients with moderate-to-severe pruritus.   
Secondary Objectives 
• 
To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg 
compared to placebo in improving itch-related quality-of-life 
measures in hemodialysis patients with moderate-to-severe 
pruritus.  
• 
To evaluate the safety of IV CR845 at a dose of 0.5 mcg/kg in 
hemodialysis patients with moderate-to-severe pruritus. 
NUMBER OF 
PATIENTS 
The planned sample size is 350 (175 per treatment group) male and 
female hemodialysis patients with moderate-to-severe pruritus.  The 
sample size may be increased to 500 patients (250 per treatment group) 
based on the results of a planned interim assessment conducted when 
approximately 50% of the planned 350 patients have been randomized 
and have either completed the 12-week Treatment Period or have 
discontinued study drug early. 
STUDY 
POPULATION 
Inclusion Criteria: 
To be eligible for inclusion into the Double-blind Phase of the study, a 
patient must meet the following criteria: 
1. Willing and able to provide written informed consent prior to 
participating in this study; 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 5 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
2. Able to communicate clearly with the Investigator and staff, 
able to understand the study procedures, and able and willing 
to comply with the study requirements, including providing 
written responses to questionaires; 
3. Male or female between 18 and 85 years of age inclusive; 
Note: Subjects in Korea, must be male or female between 19 
and 85 years of age, inclusive. 
4. Has end-stage renal disease (ESRD) and has been on 
hemodialysis 3 times per week for at least 3 months prior to 
the start of screening; 
Note 1: Patients who require an occasional additional dialysis 
treatment to manage fluid overload or electrolyte excesses 
may be enrolled as long as it is anticipated that no more than 
1 such treatment will be required in any given week and no 
more than 4 occasions during the 12-week double-blind 
period. Patients routinely on 4 dialyses a week will not be 
eligible. 
Note 2: Patients receiving in-home hemodialysis may 
participate as long as they have switched to in-center 
hemodialysis at least 2 weeks prior to screening and plan to 
remain on in-center hemodialysis for the duration of the 
study. 
Note 3: Patients receiving alternate dialysis modalities such 
as nocturnal dialysis will not be eligible.  
5. If female, is not pregnant or nursing during any period of the 
study;  
6. If female: 
a. Is surgically sterile; or 
b. Has been amenorrhoeic for at least 1 year and is over the 
age of 55 years; or 
c. Has a negative serum pregnancy test at screening and 
agrees to use acceptable contraceptive measures 
(eg, hormonal contraceptives, barrier with spermicide, 
intrauterine device, vasectomized partner, or abstinence) 
from the time of informed consent until 7 days after the 
last dose of study drug; 
7. If male, agrees not to donate sperm after the first dose of study 
drug until 7 days after the last dose of study drug, and agrees to 
use a condom with spermicide or abstain from heterosexual 
intercourse during the study until 7 days after the last dose of 
study drug. (Note:  No restrictions are required for a 
vasectomized male provided his vasectomy was performed 
≥4 months prior to screening);  
8. Has a prescription dry body weight between 40.0 and 135.0 kg, 
inclusive;  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 6 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
9. Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 
2 urea reduction ratio measurements ≥65%, or 1 single-pool 
Kt/V measurement ≥1.2 and 1 urea reduction ratio 
measurement ≥65% on different dialysis days during the 
3 months period prior to screening; 
10. Prior to randomization: 
a. Has completed at least four out of eight Worst Itching 
Intensity Numerical Rating Scale (NRS) worksheets from 
the start of the 7-day Run-in Period up to and including the 
pre-randomization assessment on Day 1; 
b. Has a mean baseline Worst Itching Intensity NRS score 
≥5, defined as the average of all non-missing scores 
reported from the start of the 7-day Run-in Period up to 
and including the pre-randomization assessment on Day 1. 
To be eligible for inclusion into the Open-label Extension Phase of 
the study, each patient will have to fulfill the additional following 
criteria at the time of entry into the Open-label Extension Phase:  
11. Has received at least 30 doses of the planned 36 doses of study 
drug during the Double-blind Phase of this study; 
12. Has a prescription dry body weight ≥40 kg; 
13. Continues to meet inclusion criteria 1 through 7. 
Exclusion Criteria: 
A patient will be excluded from the Double-blind Phase of the study if 
any of the following criteria are met: 
1. Known noncompliance with dialysis treatment that in the 
opinion of the Investigator would impede completion or 
validity of the study; 
2. Scheduled to receive a kidney transplant during the study; 
3. Known history of allergic reaction to opiates, such as hives 
(Note: side effects related to the use of opioids, such as 
constipation or nausea, would not exclude patients from the 
study). 
4. Has a concomitant disease or a history of any medical 
condition that, in the opinion of the Investigator, could pose 
undue risk to the patient, impede completion of the study 
procedures, or would compromise the validity of the study 
measurements, including, but not limited to: 
a. Known or suspected history of alcohol, narcotic, or other 
drug abuse, or substance dependence within 12 months 
prior to screening; 
b. Significant systolic or diastolic heart failure (eg, New 
York Heart Association Class IV congestive heart failure 
[Appendix 1, Section 14.1]); 
c. Severe mental illness or cognitive impairment (eg, 
dementia); 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 7 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
d. Any other relevant acute or chronic medical or 
neuropsychiatric condition within 3 months prior to 
screening (eg, diagnosis of encephalopathy, coma, 
delirium); 
5. New or change of treatment received for itch including 
antihistamines and corticosteroids (oral, IV, or topical) within 
14 days prior to screening; 
6. New or change of prescription for opioids, gabapentin, or 
pregabalin within 14 days prior to screening; 
7. Received another investigational drug within 30 days prior to 
the start of screening or is planning to participate in another 
clinical study while enrolled in this study; 
8. In the opinion of the Investigator, has pruritus attributed to a 
cause other than ESRD or its complications (eg, patients with 
concomitant pruritic dermatological disease or cholestatic liver 
disease) (Note: Patients whose pruritus is attributed to ESRD 
complications, such as hyperparathyroidism, 
hyperphosphatemia, anemia, or the dialysis procedure or 
prescription may be enrolled); 
9. Has localized itch restricted to the palms of the hands; 
10. Has pruritus only during the dialysis session (by patient 
report); 
11. Is receiving ongoing ultraviolet B treatment and anticipates 
receiving such treatment during the study; 
12. Participated in a previous clinical study with CR845. 
A patient will be excluded from the Open-label Extension Phase of 
the study if any of the additional following criteria are met at the 
time of entry into the Open-label Extension Phase: 
13. Completed the Double-blind Phase of this study but exhibited 
adverse events during the course of the Treatment Period that 
may preclude continued exposure to the study drug; 
14. Was noncompliant with protocol procedures during the 
Double-blind Phase of this study which is indicative of an 
inability to follow protocol procedures; 
15. Has developed a concomitant disease or any medical condition 
that, in the opinion of the Investigator, could pose undue risk to 
the patient, impede completion of the study procedures, or 
would compromise the validity of the study measurements. 
STUDY DESIGN 
This is a multicenter, randomized, double-blind, placebo-controlled 
study to evaluate the safety and efficacy of IV CR845 at a dose of 
0.5 mcg/kg administered after each dialysis session.  The study 
includes a Double-blind Phase, an Open-label Extension Phase, and a 
Follow-up Period. 
Double-blind Phase 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 8 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
The Double-blind Phase of the study will consist of a Screening Visit, a 
7-day Run-in Period and a 12-week Double-blind Treatment Period.  
Informed consent will be obtained prior to performing any study-
specific procedures.  The Screening Visit will occur within 7 to 28 days 
prior to randomization to assess eligibility.  The site has the option to 
conduct the Screening Visit within the Run-in Period at the discretion 
of the Investigator. 
Eligible patients will complete a 7-day Run-in Period during the week 
prior to randomization to confirm eligibility, preferably starting on the 
first dialysis session of that week (ie, Monday for patients on a 
Monday-Wednesday-Friday dialysis schedule or Tuesday for patients 
on a Tuesday-Thursday-Saturday dialysis schedule).  The purpose of 
the Run-in Period is to confirm that each patient has 
moderate-to-severe pruritus (ie, weekly average worst itch score ≥5), as 
measured by the patient-daily reported 24-hour Worst Itching Intensity 
NRS, and to establish a baseline itch intensity.  Patients must not be 
informed that they need to report a weekly average worst itch score ≥5 
to be enrolled in the study.  During the first visit of the Run-in Period, 
patients will be trained on completion of the 24-hour Worst Itching 
Intensity NRS and will start the reporting of their Worst Itching 
Intensity NRS daily score.  For consistency, patients will be requested 
to complete the NRS worksheets (either at home or in the dialysis unit, 
as required) each day at a similar time of day around the normal start 
time of their dialysis. 
Patients will be trained on other itch-related patient-reported outcome 
(PRO) worksheets during the Run-in Period or on Day 1 of the 
Double-blind Treatment Period. 
If patients continue to meet all inclusion and no exclusion criteria at the 
end of the 7-day Run-in Period, they will be randomized into the 
Double-blind Treatment Period in a 1:1 ratio to receive either IV 
CR845 0.5 mcg/kg or placebo.  Patients will be stratified according to 
their use or non-use of concomitant medications to treat their itch 
during the week prior to randomization (Run-in Period) as well as the 
presence or absence of specific medical conditions.  These specific 
medical conditions include: 
• 
History of fall or fracture (related to fall) 
• 
Confusional state or mental status change or altered mental 
status or disorientation 
• 
Gait disturbance or movement disorder 
Day 1 of the Double-blind Treatment Period will be defined as the day 
of administration of the first dose of study drug and will occur 
preferably on the first dialysis session of the first treatment week (ie, 
Monday for patients on a Monday-Wednesday-Friday dialysis 
schedule, or Tuesday for patients on a Tuesday-Thursday-Saturday 
dialysis schedule).  Patients will be administered CR845 or matched 
placebo as an IV bolus after the end of each dialysis session during the 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 9 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
12-week Double-blind Treatment Period.  Each patient is to receive 
CR845 or placebo 3 times weekly for a total of up to 36 doses.   
During the Double-blind Treatment Period, patients will continue to 
report their daily Worst Itching Intensity NRS score over the previous 
24 hours.  In addition, during selected study visits (Day 1 and first day 
of Weeks 5, 9, 11, and 13 [ie, Days 29, 57, 71, and 85]), they will 
complete other PRO measures (such as Skindex-10 Scale, 5-D Itch 
Scale, and Patient Global Impression of Change).  Patients will be 
instructed to record patient-reported outcome measurements, including 
Worst Itching Intensity NRS scores, at a similar time of day, whether 
in the dialysis unit (on dialysis days) or at home (on non-dialysis days). 
Blood samples for clinical laboratory tests will be collected at the 
Screening Visit and on Days 1 and 85.  Blood samples for biomarkers 
will be collected on Days 1 and 85.  Electrocardiograms (ECGs) will 
be monitored at the Screening Visit and on Day 85.  Vital signs will be 
monitored periodically, and adverse events and concomitant 
medications will be continuously recorded during the Double-blind 
Phase.  Use of antipruritic medications and missed dialysis will be 
recorded throughout the Double-blind Phase. 
A Structured Safety Evaluation will be performed once during the 
Run-in Period and weekly (preferably on Wednesday/Thursday) during 
the Double-blind Treatment Period.  The Structured Safety Evaluation 
is performed by study staff using a list of specific signs/symptoms (eg, 
mental status change, falls, gait disturbance). 
Open-label Extension Phase 
Patients who received at least 30 doses of study drug (either active or 
placebo) during the 12-week Double-blind Treatment Period and 
continue to meet other eligibility criteria will be eligible to receive 
open-label CR845 for an additional 52 weeks.  
Each patient will receive CR845 at a dose of 0.5 mcg/kg after each 
dialysis session, 3 times per week for up to 52 weeks, regardless of 
whether they had been previously administered placebo or CR845.  
Prescription dry body weight will be recorded at the start of and every 
12 weeks during the Open-label Extension Phase; if there is a ±10% or 
more change from the prescription dry body weight recorded at 
Screening, then the CR845 dose will be adjusted according to the 
newly recorded dry body weight.  
The first visit and first dosing for the Open-label Extension Phase of 
the study will occur immediately on the day of the last visit of the 
Double-blind Treatment Period or up to 1 week following the Double-
blind Treatment Period.  
Patients will complete the 5-D Itch Scale during Weeks 4, 8, 12, 24, 
36, and 52 (preferably at the end of the specified weeks).  
Clinical laboratory tests, vital signs, adverse events, and concomitant 
medications will be monitored throughout the Open-label Treatment 
Period.  Blood samples for inflammatory biomarkers will be collected 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 10 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
periodically until the Open-label End-of-Treatment or Early 
Termination Visit.  ECGs will be monitored at the Open-label 
End-of-Treatment or Early Termination Visit. 
The number and reason(s) for missed dialysis as well as the use of 
antipruritic medications will be recorded throughout the Open-label 
Extension Phase.  
The last dose of open-label study drug will be administered at the last 
dialysis visit on Week 52, or Early Termination.   
Follow-up Period 
A final safety Follow-up Visit will be conducted 7-10 days after the 
End-of-Treatment Visit of the Double-blind Treatment Period for   
patients not participating in the Open-label Extension Phase, after the 
End-of-Treatment Visit of the Open-label Extension Phase, or after the 
Early Termination Visit during either the Double-blind Treatment 
Period or the Open-label Extension Phase.  
STUDY DRUG 
Study drug will be supplied in glass vials containing an extractable 
volume of at least 1.3 mL of CR845 at a concentration of 0.05 mg/mL 
in 0.04M isotonic acetate buffer, pH 4.5. 
REFERENCE 
PRODUCT 
Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be 
provided in glass vials containing an extractable volume of at least 
1.3 mL. 
TREATMENT 
REGIMENS 
Patients will be administered CR845 0.5 mcg/kg or placebo as a single 
IV bolus 3 times a week after each dialysis session for 12 weeks during 
the Double-blind Treatment Period. 
During the Open-label Treatment Period, patients will be administered 
CR845 0.5 mcg/kg as a single IV bolus 3 times a week after each 
dialysis session for up to 52 weeks. 
STUDY DURATION 
 
 
 
 
 
Double-blind Phase:   
Screening Period:  up to 4 weeks (Screening Visit may occur during 
Run-in Period at the discretion of Investigator) inclusive of the 7-day 
Run-in Period 
Double-blind Treatment Period: 12 weeks 
Open-label Extension Phase: up to 52 weeks  
Follow-up Period: 7-10 days 
Total study duration for a single patient:  up to approximately 70 weeks 
STUDY 
ENDPOINTS 
Efficacy Endpoints 
Primary Efficacy Endpoint 
• 
Proportion of patients achieving at least a 3-point improvement 
from baseline with respect to the weekly mean of the daily 24-
hour Worst Itching Intensity NRS score at Week 12 of the 
Double-blind Treatment Period 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 11 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Secondary Efficacy Endpoints 
• 
Proportion of patients achieving ≥4-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 12 of the Double-blind 
Treatment Period.  
• 
Proportion of patients achieving ≥3-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 8 of the Double-blind 
Treatment Period.  
• 
Proportion of patients achieving ≥3-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 4 of the Double-blind 
Treatment Period.  
• 
Proportion of patients achieving ≥4-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 8 of the Double-blind 
Treatment Period.  
• 
Proportion of patients achieving ≥4-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 4 of the Double-blind 
Treatment Period.  
• 
Change from baseline in itch-related quality of life at the end 
of Week 12 of the Double-blind Treatment Period, as assessed 
by the Skindex-10 Scale total score 
• 
Change from baseline in itch-related quality of life at the end 
of Week 12 of the Double-blind Treatment Period, as assessed 
by the 5-D Itch Scale total score 
Additional efficacy endpoints are described in Section 8.7.4. 
Safety Endpoints 
The safety endpoints used to evaluate the overall safety and tolerability 
of CR845 will be adverse events, ECG, vital signs, and clinical safety 
laboratory evaluations. 
INTERIM 
ASSESSMENT 
(Double-blind Phase) 
Safety data will be reviewed on an ongoing basis by the Sponsor and a 
Data Safety Monitoring Board (DSMB). The operation of the DSMB 
will be governed by a charter that will describe the group’s meeting 
frequency, procedures, and requirements for reporting its observations 
to the Sponsor.  The DSMB will not be part of the study team and will 
receive unblinded safety results on a regular basis. 
A single interim assessment for sample size re-estimation is planned 
after approximately 50% of the first 350 randomized patients either 
complete the 12-week Double-blind Treatment Period or discontinue 
study drug prematurely.  The interim assessment will be conducted by 
an Independent Data Monitoring Committee (IDMC).  Members of the 
IDMC will not participate in the DSMB and will not be members of the 
study team.  During the interim assessment, the study team will remain 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 12 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
blinded to the data; however, the IDMC will receive unblinded 
summary results to implement the decision rule for sample size re-
estimation. The IDMC will only communicate the decision to either 
keep the original sample size or to increase it; no other results will be 
provided to blinded staff.   The DSMB will be made aware of the 
decision, but not given the results that were the basis of the decision. 
 
STATISTICAL 
ANALYSIS 
Analysis Populations 
The Enrolled Population is defined as the group of patients who sign 
informed consent. 
The intent-to-treat (ITT) Population is defined as the group of patients 
who are randomized to a treatment group. The Double-blind Safety 
Population is defined as the group of randomized patients who received 
at least 1 dose of study drug during the Double-blind Treatment Period.  
Following the intent-to-treat principle, patients in the ITT Population 
will be analyzed according to their randomized treatment, regardless of 
the actual treatment received.  Patients in the Double-blind Safety 
Analysis Population will be analyzed according to the actual treatment 
received.  The Double-blind Safety Population will be used to analyze 
all safety endpoints collected during the Double-blind Phase, while the 
ITT Population will be used to analyze all efficacy endpoints collected 
during the Double-blind Phase. 
The Per-Protocol Population is defined as the subset of patients in the 
ITT Population who do not have any major protocol deviations that 
could affect the efficacy analyses of the double-blind data.   
Inclusion in the Per-Protocol Population will be determined prior to 
unblinding the data and will be detailed in the statistical analysis plan. 
The Open-label Safety Population is defined as the group of patients 
who receive at least 1 dose of study drug in the Open-label Extension 
Phase.  The Open-label Safety Population will be used to analyze all 
safety endpoints collected during the Open-label Extension Phase, and 
during exposure to CR845 combining data from both the Double-blind 
and the Open-label Extension Phases.   
 
Safety Analyses 
Safety data will be summarized descriptively.  No inferential statistics 
are planned.  Analyses of safety data will include summaries of 
treatment-emergent adverse events including Adverse Events of 
Special Interest (AESI), serious adverse events, and adverse events 
resulting in study drug discontinuation.  Vital signs, chemistry and 
hematology data, and ECG data will be presented by visit as 
applicable, in addition to change from baseline. 
 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 13 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Efficacy Analyses (Double-blind Treatment Period) 
All efficacy analyses will be conducted on the ITT Population.  An 
analysis of the primary and secondary efficacy variables for the Per-
Protocol Population will also be performed. 
Primary Efficacy Endpoint 
The primary efficacy endpoint is defined as the proportion of patients 
achieving at least a 3-point improvement from baseline with respect to 
the weekly mean of the daily 24-hour Worst Itching Intensity NRS 
score at Week 12 (Days 79-85) of the Double-blind Treatment Period.  
The weekly mean of the 24-hour Worst Itching Intensity NRS score 
will be defined as the sum of the daily Worst Itching Intensity NRS 
score reported during a specific week during the Double-blind 
Treatment Period (eg, Days 2 to 8, Days 9 to 15, Days 16 to 22, … 
Days 79 to 85) divided by the number of days with non-missing scores 
for that week.  If the daily worst itching score is missing for >3 days 
during a specific week, the corresponding weekly mean worst itching 
score will be set to missing.  The baseline score will be defined as the 
average of the daily 24-hour Worst Itching Intensity NRS scores 
collected over the Run-in Period, including pre-randomization 
assessments collected on Day 1.  
In the primary efficacy analysis, missing NRS data will be imputed 
using a multiple imputation (MI) approach, assuming that patients who 
discontinue double-blind treatment early would have similar Worst 
Itching Intensity NRS scores as other patients in their respective 
treatment arm that have complete data:  
• 
Intermittent missing NRS scores will first be imputed using the 
Markov Chain Monte Carlo (MCMC) method implemented with 
the SAS MI procedure, which is appropriate for non-monotonic 
missing data.  
• 
NRS scores missing after patients discontinue study drug early will 
then be multiply imputed with the SAS MI procedure using a 
method appropriate for monotone missingness (eg, regression 
statement).  
• 
The proportion of patients who have an improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS score ≥ 3 points will be calculated for 
each imputed dataset. Differences between CR845 0.5 mcg/kg and 
placebo with respect to the primary endpoint will be compared 
using a logistic regression model containing terms for treatment 
group, baseline NRS score, use of prior anti-itch medication, 
presence of specific medical conditions, and country/region.  
• 
Results of the logistic regression on the multiply imputed data sets 
will be summarized by the SAS MIANALYZE procedure.   
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 14 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Sensitivity analyses of the primary efficacy endpoint will be conducted 
to evaluate the robustness of study results under different assumptions 
and imputation algorithms (Section 8.7.1). 
Secondary Efficacy Endpoints 
The proportion of patients achieving ≥4-point improvement from 
baseline at Week 12 of the Double-blind Treatment Period, the 
proportion of patients achieving ≥3-point improvement from baseline 
at Week 8 and Week 4, and the proportion of patients achieving ≥4-
point improvement from baseline at Week 8 and Week 4 with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS 
will be analyzed following a similar methodology to the one employed 
in the primary analysis of the primary endpoint.   
The Skindex-10 Scale total score and the 5-D Itch Scale total score 
change from baseline at Week 12 will be analyzed using an analysis of 
covariance (ANCOVA) model that contains treatment as fixed effect, 
with baseline score, region, and the randomization stratification 
variables as covariates.  For each domain in each questionnaire, 
missing values at Week 12 will be imputed using a MI approach, 
assuming that patients who discontinue double-blind treatment early 
would have similar domain scores as other patients in their respective 
treatment arm that have complete data: 
• 
Intermittent missing scores will first be imputed using the 
Markov Chain Monte Carlo (MCMC) method implemented 
with the SAS MI procedure, which is appropriate for non-
monotonic missing data.  
• 
The monotone missing values will then be multiply imputed 
with the SAS MI procedure using the monotone regression 
method. 
It is important to note that, in HD patients, the study drug administered 
during the last dialysis of a particular week is not cleared until the first 
dialysis of the next week. Therefore, measurements that would reflect 
treatment effect at the end of a specific week (eg. Week 4) will actually 
be collected during the first day of the next week (eg. Week 5). 
Hypothesis Testing Strategy 
Testing of the primary efficacy endpoint will be 2-sided and conducted 
at the 5% error level.  The study will be considered positive if the null 
hypothesis of no treatment difference in the primary efficacy analysis 
of the primary endpoint (proportion of patients with a ≥3-point 
improvement from baseline at Week 12 of the Double-blind Treatment 
Period with respect to the Worst Itching Intensity NRS) is rejected in 
favor of the alternative that patients randomized to CR845 experience 
significantly less itching compared to patients randomized to placebo.  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 15 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
 
To protect the Type 1 error, a gate-keeping strategy will be 
implemented.  Although the p-values corresponding to the hypothesis 
testing of the secondary variables will be reported, they will only be 
considered inferential if the primary analysis is statistically significant.  
Testing of the secondary efficacy endpoints will be performed 
sequentially at a 2-sided 5% error level in the order specified below. If 
the test of an endpoint in the sequence is not statistically significant, 
the p-value for the tests corresponding to the remaining endpoints in 
the sequence will not be considered inferential and the null hypotheses 
for the subsequent tests will not be rejected.    
1. Proportion of patients achieving ≥4-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 12 of the Double-blind 
Treatment Period  
2. Proportion of patients achieving ≥3-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 8 of the Double-blind 
Treatment Period  
3. Proportion of patients achieving ≥3-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 4 of the Double-blind 
Treatment Period  
4. Proportion of patients achieving ≥4-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 8 of the Double-blind 
Treatment Period  
5. Proportion of patients achieving ≥4-point improvement from 
baseline with respect to the weekly mean of the daily 24-hour 
Worst Itching Intensity NRS at Week 4 of the Double-blind 
Treatment Period  
6. Change from baseline in Skindex-10 Scale total score at Week 
12 of the Double-blind Treatment Period 
7. Change from baseline in 5-D Itch Scale total score at Week 12 
of the Double-blind Treatment Period 
 
Details and methods of analysis are found in Section 8.0 and will be 
described further in the statistical analysis plan. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 16 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
2.0 
Table of Contents 
1.0 Protocol Synopsis........................................................................................................ 4 
2.0 Table of Contents ...................................................................................................... 16 
3.0 List of Abbreviations ................................................................................................ 21 
4.0 Introduction ............................................................................................................... 22 
4.1 
Background and Rationale ................................................................................22 
4.2 
Clinical Experience ...........................................................................................23 
4.2.1 
Overall Exposure .......................................................................................23 
4.2.2 
Safety in Hemodialysis Patients.................................................................23 
4.2.3 
Efficacy of CR845 in Hemodialysis Patients with Uremic Pruritus ..........24 
4.2.4 
Pharmacokinetics in Hemodialysis Patients ..............................................25 
4.3 
Summary of Potential Risks and Benefits .........................................................25 
5.0 Objectives ................................................................................................................. 27 
6.0 Investigational Plan ................................................................................................... 28 
6.1 
Overall Study Design and Plan:  Description ....................................................28 
6.1.1 
Double-blind Phase ....................................................................................28 
6.1.1.1 
Screening Visit ...................................................................................... 28 
6.1.1.2 
Run-in Period ........................................................................................ 28 
6.1.1.3 
Double-blind Treatment Period ............................................................ 29 
6.1.2 
Open-label Extension Phase ......................................................................30 
6.1.3 
Follow-up Period .......................................................................................30 
6.2 
Selection of Study Population ...........................................................................33 
6.2.1 
Inclusion Criteria .......................................................................................33 
6.2.2 
Exclusion Criteria ......................................................................................35 
6.3 
Removal of Patients from Therapy or Assessment ...........................................36 
6.3.1 
Discontinuation of Individual Patients.......................................................36 
6.3.2 
Discontinuation or Suspension of Entire Study .........................................37 
6.4 
Treatments .........................................................................................................38 
6.4.1 
Treatments Administered ...........................................................................38 
6.4.2 
Identity of Investigational Product(s) ........................................................38 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 17 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6.4.2.1 
Formulation of Study Drug ................................................................... 38 
6.4.2.2 
Packaging, Labeling, and Storage Stability of Study Drug .................. 39 
6.4.2.3 
Individual Dose Labeling ...................................................................... 39 
6.4.3 
Drug Accountability...................................................................................39 
6.4.4 
Method of Assigning Patients to Treatment Groups..................................39 
6.4.5 
Preparation of CR845 ................................................................................40 
6.4.6 
Management of Missed Doses ...................................................................40 
6.4.7 
Treatment Compliance ...............................................................................40 
6.4.8 
Blinding......................................................................................................40 
6.4.9 
Prior, Concomitant, and Prohibited Medications .......................................41 
6.4.9.1 
Prior and Concomitant Medications ..................................................... 41 
6.4.9.2 
Restricted and Prohibited Medications ................................................. 41 
6.5 
Study Assessments and Procedures ...................................................................42 
6.5.1 
Schedule of Events for the Double-blind Phase ........................................42 
6.5.2 
Schedule of Events for the Open-label Extension Phase ...........................46 
6.5.3 
Efficacy Assessments.................................................................................50 
6.5.3.1 
Worst Itching Intensity Numerical Rating Scale .................................. 50 
6.5.3.2 
Skindex-10 Scale .................................................................................. 50 
6.5.3.3 
5-D Itch Scale ....................................................................................... 50 
6.5.3.4 
Patient Global Impression of Change ................................................... 51 
6.5.4 
Safety Assessments ....................................................................................51 
6.5.4.1 
Adverse Events ..................................................................................... 51 
6.5.4.2 
Structured Safety Evaluation ................................................................ 55 
6.5.4.3 
Physical Examination............................................................................ 55 
6.5.4.4 
Vital Signs ............................................................................................. 55 
6.5.4.5 
Electrocardiogram ................................................................................. 56 
6.5.4.6 
Clinical Laboratory Tests ...................................................................... 56 
6.5.4.7 
Contraception and Pregnancy ............................................................... 57 
6.5.5 
Additional Assessments .............................................................................57 
6.5.5.1 
Inflammatory Biomarkers ..................................................................... 58 
6.5.5.2 
Missed Dialysis Visits........................................................................... 58 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 18 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
7.0 Discussion and Justification of Study Design ........................................................... 59 
7.1 
Discussion of Study Design and Choice of Control Groups .............................59 
7.2 
Selection of Doses in the Study .........................................................................59 
7.3 
Appropriateness of Measurements ....................................................................59 
8.0 Statistical Methods .................................................................................................... 60 
8.1 
General Considerations .....................................................................................60 
8.2 
Determination of Sample Size ...........................................................................60 
8.3 
Randomization ...................................................................................................61 
8.4 
Interim Analysis ................................................................................................62 
8.4.1 
Sample Size Re-estimation ........................................................................62 
8.4.2 
Safety Data Review....................................................................................63 
8.5 
Analysis Populations .........................................................................................63 
8.6 
Statistical Summary and Analysis .....................................................................64 
8.6.1 
Patient Disposition .....................................................................................64 
8.6.2 
Protocol Deviations ....................................................................................64 
8.6.3 
Demographic and Baseline Characteristics ...............................................64 
8.6.4 
Medical History .........................................................................................64 
8.6.5 
Prior and Concomitant Medications ..........................................................65 
8.6.6 
Antipruritic Medication .............................................................................65 
8.7 
Efficacy Analysis ..............................................................................................65 
8.7.1 
Primary Efficacy Endpoint ........................................................................65 
8.7.2 
Secondary Efficacy Endpoints ...................................................................67 
8.7.3 
Hypothesis Testing Strategy ......................................................................69 
8.7.4 
Additional Efficacy Endpoints ...................................................................70 
8.7.4.1 
Itch-intensity Measures ......................................................................... 70 
8.7.4.2 
Itch-related Quality-of-Life Measures .................................................. 71 
8.8 
Safety Analysis ..................................................................................................71 
8.8.1 
Exposure to Study Drug .............................................................................72 
8.8.2 
Adverse Events ..........................................................................................72 
8.8.3 
Clinical Laboratory Evaluations ................................................................73 
8.8.4 
Vital Signs and ECGs ................................................................................74 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 19 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
8.9 
Additional Analyses ..........................................................................................75 
8.9.1 
Inflammatory Biomarkers ..........................................................................75 
8.9.2 
Missed Dialysis Visits and Incidence of Infection ....................................75 
9.0 Quality Control and Quality Assurance .................................................................... 76 
9.1 
Study Monitoring Plan ......................................................................................76 
9.2 
Audits and Inspections ......................................................................................76 
9.3 
Data Collection, Validation, and Analysis ........................................................77 
10.0 Ethics and Regulatory Compliance ........................................................................... 78 
10.1 
Independent Ethics Committee or Institutional Review Board .........................78 
10.2 
Ethical Conduct of the Study .............................................................................78 
10.3 
Informed Consent Process .................................................................................79 
10.4 
Patient Confidentiality .......................................................................................79 
11.0 Data Handling and Quality Assurance ...................................................................... 81 
12.0 Administrative Procedures ........................................................................................ 82 
12.1 
Protocol Adherence ...........................................................................................82 
12.2 
Publication of Study Findings ...........................................................................82 
13.0 References ................................................................................................................. 83 
14.0 Appendix ................................................................................................................... 85 
14.1 
Appendix 1:  New York Heart Association Classification of Heart Failure .....85 
14.2 
Appendix 2:  Worst Itching Intensity Numerical Rating Scale (NRS) .............86 
14.3 
Appendix 3:  Skindex-10 Scale .........................................................................87 
14.4 
Appendix 4:  5-D Itch Scale ..............................................................................88 
14.5 
Appendix 5:  Patient Global Impression of Change ..........................................90 
14.6 
Statistical Appendix ..........................................................................................91 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 20 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
LIST OF TABLES 
Table 1. 
Restricted and Prohibited Medications ..................................................... 42 
Table 2. 
Schedule of Events:  Double-blind Phase ................................................. 43 
Table 3. 
Schedule of Events:  Open-label Extension Phase ................................... 47 
Table 4. 
Power as a Function of Effect Size (N = 175 per arm) ............................. 61 
Table 5. 
Sample Size as a Function of Odds Ratio (90% Power) ........................... 61 
 
LIST OF FIGURES 
Figure 1. 
CR845-CLIN3103 Study Schematic......................................................... 32 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 21 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
3.0 
List of Abbreviations 
AESI 
adverse event of special interest 
ATC 
Anatomical Therapeutic Chemical 
CFR 
Code of Federal Regulations 
CI 
confidence interval 
CNS 
Central nervous system 
DSMB 
Data Safety Monitoring Board 
ECG 
electrocardiogram 
eCRF 
electronic case report form 
ESRD 
end-stage renal disease 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
H 
above the laboratory parameter’s reference range 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
IDMC 
Independent Data Monitoring Committee 
IEC 
Independent Ethics Committee 
IL 
interleukin 
IND 
Investigational New Drug 
IRB 
Institutional Review Board 
ISF 
Investigator Site File 
ITT 
intent-to-treat 
IV 
intravenous 
IVRS/IWRS 
interactive voice or web response system 
KOR 
kappa-opioid receptor 
L 
below the laboratory parameter’s reference range 
LS 
least squares 
MAR 
missing at random 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
multiple imputation 
MMRM 
mixed effects model with repeated measures 
MNAR 
missing not at random 
N 
within the laboratory parameter’s reference range 
NRS 
numerical rating scale 
PRO 
patient-reported outcome 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SE 
standard error 
SOC 
System Organ Class 
TEAE 
treatment-emergent adverse event 
ULN 
upper limit of normal 
Abbreviations that occur only in tables or figures are defined within the appropriate table or figure. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 22 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
4.0 
Introduction 
4.1 
Background and Rationale 
CR845 is a kappa-opioid receptor (KOR) agonist with a peripheral mechanism of action 
being developed by Cara Therapeutics, Inc. (designated as Cara Therapeutics or Sponsor 
in this protocol) as a novel therapeutic agent for the symptomatic relief of acute and 
chronic pain and pruritus. 
Opioid receptors are involved in the modulation of itch and pain signals and consist of 
3 subtypes:  mu, kappa, and delta.  These receptor subtypes are found in the central 
nervous system (CNS), in peripheral nervous system tissues, such as skin and viscera, 
and in the immune system (see Investigator’s Brochure for references and further details).  
CR845 was designed to only activate KORs located primarily in the peripheral nervous 
system, which are known to modulate itch, pain, and inflammatory signals, without 
producing the side effects associated with the activation of mu-opioid receptors, such as 
respiratory depression, abuse liability, and constipation. 
CR845 is a potent and selective KOR agonist with no activity at mu- and delta-opioid 
receptors or other receptors, ion channels, or transporters.  CR845’s unique peptidic 
structure significantly differs from other small molecule KOR agonists developed to date, 
which, for the most part, are CNS-active.  Being a hydrophilic peptide, CR845 has 
limited membrane permeability by passive diffusion, which limits its access to the CNS.  
Since CR845 does not activate receptors other than KORs and does not readily enter the 
CNS, it is expected to be safer and better tolerated than other opioid agonists, including 
CNS active kappa agonists. Thus far, CR845 has shown no abuse properties and no 
respiratory depression effects (see Investigator’s Brochure for details). 
Uremic pruritus is a chronic, unremitting, and highly bothersome condition in patients 
with chronic kidney disease that adversely affects sleep, mood, and ability to socialize 
[Kumagai 2010].  Patients with uremic pruritus frequently exhibit considerable 
mechanical skin damage because of continuous scratching with excoriations, 
superimposed infections, and chronic lesions of prurigo nodularis or skin lichenification 
often occurring.  The mechanical skin damage can become an additional source of 
itching.  Consequently, these patients are at increased risk of related morbidities 
associated with infection, eg, cellulitis, sepsis, bacteremia, cutaneous infections, and 
infections of the dialysis access, and are at higher mortality risk (>15%) 
[Pisoni 2006; Narita 2006].  Large multinational studies (Dialysis Outcomes and Practice 
Patterns) and studies based in the United States have demonstrated that approximately 
30 to 40% of hemodialysis patients have moderate-to-severe pruritus.  There are no 
approved treatments for this condition in the United States and current off-label therapies 
are unable to successfully treat uremic pruritus.  
Although the pathophysiology of moderate-to-severe pruritus in hemodialysis patients is 
not well understood, there is increasing evidence that it is likely multifactorial and that an 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 23 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
immune system dysfunction (including elevated proinflammatory activity) and imbalance 
in the endogenous opioid system (with over-expression of mu-opioid receptors in dermal 
cells and lymphocytes and concomitant downregulation of KORs) are involved 
[Kimmel 2006; Narita 2006; Phan 2012; Patel 2007; Mettang 2002; Tey 2011].  
In nonclinical studies, CR845 has been shown to exhibit antipruritic and 
anti-inflammatory properties [Investigator’s Brochure].   Thus, CR845 is intended to 
reduce the severity of itching in hemodialysis patients and thereby decrease the likelihood 
of developing additional serious conditions associated with uremic pruritus. 
4.2 
Clinical Experience 
4.2.1 
Overall Exposure 
As of the writing of this protocol, the intravenous (IV) formulation of CR845 has been 
evaluated in 722 patients and healthy volunteers across eight Phase 1 studies (including 
2 studies conducted in Japan), three Phase 2 studies for the relief of moderate-to-severe, 
acute postoperative pain, and two Phase 2 studies for the relief of moderate-to-severe 
pruritus in hemodialysis patients.  In the United States, CR845 has been evaluated both as 
an IV bolus and a 15-minute infusion of single or repeated doses ranging from 
0.5 to 40 mcg/kg. 
Of the patients exposed to IV CR845 to date, 213 hemodialysis patients (127 males and 
86 females) have received single or repeated IV injections of CR845 doses (for up to 
8 weeks) ranging from 0.5 to 6 mcg/kg across two Phase 1 studies and two Phase 2 safety 
and efficacy studies. 
4.2.2 
Safety in Hemodialysis Patients 
A review of the aggregate safety data shows that CR845 was generally well tolerated in 
hemodialysis patients when administered after each dialysis session for up to 8 weeks at 
IV doses ranging from 0.5 mcg/kg to 6 mcg/kg.  Although patients exposed to CR845 
reported more adverse events compared with placebo patients, most events were mild or 
moderate in nature.  Generally mild, transient paresthesias (facial tingling) and/or 
hypoesthesias (in different anatomic locations), mostly on the first week of dosing, as 
well as headache, dizziness, and somnolence, were the most frequently reported adverse 
events associated with CR845 administration.  Of note, side effects (eg, dysphoria and 
hallucinations) commonly associated with centrally-acting kappa opioids were not 
reported in patients exposed to CR845.  Consistent with its lack of affinity for mu-opioid 
receptors, CR845 did not cause euphoria or respiratory depression.  
CR845-CLIN2101 evaluated the safety, pharmacokinetics, and efficacy of repeated IV 
doses of CR845 compared to placebo over an 8-week treatment period in 
174 hemodialysis patients.  As expected with patients on hemodialysis, a significant 
number of the reported serious adverse events (SAEs) were considered not treatment-
related, but related to the disease and/or comorbid conditions.  There were 31 (17.8%) of 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 24 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
174 patients randomized and treated in the study who had treatment-emergent SAEs.  Of 
the 31 SAE reports, 4 (9%) occurred in 45 placebo-treated patients and 27 (21%) in 
129 CR845-treated patients.  Only 1 SAE of mental status changes (moderate in severity) 
in a patient who received CR845 1.5 mcg/kg IV was considered by the Investigator to be 
probably related to study drug.  However, based on the Sponsor’s medical review, an 
alternate etiology of urgent/emergent hypertension offers a more plausible explanation 
for the acute change in mental status.  There were 4 patient deaths (1 in placebo group, 1 
in CR845 0.5 mcg/kg group, and 2 in CR845 1.5 mcg/kg group; 2.3% of the total study 
population) in the study, all of which were considered not related to the study drug.In 
patients with normal renal function, CR845 can cause free-water diuresis (aquaresis) and 
increased serum sodium.  However, as would be expected in patients undergoing dialysis 
in whom there are few functioning nephrons, there was no evidence of aquaresis or 
significant increases in serum sodium concentrations.  There were no adverse trends in 
clinical chemistry or hematology values (drawn pre-dialysis), including no apparent 
differences between the placebo and CR845 groups in serum sodium.  There were no 
discernable differences between treatment groups in vital sign results.  Of particular note, 
among patients receiving CR845, there was no apparent reduction in blood pressure or 
respiratory rate following dosing. 
Adverse event summary tables can be found in the Investigator’s Brochure, with further 
details of the safety profile of CR845.   
4.2.3 
Efficacy of CR845 in Hemodialysis Patients with Uremic Pruritus 
The efficacy of CR845 in uremic pruritus was evaluated in two Phase 2, randomized, 
double-blind, placebo-controlled studies (CR845-CLIN2005 [Part B] and 
CR845-CLIN2101). 
CR845-CLIN2005 (Part B) included 65 hemodialysis patients with moderate-to-severe 
uremic pruritus who received either IV CR845 1.0 mcg/kg (n=33) or placebo (n=32) 
3 times per week for 2 weeks, after each hemodialysis session.  CR845 significantly 
decreased itching intensity compared with placebo (p=0.016), as measured by a visual 
analog scale (VAS) and significantly improved quality of life related to itching 
(Skindex-10 Scale) (see Investigator’s Brochure for details).  Furthermore, 
CR845-treated patients exhibited statistically significant reductions in both daytime 
(p=0.03) and nighttime (p=0.007) worst itching scores compared with placebo, and the 
reduction in itching intensity scores was similar on dialysis and nondialysis days.  The 
mean change from baseline VAS curves over time showed numerical separation between 
the treatment groups within the first week of treatment. 
CR845-CLIN2101 evaluated the safety, pharmacokinetics, and efficacy of repeated IV 
doses of CR845 compared to placebo over an 8-week treatment period in 
174 hemodialysis patients experiencing moderate-to-severe uremic pruritus daily or 
near-daily for 4.4 years on average.  The study was conducted at 33 dialysis centers and 
assessed the effect of 3 doses of CR845 (ie, 0.5 mcg/kg, n=44; 1 mcg/kg, n=41 and 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 25 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
1.5 mcg/kg, n=44) or placebo (n=45) administered at the end of each dialysis session 
(ie, 3 times/week).  The primary efficacy endpoint for Study CR845-CLIN2101 was 
based on itch intensity measurement and defined as the change from a 1-week baseline 
recorded prior to the start of study drug to the last week of the 8-week treatment period 
with respect to the weekly mean of the daily 24-hour Worst Itching Intensity numerical 
rating scale (NRS) score.  The least squares (LS) mean (±standard error [SE]) treatment 
group difference from placebo at Week 8 across all CR845 doses was -1.3 (±0.41) (95% 
confidence interval [CI]:  -2.1 to -0.5) (p=0.002) with an average NRS score reduction 
from baseline of -3.2 (±0.22) (LS mean ±SE) and 95% CI ranging from -3.7 to -2.8.  
Examination of the individual CR845 dose group results for the Full Analysis Population 
indicates that a substantial improvement over placebo was observed with all 3 doses.  
These differences from placebo were statistically significant for the lower dose group of 
0.5 mcg/kg (p<0.001) and the 1.5 mcg/kg group (p=0.019), with an effect size estimated 
as 0.82, 0.39, and 0.62 for the 0.5, 1.0, and 1.5 mcg/kg doses, respectively.  Average 
reduction from baseline (LS mean ± SE) ranged from -2.8 (±0.38) in the 1.0 mcg/kg dose 
group (95% CI ranging from -3.5 to -2.0) to -3.8 (±0.38) in the 0.5 mcg/kg dose group 
(95% CI ranging from -4.5 to -3.1).   
4.2.4 
Pharmacokinetics in Hemodialysis Patients 
CR845 is eliminated primarily through the kidney and no major metabolites have been 
identified in humans.  Consequently, total body clearance of CR845 in patients with 
severe renal impairment is reduced relative to healthy, matched, control patients 
(CR845-CLIN1005) such that plasma levels of CR845 remain relatively constant until 
cleared during dialysis in hemodialysis patients (CR845-CLIN1003 and 
CR845-CLIN2005 [Part A]).  Half-life ranges between 26 and 34 hours in hemodialysis 
patients compared to a typical range of 2 to 3 hours in patients with normal renal 
function.  Thus, lower doses of CR845 can be administered at a less frequent interval in 
hemodialysis patients to achieve the same or higher overall exposure compared to 
individuals with normal renal function.  Based on this pharmacokinetic profile, CR845 
does not need to be administered more than 3 times a week after each hemodialysis 
session, which is convenient for this patient population and ensures treatment compliance 
in a population already burdened with complex medication schedules.  
The pharmacokinetic profile of repeat-dose CR845 was studied in 24 hemodialysis 
patients who received doses of 0.5, 1.0, or 2.5 mcg/kg 3 times per week for 1 week 
(CR845-CLIN2005 [Part A]).  In this study, there were dose-proportional increases in 
maximum concentration and area under the curve, and minimal to no accumulation with 
repeat doses due to clearance of the drug by hemodialysis (see Investigator’s Brochure 
for details).  
4.3 
Summary of Potential Risks and Benefits 
During preclinical development, no specific safety findings to preclude the use of CR845 
in humans were observed.  During early clinical development, IV CR845 was 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 26 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
administered to healthy volunteers; patients with mild, moderate, or severe renal 
impairment, including end-stage renal disease (ESRD) and hemodialysis patients; 
recreational poly-drug users; and postsurgical patients.  The effects of CR845 have been 
shown to be in line with the underlying pharmacological mechanism of KOR activity.  
Consistent with the nonclinical abuse liability studies conducted to date, the results of an 
abuse-potential study in humans indicated that CR845 appears to present a low risk for 
abuse potential in humans in comparison to currently clinically used opioids.  
Overall, tingling/numbness, dizziness, fatigue and/or drowsiness/somnolence have been 
the most common adverse events.  Precaution is recommended in the operation of 
machinery for patients who experience dizziness, fatigue, and/or drowsiness/somnolence.  
This is described in the informed consent form (ICF), as appropriate, and will be 
discussed with each patient prior to initiation of the study.  In general, CR845 appeared to 
be generally well tolerated in both single- and repeat-dose clinical studies in hemodialysis 
patients, which support continued study and development of this compound. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 27 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
5.0 
Objectives 
Primary Objective  
• To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared to 
placebo in reducing the intensity of itch in hemodialysis patients with 
moderate-to-severe pruritus.   
Secondary Objectives  
• To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared to 
placebo in improving itch-related quality-of-life measures in hemodialysis 
patients with moderate-to-severe pruritus.   
• To evaluate the safety of IV CR845 at a dose of 0.5 mcg/kg in hemodialysis 
patients with moderate-to-severe pruritus. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 28 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6.0 
Investigational Plan 
6.1 
Overall Study Design and Plan:  Description 
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the 
safety and efficacy of IV CR845 at a dose of 0.5 mcg/kg administered after each dialysis 
session.  The study includes a Double-blind Phase and an Open-label Extension Phase.  
CR845 will be evaluated relative to placebo over a 12-week Double-blind Treatment 
Period in hemodialysis patients with moderate-to-severe pruritus.  At the end of the 
Double-blind Treatment Period, patients who received at least 30 doses of study drug 
during the 12-week Double-blind Treatment Period will be eligible to receive open-label 
CR845 for an additional 52 weeks.  A follow-up visit will be conducted 7-10 days after 
the last study visit on treatment or after early termination.  
6.1.1 
Double-blind Phase 
The Double-blind Phase of the study will consist of a Screening Visit, a 7-day Run-in 
Period, and a 12-week Double-blind Treatment Period.  Informed consent will be 
obtained prior to performing any study-specific procedures.  The Screening Visit will 
occur within 7 to 28 days prior to randomization in order to assess eligibility.  The 
Screening Visit can be conducted during the Run-in Period at the discretion of the 
Investigator. 
6.1.1.1 
Screening Visit 
During the Screening Visit, patients will sign the Informed Consent, and will be 
evaluated for eligibility by assessment of inclusion/exclusion criteria, medical history, 
physical examination, prescription dry body weight, pre-dialysis 12-lead 
electrocardiogram, pre-dialysis vital signs, pre-dialysis hematology and serum chemistry, 
adverse events, and prior medications. 
Serum pregnancy test for females of childbearing potential must be performed within 7 
days prior to the first study dose.  
During Screening and before the first visit of the Run-in Period, patients will be trained 
on completion of the 24-hour Worst Itching Intensity NRS scale.  Patients may also be 
trained on other patient-reported outcome (PRO) worksheets during Screening (ie, 
Skindex-10 scale, 5-D itch scale and PGIC).  
6.1.1.2 
Run-in Period 
Eligible patients will complete a 7-day Run-in Period during the week prior to 
randomization to confirm eligibility, preferably starting on the first dialysis session of 
that week (ie, Monday for patients on a Monday-Wednesday-Friday dialysis schedule or 
Tuesday for patients on a Tuesday-Thursday-Saturday dialysis schedule).  The purpose of 
the Run-in Period will be to confirm that each patient has moderate-to-severe pruritus 
(ie, weekly average score ≥5), as measured by the 24-hour Worst Itching Intensity NRS, 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 29 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
and to establish a baseline itch intensity.  These criteria for eligibility should not be 
communicated to the patients.  This period will also be used to record each patient’s use 
of itch medications.   
During the first visit of the Run-in Period, patients will start the reporting of their Worst 
Itching Intensity NRS daily score. Patients may continue to be trained on PRO 
worksheets during the Run-in Period. 
For consistency, patients will be requested to complete the NRS worksheets (either at 
home or in the dialysis unit, as required) at a similar time of day around the normal start 
time of their dialysis.   
A Structured Safety Evaluation will be performed during the Run-in Period (preferably 
on Wednesday/Thursday).  The Structured Safety Evaluation is performed by study staff 
using a list of specific signs/symptoms (eg, mental status change, falls, gait disturbance).  
6.1.1.3 
Double-blind Treatment Period 
If patients continue to meet all inclusion and no exclusion criteria at the end of the 7-day 
Run-in Period, they will be randomized into the Double-blind Treatment Period in a 
1:1 ratio to receive either IV CR845 0.5 mcg/kg or placebo.  Patients will be stratified 
according to their use or non-use of concomitant medications to treat their itch as well as 
the presence or absence of specific medical conditions. 
Day 1 of the Double-blind Treatment Period will be defined as the day of administration 
of the first dose of study drug and will occur preferably on the first dialysis day of the 
first treatment week (ie, Monday for patients on a Monday-Wednesday-Friday dialysis 
schedule or Tuesday for patients on a Tuesday-Thursday-Saturday dialysis schedule).   
Patients will be administered CR845 or matched placebo as an IV bolus after the end of 
each dialysis session during the 12-week Double-blind Treatment Period so that each 
patient will receive CR845 or placebo 3 times weekly for a total of up to 36 doses. 
During the Double-blind Treatment Period, patients will continue to report their Worst 
Itching Intensity NRS score on a daily basis, covering the previous 24 hours.  In addition, 
during selected study visits (Day 1 and first day of Weeks 5, 9, 11, and 13 [ie, Days 29, 
57, 71, and 85]), they will complete other PRO measures (such as Skindex-10 Scale, 5-D 
Itch Scale, and Patient Global Impression of Change).  Patients will be instructed to 
record patient-reported outcome measurements, including Worst Itching Intensity NRS 
scores, at a similar time of day, whether in the dialysis unit (on dialysis days) or at home 
(on non-dialysis days). 
Blood samples for inflammatory biomarkers will be collected for all randomized patients 
prior to dialysis on Day 1 and prior to the last dialysis at the End-of-Treatment Visit for 
the Double-blind Treatment Period (Day 85). 
Clinical laboratory tests and vital signs will be monitored periodically, and adverse 
events and concomitant medications will be continuously recorded during the Double-
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 30 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
blind Treatment Period. Electrocardiograms (ECGs) will be monitored at the Screening 
Visit and Day 85 or Early Termination Visit. 
The number and reason(s) for missed dialysis as well as the use of antipruritic 
medications will be recorded throughout the study. 
A Structured Safety Evaluation will be performed weekly (preferably on 
Wednesday/Thursday) during the Double-blind Treatment Period.  The Structured Safety 
Evaluation is performed by study staff using a list of specific signs/symptoms (eg, mental 
status change, falls, gait disturbance).  
6.1.2 
Open-label Extension Phase 
Patients who received at least 30 doses of study drug (either placebo or active) during the 
12-week Double-blind Treatment Period and continue to meet other eligibility criteria 
will be eligible to receive open-label CR845 for an additional 52 weeks.  The Open-label 
Extension Phase will be comprised of the Open-label Treatment Period and the Follow-
up Period.  The first visit and first dosing for the Open-label Extension Phase of the study 
will occur immediately on the day of the last visit of the Double-blind Treatment Period 
or up to 1 week following the Double-blind Treatment Period.  Each patient will receive 
CR845 at a dose of 0.5 mcg/kg after each dialysis session, 3 times per week for up to 52 
weeks, whether they had been previously administered placebo or CR845. Prescription 
dry body weight will be recorded at the start of and every 12 weeks during the Open-label 
Extension Phase; if there is a ±10% or more change from the prescription dry body 
weight recorded at Screening, then the CR845 dose will be adjusted according to the 
newly recorded dry body weight. 
Patients will complete the 5-D Itch Scale during Weeks 4, 8, 12, 24, 36, and 52 
(preferably at the end of the specified weeks). 
Clinical laboratory tests, vital signs, adverse events, and concomitant medications will be 
monitored throughout the Open-label Treatment Period.  Blood samples for inflammatory 
biomarkers will be collected periodically until the End-of-Treatment or Early 
Termination Visit.  An electrocardiogram will be performed at the End-of-Treatment or 
Early Termination Visit. 
The number and reason(s) for missed dialysis and the use of antipruritic medications will 
be recorded throughout the Open-label Extension Phase. 
The last dose of open-label study drug will be administered at the last dialysis visit in 
Week 52.  
6.1.3 
Follow-up Period 
A final safety Follow-up Visit will be conducted 7-10 days after the End-of-Treatment 
Visit of the Double-blind Treatment Period for patients not participating in the Open-
label Extension Phase, after the End-of-Treatment Visit of the Open-label Extension 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 31 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Phase, or after the Early Termination Visit during either the Double-blind Treatment 
Period or the Open-label Extension Phase.  
Vital signs, adverse events, and concomitant medications will be monitored during the 
Follow-up Period.  
The study schematic is shown in Figure 1. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072




Cara Therapeutics Inc. 
Confidential 
Page 33 of 92 
CR845-CLIN3103 
 
 
 10 September 2019                                                                                                                       Version 2.2 
 
 
6.2 
Selection of Study Population 
Patients with ESRD receiving hemodialysis 3 times a week and experiencing 
moderate-to-severe pruritus will be considered for participation in this study. 
A screening log of potential study candidates will be maintained at each study site. 
Patients providing informed consent will be screened for inclusion in the study.  All 
eligibility criteria must be met before a patient is randomized.   
Rescreening will be considered on an individual patient basis and must first be approved 
by the Sponsor or designee.  However, rescreening will not be permitted if a patient 
missed the entry criteria for itch intensity, ie mean NRS score < 5. A patient can only be 
rescreened once. Rescreening can only occur after at least two weeks from screening. 
6.2.1 
Inclusion Criteria 
To be eligible for inclusion into the Double-blind Phase of the study, a patient must meet 
the following criteria:  
1. Willing and able to provide written informed consent prior to participating in this 
study; 
2. Able to communicate clearly with the Investigator and staff, able to understand the 
study procedures, and able and willing to comply with the study requirements, 
including providing written responses to questionnaires; 
3. Male or female between 18 and 85 years of age, inclusive; 
Note: Subjects in Korea must be male or female between 19 and 85 years of age, 
inclusive; 
4. Has ESRD and has been on hemodialysis 3 times per week for at least 3 months 
prior to the start of screening;  
Note 1:  Patients who require an occasional additional dialysis treatment to 
manage fluid overload or electrolyte excesses may be enrolled as long as it is 
anticipated that no more than 1 such treatment will be required in any given week 
and no more than 4 occasions during the 12-week double-blind period. Patients 
routinely on 4 dialyses a week will not be eligible. 
Note 2:  Patients receiving in-home hemodialysis may participate as long as they 
have switched to in-center hemodialysis at least 2 weeks prior to screening and 
plan to remain on in-center hemodialysis for the duration of the study. 
Note 3:  Patients receiving alternate dialysis modalities such as nocturnal dialysis 
will not be eligible. 
5. If female, is not pregnant or nursing during any period of the study;  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 34 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6. If female: 
a. Is surgically sterile; or 
b. Has been amenorrhoeic for at least 1 year and is over the age of 55 years; 
or 
c. Has a negative serum pregnancy test at screening and agrees to use 
acceptable contraceptive measures (eg, hormonal contraceptives, barrier 
with spermicide, intrauterine device, vasectomized partner, or abstinence) 
from the time of informed consent until 7 days after the last dose of study 
drug; 
7. If male, agrees not to donate sperm after the first dose of study drug until 7 days 
after the last dose of study drug, and agrees to use a condom with spermicide or 
abstain from heterosexual intercourse during the study until 7 days after the last 
dose of study drug. (Note:  No restrictions are required for a vasectomized male 
provided his vasectomy was performed ≥4 months prior to screening); 
8. Has a prescription dry body weight between 40.0 and 135.0 kg, inclusive; 
9. Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 2 urea reduction 
ratio measurements ≥65%, or 1 single-pool Kt/V measurement ≥1.2 and 1 urea 
reduction ratio measurement ≥65% on different dialysis days during the 3 months 
period prior to screening; 
10. Prior to randomization:  
a. Has completed at least four out of eight Worst Itching Intensity Numeral 
Rating Scale (NRS) worksheets from the start of the 7-day Run-in Period 
up to and including the pre-randomization assessment on Day 1;  
b. Has a mean baseline Worst Itching Intensity NRS score ≥5, defined as the 
average of all non-missing scores reported from the start of the 7-day 
Run-in Period up to and including the pre-randomization assessment on 
Day 1. 
To be eligible for inclusion into the Open-label Extension Phase of the study, each 
patient will have to fulfill the additional following criteria at the time of entry into 
the Open-label Extension Phase: 
11. Has received at least 30 doses of the planned 36 doses of study drug during the 
Double-blind Phase of this study; 
12. Has a prescription dry body weight ≥40 kg; 
13. Continues to meet inclusion criteria 1 through 7. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 35 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6.2.2 
Exclusion Criteria 
A patient will be excluded from the Double-blind Phase of the study if any of the 
following criteria are met: 
1. Known noncompliance with dialysis treatment that in the opinion of the 
Investigator would impede completion or validity of the study; 
2. Scheduled to receive a kidney transplant during the study; 
3. Known history of allergic reaction to opiates, such as hives (Note:  side effects 
related to the use of opioids, such as constipation or nausea, would not exclude 
patients from the study); 
4. Has a concomitant disease or a history of any medical condition that, in the 
opinion of the Investigator, could pose undue risk to the patient, impede 
completion of the study procedures, or would compromise the validity of the 
study measurements, including, but not limited to: 
a. Known or suspected history of alcohol, narcotic, or other drug abuse, or 
substance dependence within 12 months prior to screening; 
b. Significant systolic or diastolic heart failure (eg, New York Heart 
Association Class IV congestive heart failure [Appendix 1, Section 14.1]); 
c. Severe mental illness or cognitive impairment (eg, dementia); 
d. Any other relevant acute or chronic medical or neuropsychiatric condition 
within 3 months prior to screening (eg, diagnosis of encephalopathy, coma, 
delirium); 
5. New or change of treatment received for itch including antihistamines and 
corticosteroids (oral, IV, or topical) within 14 days prior to screening; 
6. New or change of prescription for opioids, gabapentin, or pregabalin within 
14 days prior to screening; 
7. Received another investigational drug within 30 days prior to the start of 
screening or is planning to participate in another clinical study while enrolled in 
this study; 
8. In the opinion of the Investigator has pruritus attributed to a cause other than 
ESRD or its complications (eg, patients with concomitant pruritic dermatological 
disease or cholestatic liver disease) (Note:  Patients whose pruritus is attributed to 
ESRD complications, such as hyperparathyroidism, hyperphosphatemia, anemia, 
or the dialysis procedure or prescription may be enrolled); 
9. Has localized itch restricted to the palms of the hands; 
10. Has pruritus only during the dialysis session (by patient report); 
11. Is receiving ongoing ultraviolet B and anticipates receiving such treatment during 
the study; 
12. Participated in a previous clinical study with CR845. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 36 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
A patient will be excluded from the Open-label Extension Phase of the study if any of 
the additional following criteria are met at the time of entry into the Open-label 
Extension Phase: 
13. Completed the Double-blind Phase of this study but exhibited adverse events 
during the course of the Treatment Period that may preclude continued exposure 
to the study drug; 
14. Was noncompliant with protocol procedures during the Double-blind Phase of 
this study which is indicative of an inability to follow protocol procedures;  
15. Has developed a concomitant disease or any medical condition that, in the opinion 
of the Investigator, could pose undue risk to the patient, impede completion of the 
study procedures, or would compromise the validity of the study measurements. 
6.3 
Removal of Patients from Therapy or Assessment 
6.3.1 
Discontinuation of Individual Patients 
A patient may withdraw from the study at any time at his/her own request for any reason 
without prejudice to future medical care by the physician or at the institution.   
A patient may be withdrawn at any time due to the following reasons: 
1. At the discretion of the Investigator or the Sponsor for safety, behavioral, 
compliance, or administrative reasons, including, but not limited to:  
a. Lost to follow-up; 
b. Adverse event; 
c. Lack of therapeutic efficacy;  
d. Pregnancy; 
e. Eligibility (Inclusion/exclusion criteria); 
f. Subject non-compliance; 
g. Subject withdrew consent. 
2. If a patient misses 3 consecutive doses either on Week 11 or Week 12 of the 
Double-blind Treatment Period (these patients may still be eligible for the 
Open-label Extension Phase at the discretion of the Investigator in consultation 
with the Sponsor).  
3. If patient misses 6 consecutive doses at any time during the Double-blind 
Treatment Period (these patients may still be eligible for the Open-label 
Extension Phase at the discretion of the Investigator in consultation with the 
Sponsor). 
4. At the discretion of the Sponsor/Medical Monitor, if a patient receives a 
prohibited concomitant medication according to Table 1. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 37 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
5. Any patient who becomes pregnant during treatment must be withdrawn from 
the study (see Section 6.5.4.7). 
Whenever possible, withdrawal of a patient from study drug by the Investigator should be 
discussed with the Medical Monitor before the patient stops study drug.  
If study drug is discontinued, regardless of the reason, an Early Termination Visit should 
be completed at the first dialysis after the last dose of study drug or, if not feasible during 
that timeframe, as soon as feasible.  If at all possible, a Follow-up Visit is to be completed 
7-10 days after the Early Termination Visit.  
A patient may withdraw consent from continued participation in the study at any time. 
Although a patient will not be obliged to give a reason for withdrawing prematurely, the 
Investigator must make a reasonable effort to obtain the reason while fully respecting the 
patient’s rights.  The reason(s) for termination and date of stopping study drug must be 
recorded on the electronic case report form (eCRF) and source documents. 
If a patient discontinues early due to an adverse event, the event will be followed until 
resolution, the patient returns to baseline status, the condition stabilizes, or the patient is 
lost to follow-up. 
A patient will be considered lost to follow-up when no response is received from the 
patient after at least 3 documented attempts to contact the patient over a minimum time of 
2 weeks by the study site. 
If the patient withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
Patients who discontinue after the administration of the first dose of study drug will not be 
replaced. 
6.3.2 
Discontinuation or Suspension of Entire Study 
The Sponsor may suspend or terminate the study or part of the study at any time 
for any reason.  Reasons may include the following, among others: 
1. Investigators have not been able to enroll patients within a reasonable 
period of time or according to inclusion/exclusion criteria; 
2. The target number of subjects required for the study is enrolled 
earlier than expected; 
3. Unexpected safety concern. 
If the study is suspended or terminated, the Sponsor will ensure that applicable regulatory 
agencies and Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) 
are notified, as appropriate.  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 38 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Should the study be closed prematurely, all study materials (eg, completed, partially 
completed, and blank eCRFs, as well as study drug) must be returned to the Sponsor or 
destroyed at the site according to instructions which will be provided by the Sponsor, as 
applicable.  
6.4 
Treatments 
Additional information on the study drug and its preparation, administration, storage, 
supply, disposition, and accountability can be found in the Pharmacy Section of the 
Investigator Site File (ISF). 
6.4.1 
Treatments Administered 
The study drug will be dispensed by qualified staff members who have received training 
on study drug handling and administration and as per local regulations.   
Patients will receive IV CR845 at a dose of 0.5 mcg/kg or placebo after each dialysis 
session, generally 3 times per week for up to 64 weeks (ie, 12 weeks double-blind and 
52 weeks open-label) as an IV bolus into the venous line of the dialysis circuit at the end 
of each dialysis session and may be given either during or after rinse back of the dialysis 
circuit.  If the dose is given after rinse back, following the IV push of study drug the 
venous line must be flushed with at least 10 mL of normal saline. If the dose is given 
during rinse back, no additional normal saline is needed to flush the line.  If a patient 
receives additional dialysis during a given week for any reason, an additional dose of 
CR845 or placebo will be administered following dialysis.  A maximum of 4 doses per 
week is allowed.  No additional doses will be given for patients receiving an additional 
unscheduled ultrafiltration treatment. 
The patient’s prescription dry body weight (ie, the target post-dialysis weight, as 
determined by the patient’s nephrologist or dialysis unit during screening) will be used to 
calculate the dose of the study drug to be administered throughout the Double-blind 
Treatment Period. 
During the Open-label Extension Phase, the patient’s current prescription target dry body 
weight should be compared to the screening dry body weight. If the difference is less than 
±10%, then continue dosing based on the patient’s dry body weight recorded at screening. 
If the difference is ±10% or more, use the patient’s newly recorded dry body weight to 
calculate the volume of CR845 to be administered. Dosing will be adjusted every 12-
weeks if prescription dry body weight changes by ±10% or more from dry body weight 
recorded at screening.  
6.4.2 
Identity of Investigational Product(s) 
6.4.2.1 
Formulation of Study Drug 
Study drug will be supplied by the Sponsor as a solution in 2-mL glass vials containing a 
minimum extractable volume of 1.3 mL of CR845 at a concentration of 0.05 mg/mL in 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 39 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
0.04 M isotonic acetate buffer, pH 4.5.  The composition of the CR845 solution is CR845 
(free base), acetic acid, sodium acetate trihydrate, sodium chloride, hydrochloric acid, and 
water for injection. 
Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be provided in 2-mL glass 
vials containing a minimum extractable volume of 1.3 mL.  The composition of the 
placebo buffer solution is acetic acid, sodium acetate trihydrate, sodium chloride, 
hydrochloric acid, and water for injection.  The placebo buffer is identical to the buffer 
solution used in the CR845 solution and has identical appearance as the solution 
containing the active ingredient.  The placebo buffer solution will be packaged, stored, 
and shipped identically to the CR845 solution. 
6.4.2.2 
Packaging, Labeling, and Storage Stability of Study Drug 
Study drug will be shipped at 15°C to 30°C.  Temperature will be monitored during 
shipment and verified and recorded in the pharmacy log by the pharmacist upon arrival at 
the site.  The vials must be stored at a temperature ranging from 15°C to 30°C upon 
receipt and the temperature will be monitored accordingly. 
For the Double-blind Treatment Period vials will be packaged (blinded) in boxed kits (also 
blinded) containing 40 vials per box (4 extra vials for backup).  Kits will be labeled with 
patient ID number and kit number.  A single box of vials will be assigned to a patient. 
For the Open-label Extension Phase, vials will be packaged in boxed kits containing 
12 vials per box.  Kits will be labeled with patient ID number and kit number.  A single 
box of vials will be assigned to a patient. 
Labeling of the vials and kits will conform to the regulations required by each country.  
6.4.2.3 
Individual Dose Labeling 
One syringe will be prepared for each patient on each dosing day.  Syringes and syringe 
labels will be provided.  Refer to the ISF for details. 
6.4.3 
Drug Accountability 
All supplies will be maintained under adequate security by the pharmacist or approved 
staff at the investigational site.  At the end of each injection, the used vials will be stored 
until the study monitor performs accountability.  Details of study drug accountability and 
return are provided in the ISF.  
The Sponsor (or delegated person) will be permitted, at intervals and upon request during 
the study, to check the supplies, storage and dispensing procedures, and records. 
6.4.4 
Method of Assigning Patients to Treatment Groups 
Before the start of the study, computer-generated randomization schedules will be 
prepared.  Randomization will be performed using an interactive voice or web response 
system (IVRS/IWRS).  Patients will be randomized in a 1:1 ratio to receive either CR845 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 40 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
0.5 mcg/kg IV or matching placebo IV during the Double-blind Treatment Period.  
Patients will be stratified into 2 strata according to their use or non-use of concomitant 
medications to treat their itch during the pre-randomization week (Run-in Period) as well 
as the presence or absence of specific medical conditions.  These specific medical 
conditions include: 
• History of fall or fracture (related to fall) 
• Confusional state or mental status change or altered mental status or disorientation 
• Gait disturbance or movement disorder 
All eligible patients will receive CR845 at a dose of 0.5 mcg/kg starting on Day 1 of the 
Open-label Extension Phase. 
6.4.5 
Preparation of CR845 
In the Double-blind Phase of the study, a single vial of study drug will be used for each 
patient.  Each patient’s prescription dry body weight will not exceed 135.0 kg. 
In the Open-label Extension Phase of the study, 1 vial of CR845 will be used for patients 
with a prescription dry body weight ≤135.0 kg.  For patients with a prescription dry body 
weight >135.0 kg, 2 vials of CR845 will be used to ensure that the full volume of study 
drug can be prepared.  Further details will be provided in the ISF.  
Information on the study drug preparation can be found in the Pharmacy Manual. 
6.4.6 
Management of Missed Doses  
If a patient misses a dialysis visit and the planned dose of CR845 for that visit, dosing 
should resume at the next dialysis visit.  
Contact the Medical Monitor if patient compliance or safety is of concern. 
6.4.7 
Treatment Compliance 
Patient compliance with study drug is documented as part of standard procedures at the 
dialysis units where study drug is administered.  
6.4.8 
Blinding 
During the Double-blind Treatment Period, patients, Investigators, study staff, and the 
Sponsor will be blinded to study drug assignment. 
For medically urgent or emergent situations that necessitate knowledge of study drug 
assignment for patient management, the blind may be broken via the IVRS/IWRS.  Except 
for when patient’s care requires the treatment assignment immediately, the Medical 
Monitor should be contacted prior to breaking the blind.  The Sponsor and Medical 
Monitor will receive a report whenever a patient blind is broken. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 41 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6.4.9 
Prior, Concomitant, and Prohibited Medications 
6.4.9.1 
Prior and Concomitant Medications 
Prior medications (including vitamins and herbal supplements) are defined as those that 
the patient has taken any time during the 3 months prior to the first dose of study drug on 
Day 1 of the Double-blind Treatment Period.  Concomitant medications are medications 
that are taken from after the start of the first dose of study drug on Day 1 of the 
Double-blind Treatment Period through the end of the Follow-up Period.   
Use of antipruritic medications during the study will be recorded on an ongoing basis, 
starting at screening. Patients having a prescription PRN for the use of anti-itch 
medication will be stratified as using anti-itch medication even if such medications were 
not reported to be used during the Run-In period. Medications known for potential anti-
pruritic effects but used for a different indication (ex. use of gabapentin for pain 
management) will not be reported as anti-pruritic medications.  
All prior and concomitant medications, including over-the-counter medications used by 
patients during this study, are to be recorded in the appropriate page of the eCRF, as 
applicable.  
6.4.9.2 
Restricted and Prohibited Medications 
During the Treatment Period for either the Double-blind Phase or Open-label Extension 
Phase, the following medications will be restricted or prohibited (Table 1). 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics, Inc. 
Confidential 
Page 42 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Table 1. 
Restricted and Prohibited Medications  
Drug, Drug Class, or Treatment 
Restrictions During the Treatment Period 
Investigational drug (other than the study 
drug) 
Not allowed 
Ultraviolet B treatments 
Not allowed 
Naloxone, naltrexone, or mixed 
agonist-antagonists (eg, buprenorphine and 
nalbuphine) 
Not allowed from the start of dosing of the 
Double-blind Treatment Period to the end of 
the Open-label Treatment Period, unless 
needed to treat an adverse event or emergent 
medical condition acutely. 
Antihistamines (oral, IV, or topical) 
Corticosteroids (oral, IV, or topical) 
treatments 
Opioids 
Gabapentin, pregabalin 
Changes to current prescription should be 
avoided from screening to the end of the 
Double-blind Treatment Period unless for the 
acute treatment of an adverse event or 
emergent medical condition (in this case, 
notify the study medical monitor and, as 
appropriate, report adverse events). 
No new medication to treat itch should be 
initiated during the Double-blind Treatment 
Period. 
All new concomitant medications or change of frequency and doses of a concomitant 
medication will be recorded. 
6.5 
Study Assessments and Procedures 
6.5.1 
Schedule of Events for the Double-blind Phase 
Study procedures for the Double-blind Treatment Period are summarized in Table 2.   
An ICF will need to be signed prior to initiation of the Screening Visit and any procedures 
that follow.  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072






Cara Therapeutics Inc. 
Confidential 
Page 45 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
a. 
Each visit during the Double-blind Treatment Period will coincide with the patient’s normal dialysis treatments. 
b. 
The End-of-Treatment Visit in the Double-blind Phase will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 13 [Day 85]), which also corresponds to Day 1 
of the Follow-up Period (FU Day 1). Only patients not participating in the Open-label Extension Phase are required to complete the Follow-up Period. 
c.     Medical history will be updated on Day 1 with any changes since the Screening Visit, and inclusion/exclusion criteria will be confirmed prior to randomization.  Antipruritic medication will be 
updated at each dialysis visit during the Run-in Period. 
d 
Electrocardiograms must be performed prior to the start of dialysis at Screening, Day 85 (End of Treatment), or at Early Termination visit. 
e 
Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded on Days 1, 15, 29, 43, 57, 71 and 85 (End of Treatment), or at Early Termination visit only 
when the patient is in a sitting or semi-recumbent position.  Heart rate will be measured at each dialysis; if heart rate is clinically significant and outside the prespecified visits per the Schedule of 
Events, the heart rate will be recorded on the relevant CRF page.  
f 
Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded at the Follow-up Visit (7-10 days after EoT/ET visit).  Heart rate will be measured at each 
dialysis. 
g. 
Blood samples for clinical laboratory evaluation will be taken at Screening, and on Days 1 and 85 (End of Treatment), or at Early Termination visit only.  
h. 
Training on Worst Itching Intensity NRS will be conducted prior to the first day of the Run-in Period (Day -7).   
i. 
Training on Skindex-10 Scale and 5-D Itch Scale may be performed at any time during Screening prior to randomization on Day 1 of the Double-blind Treatment Period. 
j. 
Patients will be requested to complete their Worst Itching Intensity NRS worksheets each day at a similar time (either at home on non-dialysis days around the normal start time of their dialysis or 
in the dialysis unit).  On dialysis days, the worksheets will be completed prior to or during dialysis, but must be completed prior to dosing. 
k. 
5-D Itch Scale and Skindex-10 Scale completed on Day 1 and the first visit of Weeks 5, 9 and 11 (on Days 29, 57 and 71) and Week 13 (Day 85).  The 5-D Itch Scale will preferably be completed 
first.  If the first visit of the week is missed, the patient may complete the worksheets at their next visit for the same week.  The worksheets will be completed prior to or during dialysis (preferably 
within 1 hour of the dialysis), but must be completed prior to dosing. 
l. 
Biomarker samples must be collected prior to the start of dialysis on Day 1 and Day 85.  
m. 
Concomitant medications including antipruritic medication will be updated at each dialysis visit during the Double-blind Treatment Period, and until the end of the Follow-up Period.  
n. 
A list of specific signs/symptoms will be verified with the patient by qualified site staff, preferably to be completed on Wednesday/Thursday each week during the Run-in Period, the Double-blind 
Treatment Period and the Follow-up Period.  It is not to be completed on Monday/Tuesday.  
o. 
The serum pregnancy test must be performed within 7 days prior to the first study dose. 
 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 46 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6.5.2 
Schedule of Events for the Open-label Extension Phase 
Study procedures for the Open-label Extension Phase are summarized in Table 3.  
The safety assessment visit may occur on any chosen dialysis day of a scheduled week as 
long as all assessments are completed during that visit.  Patients who miss one of the 
scheduled study visit weeks (eg, Week 4 of open-label treatment) may complete this visit 
at their next dialysis treatment if conducted within 2 weeks of the scheduled visit.  
Unscheduled visits may be necessary for outstanding, unresolved adverse events 
(eg, additional safety laboratory or clinical evaluations).  At minimum, for any 
unscheduled visit, the reason for the visit will be recorded, the adverse events reported, as 
well as changes to concomitant medications, as applicable.  Additional testing 
(eg, laboratory tests, vital signs, ECGs) will be performed as clinically indicated. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072






Cara Therapeutics Inc. 
Confidential 
Page 49 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
i. 
To be completed in the dialysis unit at any time prior to or during dialysis, but must be done prior to dosing.  Preferably at the end of the specified week, which corresponds to 
the beginning of the following calendar week (ie, end of Week 4 is the Monday/Tuesday of Week 5). 
j. 
Biomarker samples must be collected prior to the start of dialysis.  
k. 
Adverse events and concomitant medications will be recorded starting on Day 1 of the Open-label Extension Phase.   
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 50 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6.5.3 
Efficacy Assessments 
The effect of CR845 on itch will be measured by means of the following PRO measures:  
• Worst Itching Intensity NRS score 
• Skindex-10 Scale 
• 5-D Itch Scale  
• Patient Global Impression of Change 
Patients will be trained on completion of the Worst Itching Intensity NRS scale prior to 
the first visit of the Run-in Period, and will be trained on the other itch-related PRO 
measures at any time prior to Day 1 of the Double-blind Treatment Period.  All 
questionnaires must be completed in strict adherence to the Training Manual for Patient 
Reported Assessments. 
6.5.3.1 
Worst Itching Intensity Numerical Rating Scale 
Intensity of itch will be measured using an NRS scale (Appendix 2, Section 14.2) on a 
worksheet on which patients will be asked to indicate the intensity of the worst itching 
they experienced over the past 24 hours by marking one of 11 numbers, from 0 to 10, that 
best describes it, where “0” is labeled with the anchor phrase “no itching” and “10” is 
labeled “worst itching imaginable.”  Patients will be provided with these worksheets to 
record their 24-hour worst itching assessment scores, both at the clinic on dialysis days 
and at home on nondialysis days.   
The Worst Itching Intensity NRS has been widely utilized for evaluation of chronic itch, 
including uremic pruritus [Kumagai 2010; Pisoni 2006; Mathur 2010; Ständer 2013]. 
6.5.3.2 
Skindex-10 Scale 
Developed specifically for uremic pruritus, the Skindex-10 Scale (Appendix 3, 
Section 14.3) is an instrument for measurement of quality-of-life that correlates with itch 
intensity [Mathur 2010].  Patients are asked to mark 1 of 7 boxes numbered from 0 
(labeled with the anchor phrase “never bothered”) to 6 (labeled as “always bothered”) for 
each of the 10 questions describing how often they have been bothered by their itch and 
its impact over the past week.  The total score is the sum of the numeric value of each 
answered question.  The total score is subdivided into 3 domain scores, which are sums 
of the scores of the following questions:  disease domain (questions 1 to 3), 
mood/emotional distress domain (questions 4 to 6), and social functioning domain 
(questions 7 to 10). 
6.5.3.3 
5-D Itch Scale 
The 5-D Itch Scale was developed as a brief, multidimensional questionnaire designed to 
be useful as an outcome measure in clinical studies.  The 5 dimensions of itch assessed 
are degree, duration, direction, disability, and distribution (Appendix 4, Section 14.4).  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 51 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Patients are asked to mark boxes that best describe the impact of their itch over the past 
2 weeks.  The scale has been validated in patients with chronic pruritus, including 
hemodialysis patients and has been shown to be sensitive to changes in pruritus over time 
[Elman 2010]. 
6.5.3.4 
Patient Global Impression of Change 
The Patient Global Impression of Change is a global PRO measure that assesses the 
change in itch (no change, improvement or worsening) overall relative to the start of the 
study [Dworkin 2005].  The scale has only 1 item, and the patient is asked to mark the 
category that best describes the change in itch ranging from “Very Much Improved” to 
“Very Much Worse” (Appendix 5, Section 14.5). 
6.5.4 
Safety Assessments 
During both the Double-blind and Open-label Extension Phases, the safety assessments 
for each patient are the following: 
• Severity, seriousness, and relationship of adverse events to study drug  
• Structured Safety Evaluation by site staff (Double-blind Phase only)  
• Physical examination 
• Vital signs  
• 12-lead ECGs 
• Clinical laboratory tests 
 
6.5.4.1 
Adverse Events 
Definition of Adverse Events 
An adverse event is any untoward medical occurrence in a patient or clinical 
investigational patient administered a medicinal product and which does not necessarily 
have to have a causal relationship with this treatment.  An adverse event can therefore be 
any unfavorable and unintended sign (including an abnormal laboratory finding, for 
example), symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product. 
In this study, adverse events will be captured from the time a patient signs the ICF to the 
Follow-up Visit and include the following: 
• Any new sign, symptom, or disease; 
• Any new clinically significant or symptomatic laboratory/diagnostic test 
abnormality; 
• Any clinically significant worsening of laboratory/diagnostic test abnormality; 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 52 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
• Any worsening (ie, clinically significant change in frequency, nature, and/or 
intensity) of a pre-existing condition.  
A pre-existing condition is a condition that is present prior to signing the ICF for the 
study.  Pre-existing conditions, such as illnesses, symptoms, reactions, progression of 
disease states, and other comorbidities, as well as laboratory/diagnostic test 
abnormalities, will be documented in the patient’s record as medical history.  
Signs and symptoms will be reported individually as adverse events (non-serious), unless 
a medical diagnosis was provided.  Medical diagnosis, whenever provided, will be 
reported rather than individual signs and symptoms.   
Any adverse event that satisfies any of the seriousness criteria described below will be 
reported as an SAE using the SAE Report Form, in addition to documenting in the eCRF.  
Serious adverse events that occurred up to 30 days after the last dose of study drug need 
to be documented on an SAE Report Form if they are deemed by the Investigator to be 
“Related” to study drug. 
An SAE that occurred after a period of 30 days from the last dose of study drug must be 
reported when the investigator becomes aware of it and if there is a possible relationship 
to the study drug or the conduct of the study. 
Adverse Event Severity Assessment 
The Investigator will assess the severity (ie, intensity) of each adverse event (serious and 
non-serious) reported during the study based on his/her clinical judgment.  The severity 
of each adverse event will be assigned to one of the following categories: 
Mild: 
Transient, requires no special treatment, is easily tolerated by the 
patient, causes minimal discomfort, and does not interfere with the 
patient’s daily activities 
Moderate: 
Introduces a level of inconvenience or concern to the patient that may 
interfere with daily activities, but usually is ameliorated by simple 
therapeutic measures 
Severe: 
Interrupts a patient’s usual daily activity and requires systemic drug 
therapy or other treatment 
 
Definition of Serious Adverse Events 
An SAE is any untoward medical occurrence that: 
• Results in death; 
• Is life-threatening; 
NOTE:  The term "life-threatening" in the definition of "serious" refers to an 
event in which the patient was at risk of death at the time of the event; it does 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 53 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
not refer to an event which hypothetically might have caused death if it were 
more severe. 
• Requires inpatient hospitalization or prolongation of existing hospitalization; 
• Results in persistent or significant disability/incapacity; or 
• Is a congenital anomaly/birth defect. 
Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in other situations, such as important medical events that may not 
be immediately life-threatening or result in death or hospitalization, but may jeopardize 
the patient or may require intervention to prevent one of the other outcomes listed in the 
definition above.  These are usually considered serious. 
Severe versus Serious Adverse Event 
The term “severe” is used to describe the intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); the event itself, however, may be of 
relatively minor medical significance (such as severe headache).  An adverse event as 
well as an SAE must be assessed for severity.  An adverse event that is assessed as severe 
should not be confused with an SAE.  “Severity” is not the same as “Serious,” which is 
based on patient outcome or reaction criteria usually associated with events that pose a 
threat to a patient’s life or functioning.  Seriousness (not severity) serves as a guide for 
defining regulatory reporting obligations. 
Adverse Event Causality or Relatedness to the Study Drug 
Every effort should be made by the Investigator to explain each adverse event and assess 
its relationship, if any, to study drug.  The Investigator should consider many factors, 
including, but not limited to, temporal association of the event and date/time of study 
drug, duration of study drug, medical/biologic plausibility, pharmacology and adverse 
event profile of study drug, medical history (past medical history, underlying disease, 
comorbidities, intercurrent illness), concomitant medications, medical judgment, 
dechallenge, rechallenge, drug interaction, other plausible causes, etc., to determine the 
causality assessment of an event.   
The Investigator as well as the Sponsor will determine adverse event/SAE causality as 
‘Related’ or ‘Not Related’ to study drug.  Although there is no international consensus on 
how to define ‘Related’ and ‘Not Related,’ in general, an event is considered ‘Related’ if 
there is reasonable possibility that the event is related to study drug rather than to any 
other possible cause(s).  Conversely, an event is considered ‘Not Related’ if there is 
reasonable possibility that the event is related to other factors than the study drug. 
Adverse Event Documentation and Follow-up 
All adverse events, including observed, elicited, or volunteered problems, complaints, or 
symptoms are to be recorded on the adverse event page in the patient’s eCRF from the 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 54 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
time the patient signs the ICF and until the Follow-up Visit/early termination, whether or 
not judged by the Investigator to be related to study drug.  The need to capture this 
information is not dependent upon whether adverse events are related to study drug.  
Serious adverse events that occurred up to 30 days after the last dose of study drug need 
to be documented on an SAE Report Form if they are deemed by the Investigator to be 
“Related” to study drug. 
Each adverse event is to be documented with a verbatim/reported term, start and stop date 
and time, severity, causal relationship to study drug, action taken with study drug, and 
outcome (resolved, resolved with sequelae, resolving, fatal, unknown).  The Investigator 
must review new adverse events and the outcome of ongoing adverse events frequently 
throughout the study.  
In addition to recording all adverse events (serious and non-serious) in the patient’s 
eCRF, all SAEs must also be documented on the SAE Report Form for the study. 
The Investigator will follow all adverse events until they resolve, the Investigator 
assesses them to be stable, or the patient’s participation in the study ends, whichever 
comes first.  In addition, the Investigator will follow all adverse events assessed as related 
to study drug that are ongoing at the time of the patient’s last visit, until they resolve or 
the Investigator assesses them as stable, even if the patient's participation in the study has 
ended.  Resolution of such events is to be documented in the patient’s record as 
appropriate.  
It is anticipated that some patients may undergo procedures and/or experience events that 
are common in the study population under investigation, independent of study therapy.  
Preplanned procedures and procedures (eg, kidney transplant, catheter replacement) or 
events that are independent of study therapy, according to the Investigator’s assessment, 
will be documented as specified in the Safety Management Plan.   
Serious Adverse Event Notification, Documentation, and Reporting 
The Investigator will report an SAE within 24 hours of becoming aware of the event.  An 
SAE Report Form will be completed regardless of relationship to the study drug.  The 
initial report will not be delayed in order to obtain additional information.  Any additional 
information will be reported as a follow-up to the initial report within 24 hours of 
collection. 
Details for reporting and follow-up of SAEs are provided in the ISF. 
In the event of any SAE (other than death) occurring after the last dose of study drug and 
prior to the Follow-up Visit, the patient will be instructed to contact the Investigator or 
designee immediately using the instructions provided on the ICF.   
The Medical Monitor will review reported SAEs and may contact the Investigator 
directly for further information. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 55 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
The Sponsor will comply with the applicable local regulatory requirements related to 
reporting of SAEs to the appropriate regulatory authorities in the countries and regions 
this study is conducted, while the Investigator and designated study personnel will 
comply with the applicable local regulatory requirements related to reporting of SAEs to 
the IRB/IEC and the Sponsor.   
It is the responsibility of the Sponsor or designee to send all regulatory reports to the 
appropriate regulatory authorities.  Adverse events that are serious, related to the study 
drug, and unexpected (per the Investigator’s Brochure) will be reported to the regulatory 
authorities as specified in the Safety Management Plan. 
For regulatory reporting purposes, the Sponsor can upgrade the Investigator’s assessment 
(eg, from not related to related); however, Sponsor cannot downgrade the Investigator’s 
assessment unless the Investigator determines that a re-assessment of causality is 
necessary.  The Medical Monitor will review and comment on any upgrade made to a 
report.  If there is any doubt concerning the relationship between study drug and the 
event, then the relationship should be considered to be related to study drug. 
As applicable, the Sponsor will also notify other participating Investigator(s) of all IND 
Safety Reports to ensure prompt notification of significant new adverse events or risks 
with respect to study drug.  This notification will occur as soon as possible and in 
compliance with country-specific regulations. 
Refer to the Safety Management Plan for further details about SAE reporting and 
processing.  The Medical Monitor should be contacted by study sites requiring additional 
clarification on an SAE. 
6.5.4.2 
Structured Safety Evaluation 
A weekly Structured Safety Evaluation will also be used during the Double-Blind Phase 
to proactively identify and monitor adverse events of special interest. 
The Structured Safety Evaluation will be performed once during the Run-in Period and 
weekly (preferably on Wednesday/Thursday) during the Double-blind Treatment Period.  
The Structured Safety Evaluation will be performed by qualified study staff using a list of 
specific signs/symptoms, including mental status change, falls and gait disturbance.  
6.5.4.3 
Physical Examination 
Physical examinations will include an examination of the heart, lungs, abdomen, 
extremities, and neurological and vascular systems.  Clinically significant abnormalities 
or worsening findings observed after the first dose of study drug will be reported as 
treatment-emergent adverse events (TEAEs).  
6.5.4.4 
Vital Signs 
Vital signs include sitting or semi-recumbent body temperature, heart rate, and blood 
pressure and will be measured prior to start of dialysis.   
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 56 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Measurements will be repeated if a value is out of the reference range due to a technical 
issue, considered abnormal for the patient, or for other medical concerns.  Only the 
repeated measurement will be recorded. 
In the event of a clinically significant change in blood pressure and/or heart rate, the 
Investigator and dialysis staff will evaluate and manage the patient per standard dialysis 
unit practices with knowledge of the patient’s typical blood pressure and heart rate 
excursions. 
Heart rate will be collected at each dialysis; if clinically significant and outside the 
prespecified visits per schedule of events, the heart rate will be recorded on the relevant 
CRF page. 
6.5.4.5 
Electrocardiogram 
The 12-lead ECGs will be obtained prior to the start of dialysis and will be read locally 
by the Investigator or qualified designee.  Electrocardiograms read by a qualified 
designee must be endorsed by the Investigator.  Clinically significant abnormalities or 
worsening findings observed after the first dose of study drug will be reported as 
treatment-emergent adverse events (TEAEs).  
6.5.4.6 
Clinical Laboratory Tests 
Blood samples for clinical laboratory tests including hematology, serum chemistry, and 
serum pregnancy will be taken prior to dialysis and will be analyzed by a central 
laboratory.  The laboratory tests include the following: 
Assessment 
Parameters to be analysed 
Serum Chemistry 
 
Albumin, Alkaline Phosphatase, ALT/SGPT, AST/SGOT, Bilirubin 
(Total), BUN, Calcium, Chloride, Creatinine, Glucose, Phosphorus, 
Potassium, Sodium 
Hematology 
Basophil %, Basophil (Absolute), Eosinophil %, Eosinophil 
(Absolute), Hematocrit, Hemoglobin, Lymphocyte %, Lymphocyte 
(Absolute), MCH, MCHC, MCV, Monocyte %, Monocyte 
(Absolute), Neutrophil %, Neutrophil (Absolute), Platelet, RDW, 
Red Blood Cells, White Blood Cells 
Serum Pregnancy (females of 
childbearing potential only) 
Human chorionic gonadotropin (HCG) 
Processing and shipment of central laboratory samples will be described in the 
Laboratory Manual.  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 57 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
6.5.4.7 
Contraception and Pregnancy 
All females of childbearing potential will have blood samples taken at Screening for 
serum pregnancy testing.  Females are considered to be of childbearing potential unless 
they are:  
• Surgically sterile (ie, tubal ligation, bilateral oophorectomy, and/or 
hysterectomy); or 
• Over 55 years of age and have not had a menstrual period in at least 1 year 
Once they have consented to participate in the study, all women of childbearing potential 
will be counseled on the importance of avoiding pregnancy and on the need to practice 
adequate birth control for the duration of the study, from screening until 7 days after the 
last dose of study drug. 
Medically acceptable methods of birth control include hormonal contraceptives for at 
least 1 cycle of treatment before study enrollment, an intrauterine device, and barrier with 
spermicide.  
Per inclusion criteria, male patients will agree not to donate sperm after the first dose of 
study drug until 7 days after the last dose of study drug, and will agree to use a condom 
with spermicide or abstain from heterosexual intercourse during the study until 7 days 
after the last dose of study drug.  No restrictions are required for a vasectomized male, 
provided his vasectomy was performed ≥4 months prior to dosing. If sexual abstinence is 
chosen by the patient, it must be the preferred and usual lifestyle of the patient and must 
be practiced for the entire duration of the study. 
Women will be counseled to contact the Investigator or his/her staff immediately if 
pregnancy is suspected.  Males will be instructed to report to the Investigator if their 
partner becomes pregnant during the study. 
If a patient becomes pregnant during the Double-blind Treatment Period or Open-label 
Extension Phase or within 7-10 days after the last dose of study drug, the Investigator 
will immediately discontinue the patient from the study and contact the Sponsor or 
designee.  Diligent efforts will be made to determine the outcome for all pregnancies in 
the clinical study.  Information on the status of the mother and the child will be 
forwarded to the Sponsor.  Generally, follow-up will occur within 6 to 8 weeks following 
the estimated delivery date.  Any premature termination of the pregnancy will be 
reported.  Both maternal and paternal exposure will be collected.  For exposure involving 
the female partner of a male patient, the necessary information must be collected from the 
patient while respecting the confidentiality of the partner.  A pregnancy report will be 
completed. 
6.5.5 
Additional Assessments 
The following additional assessments will be collected during the Double-blind and 
Open-label Extension Phases: 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 58 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
• Inflammatory biomarkers 
• Missed dialysis visits 
 
6.5.5.1 
Inflammatory Biomarkers 
Inflammatory biomarkers, such as interleukin (IL)-6, IL-8, and granulocyte 
macrophage-colony stimulating factor will be measured, as defined in the statistical 
analysis plan (SAP).  A blood sample of sufficient volume to provide for replicate assays 
of each biomarker will be collected prior to dialysis per the schedules of events.   
Detailed instructions for biomarker sample collection and processing will be provided in 
the laboratory manual. 
6.5.5.2 
Missed Dialysis Visits 
The number and reason(s) for missed dialysis will be recorded. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 59 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
7.0 
Discussion and Justification of Study Design 
7.1 
Discussion of Study Design and Choice of Control Groups 
The double-blind part of the study was designed to evaluate the efficacy and safety of 
IV CR845 in hemodialysis patients with moderate-to-severe pruritus.  A randomized, 
double-blind design was chosen to minimize bias.  A 12-week duration of treatment was 
selected to demonstrate durability of the efficacy observed in a prior 8-week treatment 
study (ie, Study CR845-CLIN2101) and to further evaluate safety during a longer 
exposure.  The primary efficacy endpoint was determined using the Worst Itching 
Intensity NRS scale, which measures itching intensity over 24 hours.  This scale has been 
validated for this patient population and is identical to the primary efficacy endpoint used 
in the dose-ranging, Phase 2 study, CR845-CLIN2101.   
The open-label part of the study was designed to evaluate the long-term safety of CR845 
0.5 mcg/kg IV administered after each dialysis session (generally 3 times per week for up 
to 52 weeks) in patients who completed the 12-week Double-blind Treatment Period of 
this study.  This design is commonly used in clinical development to obtain long-term 
safety information.  The duration of the study is in accordance with International Council 
for Harmonisation (ICH) and FDA guidance [Guidance for Industry February 2016]. 
7.2 
Selection of Doses in the Study 
The combined safety, pharmacokinetic, and efficacy data from CR845-CLIN2101 
provided the basis for the selection of the dose and dose regimen of CR845 to be used in 
this study.  The lowest dose tested (0.5 mcg/kg IV) appeared to be well tolerated and 
effective at reducing itch intensity over a period of 8 weeks. 
7.3 
Appropriateness of Measurements 
Standard clinical, laboratory, and statistical procedures and methodology will be utilized 
in this study.  The PRO assessments to be used in this study are appropriate. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 60 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
8.0 
Statistical Methods 
8.1 
General Considerations 
This section describes the statistical analysis of efficacy and safety data collected during 
the Double-blind Phase only.  The analysis of safety and efficacy data collected during 
the Open-label Extension Phase will be included in the SAP. 
The SAP will provide a detailed description for the handling of missing data, patient 
eligibility criteria for the analysis, and statistical methodology.  If differences occur 
between analyses of double-blind data described in the SAP and the current protocol, 
those found in the SAP will assume primacy.  In addition, the SAP will provide details 
for the analysis of data collected during the Open-label Extension Phase, including the 
analysis of safety data during exposure to CR845 across both the Double-blind and the 
Open-label Extension Phases. 
Unless otherwise noted, continuous variables will be summarized using number of 
non-missing observations, mean, standard deviation, median, minimum, and maximum; 
categorical variables will be summarized using the frequency count and the percentage of 
patients in each category.  In addition to the descriptive summaries, pertinent data listings 
will be provided.  
All analyses will be performed using SAS® version 9.2 or higher, unless otherwise 
specified. 
8.2 
Determination of Sample Size 
The planned sample size for this study is 350 (175 per treatment group) male and female 
hemodialysis patients with chronic moderate-to-severe pruritus (mean baseline 24-hour 
Worst Itching Intensity NRS score ≥5), randomized at approximately 95 clinical sites.  
The sample size may be increased to 500 patients (250 per treatment group) based on the 
results of a planned unblinded interim assessment conducted when approximately 50% of 
the planned 350 first patients have been randomized and have either completed the 
12-week Double-blind Treatment Period or have discontinued from double-blind 
treatment early.  The planned interim assessment will be conducted by an Independent 
Data Monitoring Committee (IDMC).  Details related to the sample size re-estimation are 
included in Section 8.4.1. 
The sample size calculation is based on results of a completed Phase 2 double-blind, 
placebo-controlled study (CR845-CLIN2101) of CR845 in hemodialysis patients who 
had moderate-to-severe pruritus.  In this study, approximately 30% of patients 
randomized to the placebo group reported ≥3-point improvement from baseline with 
respect to the 24-hour Worst Itching Intensity NRS at the end of treatment (Week 8).  
The proportion of patients who received CR845 and reported a similar improvement in 
itch scores ranged from approximately 60% to 45% (ie, 30% to 15% difference from 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 61 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
placebo), depending on the dose of active study drug (0.5 mcg/kg, 1.0 mcg/kg, 1.5 
mcg/kg).   
Given a sample size of 350 patients (175 per treatment group) and assuming a true 
response rate of 30% for the placebo group and a true response rate of 50% for the 
CR845 group (defining response as an improvement from baseline ≥3 points with respect 
to the Worst Itching Intensity NRS at Week 12), a 2-sided continuity corrected 
Chi-square will have 96% power to detect a treatment difference.  The power of this test 
statistic would be ≥84% for differences from placebo as low as 0.16 (Table 4). 
Table 4. 
Power as a Function of Effect Size (N = 175 per arm) 
Placebo Response 
0.30 
0.30 
0.30 
0.30 
CR845 Response 
0.50 
0.48 
0.46 
0.45 
Odds Ratio 
2.333 
2.154 
1.988 
1.909 
Powera 
96% 
92% 
84% 
79% 
a. 
Power for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error. 
Based on results of a planned interim assessment, the sample size may be increased up to 
500 patients (250 per treatment group).  Given this maximum sample size, and assuming 
a true response rate of 30% in the placebo group, a 2-sided continuity corrected 
Chi-square would have approximately 90% power to detect a treatment difference when 
the CR845 response rate is 45% (a 15% difference from placebo) (Table 5). 
Table 5. 
Sample Size as a Function of Odds Ratio (90% Power) 
Placebo Response 
0.30 
0.30 
0.30 
0.30 
0.30 
CR845 Response 
0.50 
0.48 
0.46 
0.45 
0.44 
Odds Ratio 
2.333 
2.154 
1.988 
1.909 
1.833 
Sample Sizea 
134 
164 
204 
230 
262 
a. 
Sample size for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error. 
8.3 
Randomization  
Before the start of the study, a computer-generated randomization schedule will be 
prepared.  Randomization will be performed using an IVRS/IWRS.  Patients will be 
randomized in a 1:1 ratio to receive either CR845 0.5 mcg/kg IV or matching placebo IV 
during the Double-blind Treatment Period.  Patients will be stratified according to their 
use or non-use of concomitant medications to treat their itch during the week prior to 
randomization (Run-in Period) as well as the presence or absence of specific medical 
conditions.  These medical conditions include: 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072






Cara Therapeutics Inc. 
Confidential 
Page 64 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
The Open-label Safety Population is defined as the group of patients who receive at least 
1 dose of study drug in the Open-label Extension Phase.  The Open-label Safety 
Population will be used to analyze all safety endpoints collected during the Open-label 
Extension Phase, and during exposure to CR845 combining data from both the Double-
blind and the Open-label Extension Phases.  
8.6 
Statistical Summary and Analysis 
8.6.1 
Patient Disposition 
For the Double-blind Phase, the number of patients enrolled, treated, completed, or 
discontinued from the study, along with the reason for discontinuation, will be 
summarized overall and by treatment group.   
For all categories of patients (except for the screened patients), percentages will be 
calculated using the number of enrolled patients as the denominator.  
In addition, the number of patients in each analysis population will be tabulated. 
8.6.2 
Protocol Deviations 
Protocol deviations will be identified in several ways:  through programmatic checks, 
through medical reviews, and by clinical research associates during site monitoring.  
Protocol deviations will be classified as minor or major prior to the database lock.  Major 
protocol deviations will be summarized by treatment group.  All protocol deviations will 
be listed.   
8.6.3 
Demographic and Baseline Characteristics 
Demographic and baseline patient characteristics will be summarized overall and by 
treatment group and will include age at screening, age category (<45, 45 to >65, 65 to 
<75, ≥75), gender, ethnicity, race, and prescription dry body weight (kg).  Height will not 
be collected. 
Baseline characteristics of the disease will also be summarized overall and by treatment 
group, and will include variables such as etiology of chronic kidney disease, years since 
ESRD, duration of pruritus, and time on chronic hemodialysis. 
8.6.4 
Medical History 
Medical history data will be coded using Medical Dictionary for Regulatory Activities 
(MedDRA) and summarized by MedDRA System Organ Class (SOC), Preferred Term, 
and treatment group.  The data will also be listed, including the verbatim investigator 
description of the relevant medical condition, the coded terms (SOC, Preferred Term), 
start date, end date, and whether or not the condition is ongoing. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 65 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
A separate coding listing will be created with all the distinct levels of SOC, Preferred 
Terms, and the verbatim investigator description reported in the study.  Sorting will be 
alphabetically by SOC, Preferred Term, and then verbatim description. 
8.6.5 
Prior and Concomitant Medications 
All medications will be coded using the World Health Organization Drug Dictionary.  All 
prior and concomitant medications will be listed and summarized separately by 
Anatomical Therapeutic Chemical class 3 (ATC 3), Preferred Term, and treatment group.  
The use of medications will be summarized separately by study period.  Additionally, a 
coding listing of unique medications and their corresponding coding will be presented. 
8.6.6 
Antipruritic Medication 
Prior and concomitant antipruritic medications will be summarized separately by study 
period; summaries will be presented by ingredient rather than by ATC codes. 
8.7 
Efficacy Analysis 
8.7.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is defined as the proportion of patients achieving ≥3-point 
improvement from baseline with respect to the weekly mean of the daily 24-hour Worst 
Itching Intensity NRS at Week 12 (Days 79 to 85) of the Double-blind Treatment Period. 
The weekly mean of the 24-hour Worst Itching Intensity NRS score will be defined as the 
sum of the daily Worst Itching Intensity NRS scores reported during a specific week 
during the Double-blind Treatment Period (eg, Days 2 to 8, Days 9 to 15, Days 16 to 22, 
… Days 79 to 85) divided by the number of days with nonmissing scores for that 
week.  If the daily worst itching score is missing for >3 days during a specific week, the 
corresponding weekly mean worst itching score will be set to missing.  The baseline 
score will be defined as the average of the daily 24-hour Worst Itching Intensity NRS 
scores collected over the Run-in Period, including pre-randomization assessments 
collected on Day 1.   
In the primary efficacy analysis, missing NRS data will be imputed using a multiple 
imputation (MI) approach, assuming that patients who discontinue double-blind treatment 
early would have similar Worst Itching Intensity NRS scores as other patients in their 
respective treatment arm that have complete data: 
• Intermittent missing NRS scores will first be imputed using the Markov Chain 
Monte Carlo (MCMC) method implemented with the SAS MI procedure, which is 
appropriate for non-monotonic missing data.  
• NRS scores missing after patients discontinue study drug early will then be 
multiply imputed with the SAS MI procedure using a method appropriate for 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 66 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
monotone missingness (eg, regression statement).  Details on the MI procedure 
can be found in Appendix 14.6. 
• The proportion of patients who have an improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS score 
≥3 points will be calculated for each imputed dataset.  Differences between 
CR845 0.5 mcg/kg and placebo with respect to the primary endpoint will be 
compared using a logistic regression model containing terms for treatment group, 
baseline NRS score, use of prior anti-itch medication, presence of specific 
medical conditions, and country/region.  
• Results of the logistic regression on the multiply imputed data sets will be 
summarized by the SAS MIANALYZE procedure.   
The final p-value will be calculated using the Cui, Hung, Wang (CHW) procedure where 
the z-score is a weighted average of the z-score at the interim and the z-score observed 
for data collected after the interim, following the formula below. 
                   Zfinal=Zinterim * √(n/N) + Zpost-interim * √(1- n/N) 
where n is the number of patients at the interim and N is the initial number of patients 
planned (300). 
Sensitivity analyses of the primary efficacy endpoint will be conducted to evaluate the 
robustness of study results under different assumptions and imputation algorithms.  For 
each of these sensitivity analyses, the final p-value will be calculated based on the CHW 
procedure, using the formula specified above. 
• Sensitivity 1: Early discontinuations as nonresponders  
Patients who discontinue study drug early will be considered nonresponders.  The 
imputed data will be analyzed using a logistic regression model similar to the 
primary analysis.  
• Sensitivity 2: Multiple imputation; missing not at random (MNAR) 
This sensitivity analysis is an implementation of a pattern mixture model that 
draws from different populations based on the reason for withdrawal.   
o Intermittent missing NRS scores will first be imputed using the MCMC 
method with the SAS MI procedure, which is appropriate for non-monotonic 
missing data. 
o For patients who discontinued study drug due to adverse events, NRS scores 
missing after discontinuation will be imputed using the distribution of the 
baseline value of all patients’ daily worst itching score assuming a trimmed 
normal (from 5 to 10).  
o For patients who discontinue due to reasons other than adverse event, missing 
NRS scores after patients discontinue study drug early will be multiply 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 67 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
imputed using multiple calls of the SAS MI procedure using data from 
patients within the same treatment group that have complete data at that time.  
The proportion of patients who have an improvement from baseline with 
respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS 
score ≥3 points will be calculated for each imputed dataset 
o Similar to the primary analysis, results of the logistic regression on the 
multiply imputed data sets will be summarized by the SAS MIANALYZE 
procedure.   
• Sensitivity 3: Tipping point analysis 
Multiple imputation with mixed missing data mechanisms (MNAR for a missing 
data pattern and MAR for others) will be used to assess the robustness of the 
MAR assumption.  This sensitivity analysis is to investigate the departure from 
MAR assumption by progressively decreasing the treatment differences with 
respect to the NRS scores over the missing visits in active treatment group until 
conclusion from the primary analysis is overturned.  The MI procedure includes 
the following steps: 
o Uses MCMC methodology from PROC MI by treatment group to impute the 
intermittent missing data to a monotone missing pattern 
o Uses a standard MAR-based MI approach from PROC MI to impute data from 
monotone missing data 
o For patients in the active treatment group, shift parameter from PROC MI will 
be progressively applied to impute the missing data, until the p-value >0.05 
To evaluate the potential impact of the IA on the properties of statistical inference at the 
end of the trial, the primary and sensitivity analyses of the primary endpoint will also be 
presented separately for the sample of patients enrolled into the study after the IA. 
8.7.2 
Secondary Efficacy Endpoints 
The secondary efficacy endpoints are the: 
• Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12 
(Day 79 to 85) of the Double-blind Treatment Period; 
• Proportion of patients achieving ≥3-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8 
of the Double-blind Treatment Period;  
• Proportion of patients achieving ≥3-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4 
of the Double-blind Treatment Period; 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 68 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
• Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8 
of the Double-blind Treatment Period;  
• Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4 
of the Double-blind Treatment Period; 
• Change from baseline in itch-related quality of life at the end of Week 12 of the 
Double-blind Treatment Period, as assessed by the Skindex-10 Scale total score; 
• Change from baseline in itch-related quality of life at the end of Week 12 of the 
Double-blind Treatment Period, as assessed by the 5-D Itch Scale total score. 
The proportion of patients achieving ≥4-point improvement from baseline at Week 12 of 
the Double-blind Treatment Period, the proportion of patients achieving ≥3-point 
improvement from baseline at Week 8 and Week 4, and the proportion of patients 
achieving ≥4-point improvement from baseline at Week 8 and Week 4 with respect to the 
weekly mean of the daily 24-hour Worst Itching Intensity NRS will be analyzed 
following a methodology similar to the one employed for the primary analysis of the 
primary endpoint. 
• Intermittent missing scores will first be imputed using the Markov Chain Monte 
Carlo (MCMC) method implemented with the SAS MI procedure, which is 
appropriate for non-monotonic missing data;  
• The monotone missing values will then be multiply imputed with the SAS MI 
procedure using the monotone regression method; 
• For each stage, MI will be performed within treatment group with covariates for 
baseline score, region, both randomization stratification factors, and all non-
missing visit scores for each domain of the questionnaire; 
• For each questionnaire, the total score at each visit will be computed from the 
domain scores for each imputed dataset; 
The Skindex-10 Scale total score and the 5-D Itch Scale total score change from baseline 
at Week 12 will be analyzed using an analysis of covariance (ANCOVA) model that will 
contain treatment as fixed effect, with baseline score, region, and the randomization 
stratification variables as covariates.  The baseline 5-D total score and the Skindex-10 
total score will be defined as the value collected on Day 1, prior to randomization.  
For each domain in each questionnaire, missing values at Week 12 will be imputed using 
an MI approach, assuming that patients who discontinue double-blind treatment early 
would have similar domain scores as other patients in their respective treatment arm that 
have complete data: 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 69 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
• The ANCOVA analysis described above will be implemented for each imputed 
dataset. Results of the ANCOVA on the multiply imputed data sets will be 
summarized by the SAS MIANALYZE procedure.  
The LS means, standard errors, 95% CIs, and differences between treatment groups 
reported with LS means, standard errors, and 95% CIs derived from the ANCOVA on the 
imputed datasets will be reported.  
Additionally, a sensitivity analysis of the 5D Itch scale and the Skindex-10 scale will be 
performed to describe the time course of the treatment response over the 12-week 
treatment period using a mixed effects model with repeated measures (MMRM).  The 
model will contain treatment, week, and treatment-by-week interaction as fixed effects; 
baseline score, prior anti-itch medication usage, presence of specific medical conditions, 
and country/region as covariates. Repeated measures will include values collected at the 
end of Weeks 4, 8, 10, and 12 (end of treatment). It is important to note that, in HD 
patients, the study drug administered during the last dialysis of a particular week is not 
cleared until the first dialysis of the next week.  Therefore, measurements that would 
reflect treatment effect at the end of a specific week (eg. Week 4) will actually be 
collected during the first day of the next week (eg, Week 5). 
An unstructured covariance matrix will be used to model the within-subject errors. 
Should the model fail to converge, a compound symmetric covariance matrix will be used 
instead. The Kenward-Roger approximation will be used to estimate the denominator 
degrees of freedom. Missing scores will not be imputed. Assuming that the data are 
MAR, the estimates of the treatment differences calculated from the MMRM described 
above are unbiased. 
Standard descriptive statistics will be reported for each time point on the values and 
changes from baseline along with the least squares (LS) means, standard errors, 95% CIs 
and differences between treatment groups reported with LS means, standard errors, and 
95% CIs. 
8.7.3 
Hypothesis Testing Strategy 
The efficacy of CR845 0.5 mcg/kg compared to placebo in pivotal Phase 3 study 
CLIN3103 will be evaluated based on 1 primary and 7 secondary efficacy endpoints.  
Testing of the primary efficacy endpoint will be 2-sided and conducted at the 5% error 
level.  The study will be considered positive if the null hypothesis of no treatment 
difference in the primary efficacy analysis of the primary endpoint (proportion of patients 
achieving ≥3-point improvement from baseline with respect to the Worst Itching Intensity 
NRS) is rejected in favor of the alternative that patients randomized to CR845 experience 
significantly less itching compared to patients randomized to placebo.  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 70 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
• Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12 
of the Double-blind Treatment Period;  
• Proportion of patients achieving ≥3-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8 
of the Double-blind Treatment Period;  
• Proportion of patients achieving ≥3-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4 
of the Double-blind Treatment Period;  
• Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8 
of the Double-blind Treatment Period;  
• Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4 
of the Double-blind Treatment Period;  
• Change from baseline in Skindex-10 Scale total score at Week 12 of the Double-
blind Treatment Period; 
• Change from baseline in 5-D Itch Scale total score at Week 12 of the Double-
blind Treatment Period. 
8.7.4 
Additional Efficacy Endpoints 
8.7.4.1 
Itch-intensity Measures 
• Proportion of patients who have an improvement from baseline at Week 12 of the 
Double-blind period with respect to the weekly mean of the 24-hour Worst 
Itching Intensity NRS scores ≥1 and ≥2.  The calculation of the proportions will 
be based on the NRS data using a multiple imputation (MI) approach for the 
missing data as in the primary efficacy analysis.  A figure presenting the 
proportion of patients who have an improvement from baseline in NRS scores at 
Week 12 that is ≥1, ≥2, ≥3, and ≥4 will be prepared.  
• Change from baseline in the weekly mean of the 24-hour Worst Itching Intensity 
NRS score at each week of the Double-blind Treatment Period (Week 1 to 
To protect the Type 1 error, a gate-keeping strategy will be implemented.  Although the p 
values corresponding to the hypothesis testing of the secondary variables will be 
reported, they will only be considered inferential if the primary analysis is statistically 
significant.  Testing of the secondary efficacy endpoints will be performed sequentially at 
a 2-sided 5% error level in the order specified below. If the test of an endpoint in the 
sequence is not statistically significant, the p-value for the tests corresponding to the 
remaining endpoints in the sequence will not be considered inferential and the null 
hypotheses for the subsequent tests will not be rejected.   
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 71 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Week 12).  Treatment differences between CR845 and placebo at each 
postbaseline time point will be evaluated using the same MMRM detailed in 
Section 8.7.2. 
• Proportion of patients who rate their itch condition as “Very much improved” or 
“Much Improved” at the end of Week 12 of the Double-blind Treatment 
Period/end of double-blind treatment, as measured by the Patient Global 
Impression of Change.  Treatment difference will be tested using the Cochran-
Mantel-Haenszel test, adjusting for strata.  An exact test, such as the Fisher’s 
Exact Test, may be used if the observed count in a particular cell is small (ie, <5). 
8.7.4.2 
Itch-related Quality-of-Life Measures 
Itch-related quality-of-life measures and their analyses will include: 
• Change from baseline in itch-related quality of life at each week of the 
Double-blind Treatment Period, as assessed by the 5-D Itch Scale total score.  
Treatment differences between CR845 and placebo at each postbaseline time 
point will be evaluated using the same MMRM fitted for the secondary efficacy 
analysis. 
• Change from baseline in itch-related quality-of-life at each week of the 
Double-blind Treatment Period, as assessed by the Skindex-10 Scale total score.  
Treatment differences between CR845 and placebo at each postbaseline time 
point will be evaluated using the same MMRM fitted for the secondary efficacy 
analysis. 
• Change from baseline in itch-related quality of life at Week 12 of the 
Double-blind Treatment Period and at each of the remaining weeks of the 
Double-blind Treatment Period with respect to each of the 3 domains of the 
Skindex-10 Scale.  Treatment differences with respect to each domain will be 
evaluated using a model similar to the MMRM fitted for the analysis of the 
change from baseline in the overall Skindex-10 Scale score (Section 8.7.2). 
8.8 
Safety Analysis 
Analysis of all safety data collected during the Double-blind Phase will be performed on 
the Double-blind Safety Population.  The SAP will provide further detail for the analyses 
to be applied to each safety parameter, and will also include analyses of safety data 
collected during the Open-label Extension Phase and during exposure to CR845 during 
both the Double-blind and Open-label Extension Phases.  No statistical hypothesis testing 
will be carried out and no inferential statistical analysis of the safety parameters will be 
performed.  
The baseline value for all analyses of double-blind safety parameters will be defined as 
the last value obtained prior to the first dose of double-blind study drug and will include 
both scheduled and repeat (unscheduled) observations.  
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 72 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
8.8.1 
Exposure to Study Drug 
For this study, the duration of double-blind treatment for each individual patient may be 
up to 12 weeks, for a total of approximately 36 doses of study drug administered 
immediately following each dialysis session.  Day 1 of the Double-blind Treatment 
Period will be defined as the day of administration of the first dose of study drug.  The 
last day of the Double-blind Treatment Period will be defined as the day of the dialysis 
session immediately following the last injection of study drug. 
Exposure and treatment compliance during the Double-blind Treatment Period will be 
summarized by the following parameters: 
• Duration of treatment (days) 
• Total number of doses actually received  
• Number of missed doses 
Duration of treatment (days) = (date of first dialysis after last dose) – (date of first dose) 
+ 1. 
If a patient receives additional dialysis during a given week for any reason, an additional 
dose of CR845 will be administered following dialysis.  A maximum of 4 doses per week 
is allowed.  No additional doses will be given for patients receiving an additional 
unscheduled ultrafiltration treatment.  The number of patients getting such an extra 
treatment will be summarized. 
8.8.2 
Adverse Events 
All adverse events, as reported by the site, will be coded using MedDRA to MedDRA 
SOC and Preferred Term for standardization and summary purposes.   
All reported adverse events (whether or not treatment-emergent) will be included in a 
by-patient adverse event listing.  Only TEAEs will be included in summary tables which 
will present results by treatment group and by study period, as appropriate.   
Adverse events that are considered “treatment emergent” relative to the Run-in Period are 
identified as any adverse event with an onset date after the start of the Run-in Period and 
up to the first dose of study drug during the Double-blind Period. 
Adverse events that are considered “treatment emergent” relative to the Double-blind 
Period are identified as any adverse event  
• with an onset date after the first dose of the double-blind study drug up to the 
Follow-up Visit or Early Termination Visit (or 7 to 10 days after the last dose if 
no Early Termination Visit was conducted), whichever is later, for patients who 
do not enter the Open-label Extension Phase. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 73 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
• with an onset date after the first dose of the double-blind study drug up to the first 
dose of open-label drug for patient who continue into the Open-label Extension 
Phase.  
The number and percentage of patients experiencing TEAEs will be summarized by 
treatment group and by period.  A patient will be counted only once in the incidence 
count for a MedDRA SOC or Preferred Term, although a patient may have multiple 
occurrences (start and stop) of an event associated with a specific MedDRA Preferred 
Term or SOC.  The most frequent TEAEs (≥5% of patients in any treatment group) will 
also be tabulated by SOC and Preferred Term. 
The incidence and percentage of patients experiencing treatment-emergent SAEs and 
TEAEs leading to study discontinuation will be presented by the appropriate MedDRA 
SOC and Preferred Term.  Adverse events that result in death will also be summarized. 
Treatment-emergent adverse events will also be summarized by severity for each study 
period of the Double-blind Phase and by relationship to double-blind study drug for the 
Double-blind Period.  If the severity and/or relationship to the study drug of an adverse 
event is missing, a worst-case scenario will be assumed (ie, the adverse event will be 
categorized as “severe” and/or “related” to the study drug).  If a patient reports the same 
TEAE multiple times the event with the worst severity and the strongest relationship to 
study drug will be tabulated. 
For each period of the Double-blind Phase, an overall summary table will be provided, 
presenting for each treatment group:  the number and percentage of patients with an 
adverse event (both treatment and non-treatment emergent) during that period, a TEAE, 
serious TEAE, related TEAE, severe TEAE, TEAE leading to dose interruption, and 
TEAE leading to study drug discontinuation.  This table will also include the number of 
events for each specific Preferred Term.  
All adverse events will be listed in chronological order, including patient identifier, age, 
race, gender, a flag indicating whether the event was treatment-emergent, and all related 
event status information (start and stop dates, whether the event was ongoing, study day 
of onset, severity, seriousness, relationship to study medication, action taken with study 
treatment, and outcome).  Separate listings will be generated for SAEs, deaths, and 
adverse events leading to study drug discontinuation.  Additionally, a coding list of 
Preferred Terms and the verbatim text associated with them will be produced. 
8.8.3 
Clinical Laboratory Evaluations 
Summary statistics for each scheduled time point measured and mean changes from 
baseline to each time point (when applicable) will be presented for clinical laboratory 
results.   
All laboratory evaluation summaries will include the patients in the Double-blind Safety 
Population who have at least 1 postbaseline time point (for criteria based on postbaseline 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 74 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
assessments) and with both a baseline and at least 1 postbaseline time point (for criteria 
evaluating changes from baseline). 
Laboratory values will be reported in Système International units.   
Laboratory test results will be assigned an L/N/H classification according to whether the 
value was below (L), within (N), or above (H) the laboratory parameter’s reference range.  
Comparisons will be based on 3×3 tables (shift tables) that, for a particular laboratory 
test, compare the baseline L/N/H classification to the highest and/or lowest L/N/H 
classification during the treatment period.  Clinically important laboratory values based 
on prespecified criteria defined in the SAP will also be summarized. 
Additionally, alanine aminotransferase, aspartate aminotransferase, bilirubin, and alkaline 
phosphatase will be presented in a separate listing, with 3× and 5×ULN flagged for 
alanine aminotransferase and aspartate aminotransferase; 2×ULN flagged for bilirubin, 
and 1.5×ULN flagged for alkaline phosphatase. 
8.8.4 
Vital Signs and ECGs 
Summary tables will include descriptive statistics for baseline and each postbaseline 
assessment.  Descriptive statistics will be calculated on both the actual score and the 
change from baseline score.  Baseline is defined as the last measurement taken on or prior 
to the first day of dosing.  Note that the Day 1 assessment can be included in the 
evaluation of baseline if that the assessment is performed prior to dosing.  
All vital sign summaries will include the patients in the Double-blind Safety Population 
who have at least a postbaseline time point (for criteria based on postbaseline 
assessments) and with both a baseline and at least 1 postbaseline time point (for criteria 
evaluating changes from baseline). 
Clinically notable vital signs will be identified based on the criteria defined in the SAP.  
For each vital sign parameter, the number and percentage of patients with at least 1 
notable value will be tabulated by week and overall for the Double-blind Phase. 
All vital signs will be listed in by-patient listings, including visit and collection date/time, 
and will be sorted by patient identifier and date/time of assessment.   
Electrocardiogram results include an overall interpretation of ‘normal,’ ‘abnormal but not 
clinically significant,’ or ‘abnormal and clinically significant.’  These results will be 
tabulated at each time point.   
Electrocardiogram results will be listed for each visit, including visit, whether ECG was 
performed (yes/no), explanation (if not performed), assessment date/time, study date, 
overall interpretation, and relevant medical history number or adverse event number, if 
deemed a clinically significant abnormality. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 75 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
8.9 
Additional Analyses 
8.9.1 
Inflammatory Biomarkers  
The observed value and the change in inflammatory biomarkers (eg, IL-6, IL-8, and 
granulocyte macrophage-colony stimulating factor) from pre-dose to the end of the 
Double-blind Treatment Period (Week 12) will be presented by treatment group.  
Univariate and multivariate analyses of the change in inflammatory biomarkers will be 
described in an analysis plan, separate from the study SAP. 
8.9.2 
Missed Dialysis Visits and Incidence of Infection  
The number and percentage of patients who missed 1 or more dialysis visits during the 
Double-blind Treatment Period, and the total number of missed dialyses visits will be 
tabulated overall and by treatment group.   
Incidence of infections based on adverse events, hospitalizations, and/or use of antibiotics 
for treatment of infection related to uremic pruritus will be analyzed using Fisher’s Exact 
Test.   
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 76 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
9.0 
Quality Control and Quality Assurance 
9.1 
Study Monitoring Plan 
Monitoring and auditing procedures that comply with current Good Clinical Practice 
(GCP) guidelines will be followed, including remote and onsite review of the eCRFs via 
an electronic data capture system for completeness and clarity, source document 
verification, evaluation of protocol adherence, appropriate documentation of informed 
consent procedures, safety reporting, study drug storage, and dispensation.  The study 
will be monitored by the Sponsor or its designee (contract research organization).  
Monitoring will be performed by a representative of the Sponsor or its designee (site 
monitor) who will review patient enrollment, eCRFs, source documents, drug 
accountability records, and reporting and recording of adverse events.  The site monitor 
will ensure that the investigation is conducted according to protocol design and 
regulatory requirements by frequent site visits and communications (letter, telephone, and 
facsimile). 
The site monitor(s) will follow written standard operating procedures as agreed with the 
contract research organization and the Sponsor.  The site monitor(s) will verify that the 
clinical study is conducted and data are generated, documented (recorded), and reported 
in compliance with the protocol, GCP, and the applicable regulatory requirements.  
Monitoring reports will be submitted to the Sponsor in a timely fashion as per details 
described in a clinical monitoring plan for this study. 
Name and contact information for monitors will be included in the ISF. 
9.2 
Audits and Inspections 
The investigational site will maintain appropriate medical and research records for this 
study, in compliance with ICH-GCP, regulatory, and institutional requirements for the 
protection of confidentiality of participants.  The Investigator must allow access to 
authorized persons or institutions to complete data source verification.  Source data are 
all information, original records of clinical findings, observations, or other activities in a 
clinical study necessary for the reconstruction and evaluation of the study.  Examples of 
these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, participants’ diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, 
copies or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and 
participant files and records kept at the pharmacy, laboratories, or medical-technical 
departments involved in the clinical study, as applicable.  
The investigational site will provide access to all study-related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by the Sponsor 
and inspection by local and regulatory authorities. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 77 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
9.3 
Data Collection, Validation, and Analysis 
A data management vendor will ensure that quality assurance procedures are 
implemented, beginning with the data entry system and generation of data quality control 
checks that will be run on the database.   
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 78 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
10.0 
Ethics and Regulatory Compliance 
10.1 
Independent Ethics Committee or Institutional Review Board 
A properly constituted, valid IRB or IEC and the national regulatory authority, if required 
by the applicable laws in the county, must review and approve the protocol, the 
Investigator’s Brochure, ICF, and related patient information and recruitment materials 
(if applicable) before the start of the study.  It is the responsibility of the Investigator to 
ensure that written informed consent is obtained from the patient before any activity or 
procedure is undertaken that is not part of routine care. 
The IRB/IEC will review all appropriate study documentation in order to safeguard the 
rights, safety, and well-being of the patients.  The study will only be conducted at a site 
where IRB/IEC approval has been obtained.   
If it is necessary to amend the protocol and/or ICF during the course of the study, the 
Investigator must ensure that the IRB/IEC and the national regulatory authority, if 
required by the applicable laws in the country, reviews and approves these amended 
documents.  Except for changes necessary to eliminate an immediate hazard to study 
patients, or when the change involves only logistical or administrative aspects of the 
study (eg, change in monitor, change of telephone number), no amendments to the study 
protocol will be made without the prior written agreement of the Sponsor and 
acknowledgement by the Investigator and, as applicable, the IRB/IEC and the national 
regulatory authority, if required by the applicable laws in the country.  
The Investigator(s) will maintain documentation of the composition of the IRB/IEC as 
well as all correspondence with the IRB/IEC.  The Investigator(s) will comply with local 
requirements for routine reporting to the IRB/IEC as well as local and government 
requirements for notifying the IRB/IEC of SAEs.  The Investigator will provide the 
Sponsor or its designee copies of all IRB/IEC approval notices, correspondence, annual 
reports, and final study progress reports. 
10.2 
Ethical Conduct of the Study 
The study will be conducted in accordance with the provisions of the Declaration of 
Helsinki (October 2013), FDA (CFR, Sections 312.50 and 312.56), EU (536/2014) and 
UK regulations (The Medicines for Human Use [Clinical Trials] Regulations 2004 
[No.1031]), ICH GCP (CPMP 135/95), and with the applicable regulations of the 
countries in which the study is conducted. 
The Investigator will be thoroughly familiar with the appropriate use of the study drug as 
described in the protocol, Investigator’s Brochure, and any other study-related manual(s).  
Essential clinical documents will be maintained to demonstrate the validity of the study 
and the integrity of the data collected.  A study master file must be established for the 
study, and retained according to the appropriate regulations. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 79 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
10.3 
Informed Consent Process 
Informed consent is required for all patients participating in this study.  The patient signs 
one informed consent for both the Double-blind Phase and the Open-label Extension 
Phase of the study. In obtaining and documenting informed consent, the Investigator must 
comply with applicable regulatory requirements and must adhere to GCP regulations.  It 
is the responsibility of the Investigator to ensure that written informed consent is obtained 
from the patient before any activity or procedure is undertaken that is not part of routine 
care. 
Informed consent is a process that is initiated prior to the individual’s agreeing to 
participate in the study and that continues throughout the individual’s study participation.  
The Investigator or designee will discuss extensively with the participant patient the 
study risks.  Copies of the current, IRB/IEC-approved ICF detailing the risks and benefits 
of study participation will be provided to the participants.  Consent forms describing in 
detail the study drug and study procedures/intervention and risks will be fully explained 
to the patient and written documentation of informed consent will be required prior to 
starting participation in the study.  Upon reviewing the document, the Investigator or 
designee will explain the research study to the participant and answer any questions that 
may arise.  The participants will sign the ICF prior to any procedures being performed 
specifically for the study.  The participants should have sufficient opportunity to discuss 
the study and process the information in the consent process prior to agreeing to 
participate.  The participants may withdraw consent at any time throughout the course of 
the study.  A signed copy of the ICF will be given to the participants for their records. 
Participants must be re-consented to the most current version of the ICF during their 
participation in the study. 
10.4 
Patient Confidentiality 
In order to maintain patient privacy, all eCRFs, study drug accountability records, study 
reports, and communications will identify the patient by assigned patient number.  The 
Investigator will grant monitor(s) and auditor(s) from the Sponsor or its designee and 
regulatory authority(ies) access to the patient’s original medical records for verification 
of data gathered on the eCRFs and to audit the data collection process.  The patient’s 
confidentiality will be maintained and will not be made publicly available to the extent 
permitted by the applicable laws and regulations. 
Participant confidentiality is strictly held in trust by the participating Investigators, their 
staff, and the Sponsor(s) and their agents.  This confidentiality is extended to cover 
testing of biological samples and genetic tests in addition to the clinical information 
relating to participating patients. 
The study protocol, documentation, data, and all other information generated will be held 
in strict confidence.  No information concerning the study or the data will be released to 
any unauthorized third party without prior written approval of the Sponsor. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 80 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
The study monitor or other authorized representatives of the Sponsor may inspect all 
documents and records required to be maintained by the Investigator, including, but not 
limited to, medical records (office, clinic, or hospital) and pharmacy records for the 
participants in this study. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 81 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
11.0 
Data Handling and Quality Assurance 
All participant data relating to the study will be recorded on eCRFs unless transmitted to 
the Sponsor or designee electronically (eg, laboratory data).  No data are to be recorded 
directly in the eCRFs (eg, all data will have a unique source).  The Investigator is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the eCRF. 
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
The Investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
The Sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH-GCP, and all applicable regulatory requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator for 2 years after the marketing approval of the study 
drug or after discontinuing clinical development unless local regulations or institutional 
policies require a longer retention period.  No records may be destroyed during the 
retention period without the written approval of the Sponsor.  No records may be 
transferred to another location or party without written notification to the Sponsor.  If the 
Investigator withdraws from the responsibility of keeping the study records, custody must 
be transferred to a person willing to accept the responsibility.  If a custodial change or a 
change in record location occurs, the Sponsor must be notified in writing. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 82 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
12.0 
Administrative Procedures 
12.1 
Protocol Adherence 
It is vital to the success of the study that the Investigator adhere to the details of the 
protocol, and thus to keep to a minimum the number of cases later classified as 
“incomplete,” “unusable,” or “not evaluable.”  If, in the interest of safety and/or 
well-being of a particular patient, it is necessary to depart from the protocol, then that 
protocol deviation will pertain to that individual patient only and will be documented.  
Protocol deviations due to lack of patient compliance must also be documented.   
The site monitor will review protocol deviations throughout the course of monitoring 
visits and document new findings of deviations.  The monitor will notify the Investigators 
of deviations verbally or in writing.  The IRB/IEC should be notified of all protocol 
deviations in a timely manner according to IRB/IEC requirements. 
12.2 
Publication of Study Findings 
All information regarding CR845 provided by Sponsor to the Investigator is privileged 
and confidential information.  By conducting this study, the Investigator affirms to the 
Sponsor that he/she will maintain, in strict confidence, information furnished by the 
Sponsor, including data generated from this study, except as exempted for regulatory 
purposes.  All data generated during the conduct of this study are owned by Sponsor.  
The Investigator agrees to use the information to conduct the study and will not use it for 
other purposes without written permission from Sponsor.  Partial or full data or results 
from this study cannot be published without express written consent from Sponsor.  It is 
understood that there is an obligation to provide Sponsor with complete data obtained 
during the study.  The information obtained from the clinical study will be used toward 
the development of CR845 and may be disclosed to regulatory authority, other 
Investigators, corporate partners, or consultants, as required. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 83 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
13.0 
References 
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical 
trials. Biometrics. 1999;55(3):853-7. 
Criteria Committee of the New York Heart Association. Nomenclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. Edition Number 9. Little, Brown & 
Co; Boston, Mass: 1994. pp. 253–6. 
Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical 
trials: IMMPACT recommendations. Pain. 2005;113(1-2):9–19. 
Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus.  
Br J Dermatol. 2010;162(3):587-93. 
Guidance for Industry. Determining the extent of safety data collection needed in late-
stage premarket and postapproval clinical investigations. US Department of Health and 
Human Services, Food and Drug Administration, Center for Drug Evaluation and 
Research (CDER), Center for Biologics Evaluation and Research (CBER). February 
2016. 
Investigator’s Brochure. CR845 (Difelikefalin). Edition Number 8. 7 November 2017. 
Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the 
pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 
2006;21(3):749-55. 
Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a 
novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 
337 haemodialysis patients:  a Phase III, randomized, double-blind, placebo-controlled 
study. NDT. 2010;25(4):1251-7. 
Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in 
hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8):1410-9. 
Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus-new perspectives and 
insights from recent trials. Nephrol Dial Transplant. 2002;17(9):1558-63. 
Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic 
pruritus in chronic hemodialysis patients. Kidney Int. 2006;69(9):1626-32. 
Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. 
Am J Kidney Dis. 2007;50(1):11-20. 
Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on 
validity and reliability of the visual analogue scale, numerical rating scale and verbal 
rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-7. 
Pisoni RL, Wikstrom B, Elder SJ, et al.  Pruritus in haemodialysis patients: International 
results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial 
Transplant. 2006;21(12):3495-505. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 84 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
Ständer S, Augustin M, Reich A, et al. Pruritus Assessment in clinical trials: consensus 
recommendations from the International Forum for the Study of Itch (IFSI) Special 
Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93(5):509-14. 
Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J 
Dermatol. 2011;165(1):5-17. 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 85 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
14.0 
Appendix 
14.1 
Appendix 1:  New York Heart Association Classification of Heart 
Failure 
 
[Criteria Committee of the New York Heart Association 1994] 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 86 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
14.2 
Appendix 2:  Worst Itching Intensity Numerical Rating Scale 
(NRS) 
This is a representation of the content of the instrument to be used.  Please refer to the 
Study Reference Manual for the instrument to be administered to patients and 
instructions. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 87 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
14.3 
Appendix 3:  Skindex-10 Scale 
This is a representation of the content of the instrument to be used.  Please refer to the 
Study Reference Manual for the instrument to be administered to patients and 
instructions. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 88 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
14.4 
Appendix 4:  5-D Itch Scale 
This is a representation of the content of the instrument to be used.  Please refer to the 
Study Reference Manual for the instrument to be administered to patients and 
instructions. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 89 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 90 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
14.5 
Appendix 5:  Patient Global Impression of Change 
This is a representation of the content of the instrument to be used.  Please refer to the 
Study Reference Manual for the instrument to be administered to patients and 
instructions. 
 
 
 
 
 
 
 
 
 
 
 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 91 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
14.6 
Statistical Appendix 
This appendix provides further details related to the treatment of missing data for the 
primary and sensitivity analyses of the primary endpoint. 
For multiple imputations and other instances where random seeds are required, the values 
used (in order) are: 
8392857 
2985729 
1843255 
9086284 
5547484 
8017456 
9597295  
2252256 
4821871 
9852467 
5126715 
3232132 
9841654 
3645284 
1587345 
Note that not all seeds may be required in programming the multiple imputations.  If 
additional seeds are needed, they will be chosen by adding 1 to each of the values above, 
again using them in order. 
The number of imputations for the multiple imputations will be 20.  
For the primary analysis, a multi-stage process will be applied: 
Stage 1: Subjects will have their 11-point NRS scores imputed.  First, using all visits, 
intermittent missing data will be imputed using the Markov Chain Monte Carlo (MCMC) 
method implemented with the SAS MI procedure; data imputed following subject 
discontinuation via this process will be censored out of the resulting dataset so that only 
intermittent missing data is imputed via this method.  Second, monotone missing data 
will be imputed following subject discontinuation using SAS proc MI.  For each stage, 
MI will be performed within treatment group with covariates for baseline NRS score, use 
of prior anti-itch medication, and presence of select medical conditions.  Should 
convergence issues occur due to small cell size for the one or both of the categorical 
covariates at either stage, the appropriate covariate(s) will be removed from the model. 
Stage 2: Using the resulting complete datasets, the change from baseline with respect to 
the 11-point NRS will be calculated; patients will be categorized as responder if they 
have a 3-point (or greater) improvement over baseline.  Week 12 values will serve as the 
primary timepoint.  The 20 MI runs will be analyzed independently using a logistic 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072


Cara Therapeutics Inc. 
Confidential 
Page 92 of 92 
CR845-CLIN3103 
 
 
10 September 2019 
 
Version 2.2 
 
 
model and the results combined using SAS proc MIANALYZE.  Logistic model 
covariates will include treatment, baseline NRS score, use of prior anti-itch medication, 
and presence of select medical conditions.  As with the MI, should convergence issues 
occur due to small cell sizes, the appropriate categorical covariate(s) will be dropped as 
necessary. 
Should a sample size increase occur, the above process will be implemented completely 
independently among subjects contributing the interim results and those following the 
interim analysis.  
For the tipping point analysis, a shift parameter will be applied to only subjects in the 
active group, running from 0 to 5 points in 0.25-point increments or until the conclusions 
of the analysis “tip” and the results are no longer significant.  This analysis will not be 
performed should the initial primary results fail to achieve significance. 
 
Cara Therapeutics, Inc., CR845
IND 123140, SN 0072

SAP_001.pdf: 
Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 1 of 60 
 
 
STATISTICAL ANALYSIS PLAN  
PERIOD: DOUBLE-BLIND 
09 March 2020 Final 1.1 
 
 
 
 
 
 A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 
PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND 
EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS 
WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK 
OPEN-LABEL EXTENSION 
 
 
 
PROTOCOL NUMBER CR845-CLIN3103 
 
 
 
 
 
SPONSORED BY 
 
Cara Therapeutics, Inc. 
4 Stamford Plaza 
Stamford, CT 06902 
(203) 406-3700 
 
 
PREPARED BY 
 
Rho, Inc. 
6330 Quadrangle Drive, Suite 500 
Chapel Hill, NC 27517 
Telephone: (919) 408-8000 
Fax: (919) 408-0999 
 
 
 
This document is confidential and proprietary to Cara Therapeutics. Acceptance of this document constitutes 
agreement by the recipient that no unpublished information contained herein will be reproduced, published, 
or otherwise disclosed without the prior written approval of Cara Therapeutics, except that this document 
may be disclosed to appropriate Institutional Review Boards under the condition that they keep the 
information confidential. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 2 of 60 
DOCUMENT VERSION CONTROL 
 
Version 
Number 
Date 
Comments/Changes 
Final 1.0 
10 September 
2019 
 
Final 1.1 
09 March 
2020 
 Sensitivity analyses added for 5-D and Skindex 
 K-M plots and SMQ analyses removed 
 Correction to potassium normal range and hemoglobin 
units 
 Added AE analyses by region and dialysis type 
 Added WI-NRS analyses by region and dialysis type 
 Minor edits and clarifications around AE analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 






Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 5 of 60 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS ............................................................................................ 7 
LIST OF IN-TEXT TABLES ............................................................................................. 8 
1. 
PURPOSE OF THE ANALYSES .............................................................................. 9 
2. 
PROTOCOL SUMMARY ........................................................................................ 10 
2.1 
Study Objectives ......................................................................................... 10 
2.1.1 
Primary Objective .............................................................................. 10 
2.1.2 
Secondary Objectives ........................................................................ 10 
2.2 
Overall Study Design and Plan ................................................................... 10 
2.2.1 
Double-blind Phase ........................................................................... 10 
2.2.2 
Open-label Treatment Period (Extension Phase) ............................... 12 
2.3 
Study Population ......................................................................................... 12 
2.4 
Treatment Regimens................................................................................... 12 
2.5 
Treatment Group Assignments or Randomization ....................................... 12 
2.6 
Sample Size Determination ......................................................................... 12 
3. 
GENERAL ANALYSIS AND REPORTING CONVENTIONS.................................. 14 
3.1 
Assessment Time Windows ........................................................................ 15 
4. 
ANALYSIS POPULATIONS ................................................................................... 16 
4.1 
Enrolled Population ..................................................................................... 16 
4.2 
Intent-to-treat Population ............................................................................. 16 
4.3 
Double-blind Safety Population ................................................................... 16 
4.4 
Per Protocol Population .............................................................................. 16 
5. 
STUDY SUBJECTS ............................................................................................... 18 
5.1 
Disposition of Subjects ................................................................................ 18 
5.2 
Protocol Deviations ..................................................................................... 19 
6. 
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ......................... 20 
6.1 
Demographic Characteristics ...................................................................... 20 
6.2 
Baseline Disease Characteristics ................................................................ 20 
6.3 
Medical History ........................................................................................... 21 
6.4 
Prior and Concomitant Medications ............................................................. 21 
6.4.1 
Prior Medication ................................................................................. 22 
6.4.2 
Concomitant Medication .................................................................... 22 
6.4.3 
Anti-Itch Medication ........................................................................... 22 
7. 
STUDY DRUG EXPOSURE AND TREATMENT COMPLIANCE ........................... 23 
8. 
EFFICACY EVALUATION ..................................................................................... 24 
8.1 
Overview of Efficacy Analysis Issues .......................................................... 24 
8.1.1 
Handling of Dropouts or Missing Data ................................................ 24 
8.1.2 
Multicenter Studies ............................................................................ 24 
8.1.3 
Multiplicity Handling ........................................................................... 24 
8.1.4 
Region Covariate ............................................................................... 25 
8.2 
Efficacy Variables ....................................................................................... 25 
8.2.1 
Primary Efficacy Endpoint .................................................................. 28 
8.2.2 
Primary Efficacy Analysis ................................................................... 28 
8.2.3 
Sensitivity Analyses ........................................................................... 30 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 6 of 60 
8.2.4 
Key Secondary Endpoints .................................................................. 32 
8.2.4.1 
5-D Itch Scale ....................................................................... 32 
8.2.4.2 
Skindex-10 Scale .................................................................. 33 
8.2.4.3 
Key Secondary Analyses ...................................................... 33 
8.2.5 
Other Efficacy Endpoints ................................................................... 37 
8.2.5.1 
Itch Intensity Measures ......................................................... 37 
8.2.5.2 
Itch-related Quality-of-Life Measures .................................... 39 
8.2.5.3 
Patient Global Impression of Change .................................... 39 
9. 
SAFETY EVALUATION ......................................................................................... 40 
9.1 
Overview of Safety Analysis Methods ......................................................... 40 
9.2 
Adverse Events ........................................................................................... 40 
9.3 
Deaths, Serious Adverse Events, and Other Significant Adverse Events .... 43 
9.4 
Clinical Laboratory Evaluation ..................................................................... 43 
9.5 
Vital Signs, and ECG .................................................................................. 44 
9.5.1 
Vital Signs .......................................................................................... 44 
9.5.2 
12-Lead ECGs ................................................................................... 45 
10. OTHER ANALYSES .............................................................................................. 46 
10.1 
Inflammatory Biomarkers ............................................................................ 46 
10.2 
Incidence of Infections Related to Uremic Pruritus ...................................... 46 
10.3 
Hospitalizations, Emergency Department Encounters ................................. 46 
11. INTERIM ANALYSES AND DATA MONITORING ................................................. 47 
11.1 
Sample Size Re-estimation ......................................................................... 47 
11.2 
DSMB ......................................................................................................... 48 
12. CHANGES TO THE ANALYSES PLANNED IN THE PROTOCOL ........................ 49 
13. RANDOM SEEDS FOR MULTIPLE IMPUTATION ................................................ 50 
14. SAMPLE SAS CODE ............................................................................................. 51 
15. REFERENCES ....................................................................................................... 52 
16. APPENDICES ........................................................................................................ 53 
16.1 
Schedules of Events ................................................................................... 53 
16.2 
Custom MedDRA Query (CMQ) Preferred Terms ....................................... 56 
16.3 
Adverse Events of Special Interest (AESIs) and Preferred Terms ............... 60 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 7 of 60 
LIST OF ABBREVIATIONS 
Abbreviation  
Definition  
 
 
AESI 
adverse event of special interest 
ANCOVA 
analysis of covariance 
ATC 
Anatomical Therapeutic Chemical 
CHW 
Cui, Hung, Wang 
CI 
confidence interval 
CKD 
chronic kidney disease 
CMQ 
custom MedDRA query 
CRF 
case report form 
DSMB 
Data Safety Monitoring Board 
ECG 
electrocardiogram 
eCRF 
electronic case report form 
ESA 
erythropoiesis-stimulating agents 
ESRD 
end-stage renal disease 
H 
above laboratory reference range 
ICF 
informed consent form 
IDMC 
Independent Data Monitoring Committee 
ITT 
intent-to-treat 
IV 
intravenous or intravenously 
L 
below laboratory reference range 
LS 
least squares 
MAR 
missing at random 
MCMC 
Markov Chain Monte Carlo 
MI 
multiple imputation 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMRM 
mixed effects model with repeated measures 
MNAR 
missing not at random 
N 
within laboratory reference range 
NRS 
numerical rating scale 
PGIC 
Patient Global Impression of Change 
PP 
per protocol 
PRO 
patient-reported outcome 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SOC 
system organ class 
TEAE 
treatment-emergent adverse event 
ULN 
upper limit of normal 
 
 
 
 
 
 
 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 8 of 60 
LIST OF IN-TEXT TABLES 
Table 1 
Power as a Function of Odds Ratio (N = 175 per arm) ................. 13 
Table 2 
Sample Size as a Function of Odds Ratio (90% Power) ............... 13 
Table 3 
Efficacy Variables and Analysis Methods ...................................... 26 
Table 4 
Schedule of Events: Double-blind Treatment Phase ..................... 53 
 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 9 of 60 
1. 
PURPOSE OF THE ANALYSES 
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the 
safety and efficacy of intravenous (IV) CR845 for the treatment of chronic kidney 
disease-associated puritus (CKD-aP) in hemodialysis patients at a dose of 0.5 mcg/kg 
administered after each dialysis session compared to placebo. The study includes a 
double-blind phase and an open-label extension phase.  
This statistical analysis plan (SAP) provides a detailed description of the strategy and 
statistical methodology to be used for analysis of data from the double-blind phase of the 
CR845-CLIN3103 protocol. The open-label analyses will be addressed in a separate 
document. 
The purpose of the SAP is to describe the pre-specified statistical approaches to the 
analysis of study data prior to database lock. This analysis plan is meant to supplement 
the study protocol. If differences occur between analyses described in the SAP and the 
current protocol, those found in this SAP will assume primacy. Any deviations from this 
plan will be described in the Clinical Study Report. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 10 of 60 
2. 
PROTOCOL SUMMARY 
2.1 
Study Objectives 
2.1.1 Primary Objective 
The primary objective is to evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg 
compared to placebo, in reducing the intensity of itch in hemodialysis subjects with 
moderate-to-severe pruritus. This objective will be assessed by comparing the proportion 
of subjects achieving at least a 3-point improvement from baseline with respect to the 
weekly mean of the daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) 
score at Week 12 of the Double-blind Treatment Period between placebo and CR845 
0.5 mcg/kg. 
2.1.2 Secondary Objectives 
The secondary objectives are:  
 To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared to 
placebo in improving itch-related quality-of-life measures in hemodialysis 
subjects with moderate-to-severe pruritus.  
 To evaluate the safety of IV CR845 at a dose of 0.5 mcg/kg in hemodialysis 
subjects with moderate-to-severe pruritus. 
2.2 
Overall Study Design and Plan 
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the 
safety and efficacy of IV CR845 at a dose of 0.5 mcg/kg administered after each dialysis 
session. The study includes a double-blind phase and an open-label extension phase.  
2.2.1 Double-blind Phase 
The double-blind phase of the study will consist of a Screening Visit, a 7-day Run-in 
period, and a 12-week Double-blind Treatment Period. Informed consent will be obtained 
prior to performing any study-specific procedures. The screening visit will occur within 7 
to 28 days prior to randomization to assess eligibility. The site has the option to conduct 
the Screening Visit within the Run-in period at the discretion of the investigator. 
Eligible subjects will complete a 7-day Run-in Period during the week prior to 
randomization to confirm eligibility, preferably starting on the first dialysis session of 
that week (ie, Monday for subjects on a Monday Wednesday-Friday dialysis schedule or 
Tuesday for subjects on a Tuesday-Thursday-Saturday dialysis schedule).  The purpose 
of the Run-in Period is to confirm that each subject has moderate to severe pruritus (ie, 
weekly average worst itch score ≥5), as measured by the patient-daily reported 24-hour 
Worst Itching Intensity NRS, and to establish a baseline itch intensity.   
During the first visit of the Run-in Period, subjects will be trained on completion of the 
24-hour Worst Itching Intensity NRS and will start the reporting of their Worst Itching 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 11 of 60 
Intensity NRS daily score. For consistency, subjects will be requested to complete the 
NRS worksheets (either at home or in the dialysis unit, as required) each day of the run-in 
period at a similar time of day around the normal start time of their dialysis. Subjects will 
be trained on other itch-related patient-reported outcome (PRO) worksheets at any time 
during the run-in period or on Day 1 of the Double-blind Treatment Period. 
If subjects continue to meet all inclusion and no exclusion criteria at the end of the 7-day 
Run-in Period, they will be randomized into the Double-blind Treatment Period in a 1:1 
ratio to receive either IV CR845 0.5 mcg/kg or placebo. Subjects will be stratified 
according to use and no use of concomitant medications to treat itching during the week 
prior to randomization (Run-in Period) as well as the presence or absence of specific 
medical conditions. These specific medical conditions include: 
 History of fall or fracture (related to fall) 
 Confusional state or mental status change or altered mental status or 
disorientation 
 Gait disturbance or movement disorder 
Day 1 of the Double-blind Treatment Period will be defined as the day of administration 
of the first dose of study drug and will occur on the first dialysis session day of the first 
treatment week (i.e., Monday for subjects on a Monday-Wednesday-Friday dialysis 
schedule, or Tuesday for subjects on a Tuesday-Thursday-Saturday dialysis schedule). 
Subjects will be administered CR845 or matched placebo as an IV bolus after the end of 
each dialysis session during the 12-week Double-Blind Treatment Period. Each subject is 
to receive CR845 or placebo 3 times weekly for a total of up to 36 doses.  
During the Double-blind Treatment Period, subjects will continue to report their daily 
Worst Itching Intensity NRS score over the previous 24 hours. In addition, during 
selected study visits (see Appendix 16.1), they will complete other PRO measures 
[Skindex-10 Scale, 5-D Itch Scale, and Patient Global Impression of Change (PGIC)]. 
Subjects will be instructed to record PRO measurements, including Worst Itching 
Intensity NRS scores, at a similar time of day, whether in the dialysis unit (on dialysis 
days) or at home (on non-dialysis days). 
Blood samples for clinical laboratory tests will be collected at Screening and on Days 1 
and 85. Blood samples for biomarkers will be collected on Days 1 and 85. 
Electrocardiograms (ECGs) will be monitored at the Screening Visit and Day 85. Vital 
signs will be monitored periodically, and adverse events and concomitant medications 
will be continuously recorded starting at the screening visit until the end of the Double 
Blind Treatment Period or Early Termination Visit. Use of antipruritic medications, iron, 
and erythropoiesis stimulating agents (ESAs) and any missed dialysis sessions will be 
recorded throughout the Double-blind Treatment Period. 
A Structured Safety Evaluation will be performed once during the Run-in Period and 
weekly (preferably on Wednesday/Thursday) during the Double-blind Treatment Period.  
The Structured Safety Evaluation is performed by study staff using a list of specific 
signs/symptoms (eg, mental status change, falls, gait disturbance). 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 12 of 60 
2.2.2 Open-label Treatment Period (Extension Phase) 
This SAP addresses only analyses for the double-blind phase of the study; however, an 
open-label extension phase will follow the double-blind phase, and the analyses for the 
extension phase will be covered in a separate SAP.   
2.3 
Study Population 
Subjects to be included are male and female hemodialysis subjects aged 18 years of age 
or older with end-stage renal disease (ESRD) who have been on hemodialysis 3 times per 
week for at least 3 months prior to start of screening, have moderate-to-severe pruritus 
(mean baseline Worst Itching Intensity NRS score ≥5 with at least 4 out of eight 
worksheets completed in the run-in period), and meet additional eligibility criteria. A full 
list of the inclusion and exclusion criteria can be found in the CR845-CLIN3103 protocol 
(v1.0 10APR2018). 
2.4 
Treatment Regimens 
Subjects will be administered CR845 0.5 mcg/kg or placebo as a single IV bolus 3 times 
a week after each dialysis session for 12 weeks during the Double-blind Treatment 
Period.  
During the Open-label Treatment Period, subjects will be administered CR845 
0.5 mcg/kg as a single IV bolus 3 times a week after each dialysis session for up to 
52 weeks.   
2.5 
Treatment Group Assignments or Randomization 
Before the start of the study, computer-generated randomization schedules will be 
prepared. Randomization will be performed using an interactive voice or web response 
system. Subjects will be randomized in a 1:1 ratio to receive either CR845 0.5 mcg/kg IV 
or matching placebo IV during the Double-blind Treatment Period. Subjects will be 
stratified according to use and no use of concomitant medications to treat itching during 
the week prior to randomization (Run-in Period), as well as the presence or absence of 
specific medical conditions, for a total of 4 strata. 
All eligible subjects providing consent for participation in the Open-label Treatment 
Period will receive CR845 at a dose of 0.5 mcg/kg starting on Day 1 of the Open-label 
Treatment Period. 
2.6 
Sample Size Determination 
The planned sample size for this study is 350 (175 per treatment group) male and female 
hemodialysis subjects with chronic moderate-to-severe pruritus (mean baseline 24-hour 
Worst Itching Intensity NRS score ≥5), randomized at approximately 95clinical sites. The 
sample size may be increased to 500 subjects (250 per treatment group) based on the 
results of a planned unblinded interim assessment conducted when approximately 50% of 
the planned 350 first subjects have been randomized and have either completed the 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 13 of 60 
12-week Double-blind Treatment Period or have discontinued from treatment early. The 
planned interim assessment will be conducted by an Independent Data Monitoring 
Committee (IDMC). Details related to the sample size re-estimation are included in 
Section 11. 
The sample size calculation is based on results of a completed phase 2 double-blind, 
placebo-controlled study (CR845-CLIN2101) of CR845 in hemodialysis subjects with 
ESRD who had moderate-to-severe pruritus. In this study, 30% of subjects randomized to 
the placebo group reported ≥3-point improvement from baseline with respect to the 
24-hour Worst Itching Intensity NRS at the end of treatment (Week 8). The proportion of 
subjects who received CR845 and reported a similar improvement in itch scores ranged 
from approximately 60% to 45% (i.e., 30% to 15% difference from placebo), depending 
on the dose of active study drug (0.5 mcg/kg, 1.0 mcg/kg, 1.5 mcg/kg).  
Given a sample size of 350 subjects (175 per treatment group) and assuming a true 
response rate of 30% for the placebo group and a true response rate of 50% for the 
CR845 group (defining response as an improvement from baseline ≥3 points with respect 
to the Worst Itching Intensity NRS at Week 12), a 2-sided continuity corrected 
Chi-square will have 96% power to detect a treatment difference. The power of this test 
statistic would be ≥84% for differences from placebo as low as 0.16 (Table 1).  
Table 1 
Power as a Function of Odds Ratio (N = 175 per arm) 
Placebo Response 
0.30 
0.30 
0.30 
0.30 
CR845 Response 
0.50 
0.48 
0.46 
0.45 
Odds Ratio 
2.333 
2.154 
1.988 
1.909 
Powera 
96% 
92% 
84% 
79% 
a.   Power for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error.  
Based on results of a planned interim assessment, the sample size may be increased up to 
500 subjects (250 per treatment group). Given this maximum sample size, and assuming 
a true response rate of 30% in the placebo group, a 2-sided continuity corrected 
Chi-square would have approximately 90% power to detect a treatment difference when 
the CR845 response rate is 45% (a 15% difference from placebo) (Table 2). 
Table 2 
Sample Size as a Function of Odds Ratio (90% Power) 
Placebo Response 
0.30 
0.30 
0.30 
0.30 
0.30 
CR845 Response 
0.50 
0.48 
0.46 
0.45 
0.44 
Odds Ratio 
2.333 
2.154 
1.988 
1.909 
1.833 
Sample Sizea 
134 
164 
204 
230 
262 
a.   Sample size for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error.  
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 14 of 60 
3. 
GENERAL ANALYSIS AND REPORTING CONVENTIONS 
This section discusses general policies to be employed in the analysis and reporting of the 
data from the study. Departures from these general policies will be described, if 
applicable, in the appropriate sections of this SAP. When this situation occurs, the rules 
set forth in the specific section take precedence over the general policies. 
For categorical variables, summary statistics will consist of the number and percentage of 
subjects in each category. All percentages will be rounded to one decimal point. The 
number and percentage of subjects will always be presented in the form XX (XX.X%) 
where the percentage is in parentheses. To ensure completeness, all summaries for 
categorical and discrete variables will include all categories, even if none of the subjects 
had a response in a particular category. Denominators for each analysis will be based on 
the population of interest (e.g., safety population; subjects with non-missing data). 
For continuous variables, summary statistics will consist of the number of subjects with 
data, mean, median, standard deviation, minimum, and maximum values. The summary 
statistic n will be the number of subjects with non-missing values. All means and 
medians will be reported to one more significant digit than the values being analyzed. 
Standard errors and standard deviations will be reported to two more significant digits 
than the values being analyzed. The minimum and maximum will be reported to the same 
number of significant digits as the values being analyzed. 
For tests of hypothesis of treatment group differences, the associated p-value will be 
reported. All p-values will be rounded to three decimal places; p-values that round to 
0.000 will be presented as “<0.001”. P-values are descriptive for outcomes and analyses 
not included in the multiplicity algorithm. 
In general, the baseline value will be considered the last non-missing measurement 
observed prior to the first dose of study treatment; the NRS will use the mean of the 
Run-in Period.  
For efficacy, subjects will be analyzed according to randomized treatment. For safety 
analyses, subjects will be analyzed according to the actual treatment received. Data from 
all sites will be pooled for the purpose of analysis. For analyses involving randomization 
strata, subjects will be analyzed according to actual strata recorded.  It is possible that 
some values will be updated for the strata variables between the time of the interim 
analysis and the final database lock; for the final analyses, the values from the locked 
database will be used. 
Data will be listed by treatment and subject. In general, listings will be sorted in the order 
that columns are displayed, starting with the first column on the left (treatment). Subject 
listings of data will be presented for all randomized subjects unless specified otherwise. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 15 of 60 
Unless otherwise specified, summaries will include the following treatment groups:  
 CR845 0.5 mcg/kg 
 Placebo 
SAS statistical software, version 9.4 or higher, will be used for all analyses.   
3.1 
Assessment Time Windows 
For the primary analysis variable, assessment time windows are not needed since the 
NRS Itch Intensity Assessments Log collects the individual daily scores; average Worst 
Itching Intensity NRS score for screening and each post-baseline visit week are derived 
using the daily scores.  
Assessments collected by study week that are collected at early termination visits and 
unscheduled visits will be assigned to a planned visit window, if the early termination or 
unscheduled visit day falls between +/- 3 days of the planned visit, with the exception of 
the double-blind Week 12 visit, which will use a window of +1/-3. Should more than one 
measurement fall within a visit window, priority is given first to the measurement with a 
non-missing value in the following order: first, the scheduled assessment; second, an 
early termination visit; and next, the unscheduled assessment closest to the planned day. 
In the case that two unscheduled visits are equidistant, the latest will be used. This rule 
will be applied both to efficacy and safety endpoints. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 16 of 60 
4. 
ANALYSIS POPULATIONS 
Four analysis populations will be used for this study: the Enrolled Population, the 
Intent-to-Treat (ITT) Population, the Double-blind Safety Population, the Per Protocol 
(PP) Population. 
4.1 
Enrolled Population  
The Enrolled Population is defined as the group of subjects who sign informed consent. 
4.2 
Intent-to-treat Population  
The ITT Population is defined as the group of subjects who are randomized to a treatment 
group. Following the ITT principle, subjects in the ITT Population will be analyzed 
according to their randomized treatment, regardless of the actual treatment received. The 
ITT population will be used to analyze all efficacy endpoints collected during the double-
blind phase.  
4.3 
Double-blind Safety Population  
The Double-blind Safety Population is defined as the group of randomized subjects who 
received at least one dose of double-blind study drug during the Double-blind Treatment 
Period. Subjects in the Double-blind Safety Population will be analyzed according to the 
actual treatment received. The Double-blind Safety Population will be used to analyze all 
safety endpoints collected during the double-blind phase.  
4.4 
Per Protocol Population 
The PP Population is defined as the subset of subjects in the ITT Population who do not 
have any major protocol deviations that could affect the efficacy analyses of the 
double-blind data. An analysis of the primary and secondary efficacy variables for the PP 
Population will be performed.  
The PP Population is defined as subjects who: 
 Received at least 80% of the planned study drug doses while in the study 
 Received at least one study dose in each of Week 11 and 12 of the Double-blind 
period, if present through Week 12 
 Did not receive a different treatment than the treatment to which they were 
randomized 
 Had a mean baseline Worst Itching Intensity NRS score ≥5.0 
 Had a non-missing average 24-hour weekly Worst Itching Intensity NRS score 
available for at least 75% of study weeks while in the study (weeks with 
>3 missing daily values are considered missing) 
 Did not have significant amounts of restricted and prohibited medications listed in 
protocol Section 6.4.9 based on medical review. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 17 of 60 
 Did not have other major protocol violations that would impact efficacy outcomes  
Prior to unblinding, the protocol violations and medications will be reviewed in a blinded 
manner and the PP Population will be determined. Subjects will be analyzed in the 
treatment arm to which they were randomly assigned regardless of which treatment they 
received.  


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 18 of 60 
5. 
STUDY SUBJECTS 
5.1 
Disposition of Subjects 
The number of subjects who enrolled, failed screening, were randomized, received 
treatment, completed treatment, and discontinued from treatment, along with the reason 
for discontinuation, and number of subjects who entered the Open-label Treatment Period 
will be presented by treatment group and overall for the Double-blind Treatment Period. 
Subjects randomized will also be reported by the randomization stratification factors. 
The following provides the definitions of the aforementioned groups: 
 Enrolled subjects are all subjects who sign informed consent.  
 Randomized subjects consist of all screened subjects who have a randomization 
record in the interactive voice/web randomization system. 
 Treated subjects are all subjects who received at least one dose of double-blind 
study drug.  
 Subjects who completed treatment are those randomized subjects with a “Yes” 
noted for the question “Did the subject complete the Double-blind Treatment 
Period?”. 
 Subjects who discontinue treatment early are randomized subjects with “No” 
noted for the question “Did the subject complete the Double-blind Treatment 
Period?”. Reasons for treatment discontinuation are also collected on this case 
report form (CRF). 
 Subjects who entered the Open-label Treatment Period are those who received at 
least one dose of study drug in the Open-label Treatment Period.  
For all categories of subjects (except for enrolled subjects and screen failures), 
percentages will be calculated using the number of randomized subjects as the 
denominator.  
Additionally, the analysis populations will be summarized in a table by subject counts, as 
well as in a subject listing:  
 Intent-to-treat Population; 
 Double-blind Safety Population; 
 Per Protocol Population 
The reasons for exclusion from the PP Population will also be summarized in a table by 
subject counts. Percentages will be calculated using the ITT population as the 
denominator. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 19 of 60 
5.2 
Protocol Deviations 
Protocol deviations will be identified in several ways: through programmatic checks, 
through medical reviews, and by clinical research associates during site monitoring. 
Deviations will be classified as minor or major prior to the database lock. Protocol 
deviations will be summarized by treatment group. All protocol deviations will be listed. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 20 of 60 
6. 
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS 
Demographic and baseline characteristics will be collected during the Screening Visit. 
Descriptive statistics will be provided for all demographic and baseline characteristics 
based on the Double-blind Safety Population. For categorical variables, the number and 
percentage of subjects in each category will be presented. For continuous variables, 
summaries will include the number of subjects with data, mean, median, standard 
deviation, minimum, and maximum.  
All demographic and other baseline characteristics will be provided in a listing. 
6.1 Demographic Characteristics 
Demographic and baseline variables will be summarized by treatment group and include 
the following: 
 Age at screening (years) as recorded on the CRF 
 Age category at screening (<45, ≥ 45-<65, 65-<75, ≥75) 
 Gender 
 Ethnicity  
 Race  
 Prescription dry body weight (kg) 
 Country 
 Region: USA, Western (Canada, UK, Germany, Australia, New Zealand), Eastern 
EU (Poland, Hungary, Romania, Czech Republic), Asia (Taiwan, South Korea) 
6.2 Baseline Disease Characteristics 
Baseline characteristics of the disease will also be summarized by treatment group and 
include the following: 
 Duration of pruritus (years) 
 Years since ESRD 
 Years since chronic kidney disease (CKD) 
 Years on chronic hemodialysis 
 Etiology of CKD 
 Baseline Worst Itching Intensity NRS 
 Anti-itch medication use during the Run-in Period (stratification factor) 
 Presence of specific medical conditions (stratification factor) 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 21 of 60 
 Dialysis type 
 Dialysis type by region 
Duration of pruritus (years) will be calculated as: 
(Date of the Screening Visit – the start date of the pruritus+ 1)/365.25.  
Years since ESRD will be calculated as: 
(Date of the Screening Visit – first date of ESRD+ 1)/365.25.  
Years since CKD will be calculated as: 
(Date of the Screening Visit – first date of CKD+ 1)/365.25.  
Years on chronic hemodialysis will be calculated as: 
(Date of the Screening Visit – date of first chronic hemodialysis + 1)/365.25. 
For each of the above, if partial dates are recorded, the first day of the month will be 
imputed for missing day, and January for missing month. 
6.3 
Medical History 
Medical history data consisted of a fixed list of conditions to be checked off and any 
additional self-reported medical conditions not contained on the list. Both types of 
medical history will be coded using Medical Dictionary for Regulatory Activities 
(MedDRA); however, the pre-specified medical history will use the fixed list of 
conditions as preferred terms and map to the most appropriate system organ class (SOC) 
based on MedDRA and blinded medical review. Medical history terms that were not pre-
specified will be coded for SOC and preferred term. Both types of conditions (selected 
from the fixed list or self-reported) will be combined and summarized by MedDRA SOC, 
preferred term, and treatment group. Both types of conditions will also be reported 
together for separate summaries of conditions related to dialysis, conditions worsening 
during dialysis, and conditions not related to dialysis.  The data will also be listed, 
including the verbatim investigator description of the relevant medical condition, the 
coded terms (SOC, preferred term), start date, end date, and whether or not the condition 
is ongoing. 
A separate coding listing will be created with all the distinct levels of SOC, preferred 
terms, and the verbatim investigator description reported in the study. Sorting will be 
alphabetically by SOC, preferred term, and then verbatim description. 
6.4 
Prior and Concomitant Medications 
All medications, including any antipruritic medications, taken during the 3 months prior 
to the first dose of study drug on Day 1 through the end of the Double-blind Treatment 
Phase or early termination (i.e., End-of-Treatment/Early Termination Visit) will be 
recorded.  


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 22 of 60 
These will be coded using the March 2018 World Health Organization Drug Dictionary 
Enhanced plus Herbal Dictionary. All prior and concomitant medications will be listed. 
Additionally, a listing for unique medications and their corresponding coding will be 
presented. 
6.4.1 Prior Medication 
Prior medications (including vitamins and herbal supplements) are defined as 
medications collected on the Previous or Concomitant Medications CRF page that the 
subject has taken any time during the last 3 months prior to the first dose of study drug on 
Day 1 of the Double-blind Treatment Period. Prior medications will be summarized in a 
table by treatment group using the Double-blind Safety Population. Medications will be 
reported by drug class (Anatomical Therapeutic Chemical [ATC] Level 3) and 
ingredient; a subject will be counted only once for each medication.   
6.4.2 Concomitant Medication  
Concomitant medications used during the Double-blind Treatment Period are 
medications taken from after the first dose of study drug on Day 1 of the Double-blind 
Treatment Period through the End-of-Treatment or Early Termination Visit. Concomitant 
medications during the Double-blind Treatment Period will be summarized by treatment 
group for the Double-blind Safety Population. Medications will be reported by drug class 
(ATC Level 3) and ingredient; a subject will be counted only once for each medication.  
 
6.4.3 Anti-Itch Medication 
Anti-itch medications are identified as medications where “Yes” is checked on the 
Previous or Concomitant Medications CRF page to the question “Medication was given 
to treat pruritus.”  
The prior and concomitant medication summaries described in Sections 6.4.1 and 6.4.2 
will be repeated for the anti-itch medications, but presented by ingredient (and not ATC 
level 3).  


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 23 of 60 
7. 
STUDY DRUG EXPOSURE AND TREATMENT COMPLIANCE 
For this study, the duration of double-blind treatment for each individual subject is 
expected to be 12 weeks, for a total of approximately 36 doses of study drug administered 
immediately following each dialysis session.  
The following variables will be summarized by treatment group to describe the duration 
of exposure and length of participation in the Double-blind Treatment Period: 
 Duration of double-blind treatment (days) as: (Date of first dialysis after last dose) 
– (Date of first double-blind dose) + 1. 
 Duration of double-blind phase (days), from first double-blind dose to final 
assessment.  This will be (End of double-blind participation date) – (Date of first 
double-blind dose) + 1. 
 Average dose per administration (mcg/kg) 
The following measures will be used to assess compliance: 
 Total number of double-blind doses actually received (1-3, 4-6, 7-9, etc.) 
 Total number of dialysis visits logged (1-3, 4-6, 7-9, etc.) 
 Number of missed doses  
 Number of missed dialysis visits  
 Number of subjects with extra doses  
 Number of subjects with extra dialysis visits  
If a subject receives additional dialysis during a given week for any reason, an additional 
dose of CR845 will be administered following dialysis. A maximum of 4 doses per week 
is allowed. No additional doses will be given for subjects receiving an additional 
unscheduled ultrafiltration treatment. The number of subjects getting such an extra 
treatment will be summarized. 
Missed and extra doses/dialysis will be determined as follows: 
1. Individual weeks for each subject are examined. 
2. Each subject should have 3 doses per week up to the final week of the period. 
Anything more will be counted as extra doses; anything less will be counted as 
missed doses. 
3. Subjects who do not complete through the final week of the period will be 
checked for how far they were into the week that they discontinued: 1,2 days 
means that they should have 1 dose; 3,4 = 2 doses; 5 or more =3 doses. This will 
be compared to actual doses for that week to determine missed/extra. 
4. The missed and extra doses are then summed across each subject’s weeks to get 
the total missed and extra. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 24 of 60 
8. 
EFFICACY EVALUATION 
8.1 
Overview of Efficacy Analysis Issues 
8.1.1 Handling of Dropouts or Missing Data 
A variety of approaches will be applied for subjects that have missing Week 12 averages 
of daily Worst Itching Intensity NRS; full details of these for both the primary analysis 
and sensitivity analyses may be found in Section 8.2. 
Note that a subject must report at least 4 values for a week in order for the weekly mean 
of the 24 hour Worst Itching Intensity NRS to be non-missing.  
Handling of missing data for other endpoints is discussed in the specific sections for 
those endpoints.  
8.1.2 Multicenter Studies 
The Week 12 change from baseline will be reported in a separate display with summary 
statistics by site; likewise, the counts and proportions (out of the ITT Population at that 
site) of subjects achieving ≥3-point improvement from baseline will be reported by site 
(for sites that have at least two subjects in each treatment with data present at week 12). 
Otherwise, data from all sites will be pooled for the purpose of analyses. Note that a 
covariate for the site’s region will be included in the key analyses; the country groupings 
are given in section 6.1. 
8.1.3 Multiplicity Handling 
The efficacy of CR845 0.5 mcg/kg compared to placebo in pivotal phase 3 study 
CLIN3103 will be evaluated based on 1 primary and 7 secondary efficacy endpoints.  
Testing of the primary efficacy endpoint will be 2-sided and conducted at the 5% error 
level. The study will be considered positive if the null hypothesis of no treatment 
difference in the primary efficacy analysis of the primary endpoint (proportion of subjects 
achieving ≥3-point improvement from baseline with respect to the Worst Itching Intensity 
NRS at Week 12 of the Double-blind Treatment Period) is rejected in favor of the 
alternative that subjects randomized to CR845 experience significantly less itching 
compared to subjects randomized to placebo.  
To protect the Type 1 error, a gate-keeping strategy will be implemented. Although the 
p-values corresponding to the hypothesis testing of the secondary variables will be 
reported, they will only be considered inferential if the primary analysis is statistically 
significant. Testing of the secondary efficacy endpoints will be performed sequentially at 
a 2-sided 5% error level in the order specified below. If the test of an endpoint in the 
sequence is not statistically significant, the p-value for the tests corresponding to the 
remaining endpoints in the sequence will not be considered inferential and the null 
hypotheses for the subsequent tests will not be rejected.    


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 25 of 60 
 The proportion of subjects achieving ≥4-point improvement from baseline with 
respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at 
Week 12 of the Double-blind Treatment Period will be tested first.   
 The proportion of subjects achieving ≥3-point improvement from baseline with 
respect to the Worst Itching Intensity NRS at Week 8 will be tested next, followed 
by Week 4.  
 Testing will continue with the proportion of subjects achieving a ≥4-point 
improvement at Weeks 8, followed by Week 4, in an identical manner 
 Change from baseline in Skindex-10 total score at Week 12 of the Double-blind 
Treatment Period using the ANCOVA approach in section 8.2.4.3. 
 Change from baseline in 5D total scores at Week 12 of the Double-blind Treatment 
Period using the ANCOVA approach in section 8.2.4.3. 
 
8.1.4 
Region Covariate 
For the multiple imputation algorithms and statistical models, geographical region (as 
described in section 6.1) will be included as a covariate.  Should convergence issues 
occur due to small cell size for the covariate corresponding to region, the following 
approach will be followed: a) region will first be re-defined, grouping all Asian sites with 
Eastern Europe; b) If convergence issues still occur after step a) has been completed then 
all US sites will be grouped with sites from other western countries; c) if convergence 
issues still remain after implementing steps a) and b), the term for region will dropped 
from the MI algorithm/statistical model. 
If the convergence issue occurs in the generation of a MI dataset, all outcomes based on 
that dataset will use the same region definition.   Additionally, should this occur for the 
NRS outcome, all sensitivity analysis datasets will use the same region definition and the 
models base off those datasets will use that region definition. 
If the convergence issue occurs in modeling of an outcome, all models for that particular 
outcome will use the same region definition.  For example, if the grouping of the Asian 
sites with Eastern Europe is required for the Week 4 analysis of ≥4-point improvement in 
worse itching NRS, then all models at all time points of the ≥4-point improvement in 
worse itching NRS will use that region definition.  However, this would not impact the 
choice of region for ≥3-point improvement. 
8.2 
Efficacy Variables 
Table 3 presents a summary of the study efficacy variables and types of analyses used to 
evaluate them. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 26 of 60 
 
Table 3 
Efficacy Variables and Analysis Methods 
 
Analysis Methods 
Efficacy Variables  
ANCOVA 
MMRM 
Logistic Regression 
CMH 
 
 
 
 
 
Primary 
≥3-point improvement from baseline in Worst Itching Intensity NRS at Week 12 of the Double-blind 
Treatment Period 
 
 
 
X 
 
Secondary 
 
 
 
 
≥4-point improvement from baseline in Worst Itching Intensity NRS at Week 12 of the Double-blind 
Treatment Period 
 
 
X 
 
≥3 and ≥4 -point improvement from baseline in Worst Itching Intensity NRS at Week 8 and Week 4 of the 
Double-blind Treatment Period 
 
 
X 
 
Change from baseline in Skindex-10 Scale at Week 12 of the Double-blind Treatment Period 
X 
X 
 
 
Change from baseline Week 12 in total 5-D Itch Scale score at Week 12 of the Double-blind Treatment 
Period 
X 
X 
 
 
Other Efficacy Variables 
 
 
 
 
Itch-intensity Variables 
 
 
 
 
>0-, ≥1-, ≥2-, ≥3-, ≥4-, ≥5-, ≥6-point improvement from baseline in Worst Itching Intensity NRS at Week 12 
of the Double-blind Treatment Period 
 
 
X 
 
≥3-point improvement from baseline in Worst Itching Intensity NRS at Week 12 of the Double-blind 
Treatment Period by the stratification variables 
 
 
X 
 
≥3 and ≥4-point improvement from baseline in Worst Itching Intensity NRS at Week 12 of the Double-blind 
Treatment Period by region and dialysis type (each individually) 
 
 
X 
 
Change from baseline in the weekly mean of the 24 hour Worst Itching Intensity NRS score at each week of 
the Double-blind Treatment Period 
 
X 
 
 
Proportion of subjects with “Very Much Improved” or “Much Improved” on Patient Global Impression of 
Change at Week 12 of the Double-blind Treatment Period 
 
 
 
X 
Worst Itching Intensity NRS Complete Responder 
 
 
X 
 
Itch-related Quality-of-Life Variables: 
 
 
 
 
Change from baseline in total Skindex-10 Scale score, at each week 
 
X 
 
 
Change from baseline in each of the three Skindex-10 Scale Scores, at each week 
X 
X 
 
 
≥15-point improvement from baseline in total Skindex-10 Scale score, at each week 
 
 
X 
 
Change from baseline in the total 5-D Itch Scale, at each week 
 
X 
 
 
Change from baseline in the five 5-D Itch Scale domains, at each week 
X 
X 
 
 
≥5-point improvement from baseline in total 5D Itch Scale, at each week 
 
 
X 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 27 of 60 
ANCOVA = analysis of covariance; CMH = Cochran-Mantel-Haenszel exact test; MMRM = mixed effects model with repeated measures; NRS = numerical 
rating scale


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 28 of 60 
 
8.2.1 Primary Efficacy Endpoint 
The primary efficacy endpoint is defined as the proportion of subjects achieving ≥3-point 
improvement from baseline with respect to the weekly mean of the daily 24-hour Worst 
Itching Intensity NRS at Week 12 of the Double-blind Treatment Period. 
Intensity of itch will be measured using the Worst Itching Intensity NRS (see protocol 
Appendix 2) on a worksheet in which subjects will be asked to indicate the intensity of 
the worst itching they experienced over the past 24 hours by marking 1 of 11 numbers, 
from 0 to 10, that best describes the intensity, where “0” is labeled with the anchor phrase 
“no itching” and “10” is labeled “worst itching imaginable.”  Subjects will be provided 
with these worksheets to record their 24-hour worst itching assessment scores, both at the 
clinic on dialysis days and at home on non-dialysis days.  
The weekly mean of the 24-hour Worst Itching Intensity NRS score will be defined as the 
sum of the daily Worst Itching Intensity NRS scores reported during a specific week 
during the Double-blind Treatment Period (e.g., Days 2 to 8, Days 9 to 15, Days 16 to 22) 
divided by the number of days with non-missing scores for that week. If the daily worst 
itching score is missing for >3 days during a specific week, the corresponding weekly 
mean worst itching score will be set to missing. Additionally, subjects who discontinue 
treatment but continue on study and report NRS scores will have their NRS scores 
censored following discontinuation of treatment; missing data rules will apply to these 
censored values as though they had missing values/ dropped out from the study entirely. 
The baseline score will be defined as the average of the daily 24-hour Worst Itching 
Intensity NRS scores collected over the Run-in Period, including pre-randomization 
assessments collected on Day 1. As defined in the protocol, to be randomized, subjects 
had to report at least 4 non-missing Worst Itching Intensity scores from the start of the 
7-day Run-in Period up to and including the pre-randomization assessment on Day 1. For 
subjects who deviated from the protocol and were randomized with more than 4 missing 
Worst Itching Intensity NRS scores during the 7-day Run-in Period, the baseline Itch 
NRS scores will be calculated using all available non-missing scores collected prior to 
and including the pre-randomization assessment on Day 1. These subjects will be 
included in the ITT population and excluded from the Per-Protocol population. 
8.2.2 Primary Efficacy Analysis 
In the primary efficacy analysis, missing NRS data at the end of Week 12 will be imputed 
using a multiple imputation (MI) approach, assuming that subjects who discontinue 
double-blind treatment early would have similar Worst Itching Intensity NRS scores as 
other subjects in their respective treatment arm who have complete data: 
 Intermittent missing NRS scores will first be imputed using the Markov Chain 
Monte Carlo (MCMC) method implemented with the SAS MI procedure, which is 
appropriate for non-monotonic missing data.  
 The monotone missing NRS values will then be multiply imputed with the SAS 
MI procedure using the monotone regression method.  


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 29 of 60 
 For each stage, MI will be performed within treatment group with covariates for 
baseline NRS score, both randomization stratification factors, region and the 
non-missing NRS scores for each week. Should convergence issues occur due to 
small cell size for the categorical covariates corresponding to strata (at either 
stage), those specific covariates will be removed from the model.  Convergence 
issues with the region covariate will be handled as described in section 8.1.4.  
 The proportion of subjects who have an improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS score 
≥3 points will be calculated for each imputed dataset. Differences between CR845 
0.5 mcg/kg and placebo with respect to the primary endpoint will be compared 
using a logistic regression model containing terms for treatment group, baseline 
NRS score, region, use of anti-itch medication during the week prior to 
randomization, and presence of specific medical conditions. Convergence issues 
with the region covariate will be handled as described in section 8.1.4.  
 Twenty imputations will be performed. 
 Results of the logistic regression on the multiply imputed data sets will be 
summarized by the SAS MIANALYZE procedure.  
The observed number and proportion of subjects with ≥ 3-point improvement among the 
non-imputed data will be reported along with the imputed data logistic regression 
model-based estimates of the proportions of responders, odds ratio, 95% confidence 
intervals (CIs), and p-value. 
Sample size adjustment 
The above MI process will be implemented completely independently among subjects 
contributing the interim results and those following the interim analysis. Likewise, the 
logistic regression and results described above will be generated independently for both 
samples, with the samples combined and adjusted as follows: 
The final p-value will be calculated using the Cui, Hung, Wang (CHW) procedure where 
the z-score is a weighted average of the z-score at the interim and the z-score observed 
for data collected after the interim, following the formula below:  
          ZCHW=Zinterim * √(n/N) + Zpost-interim * √(1- n/N) 
where n is the number of randomized subjects at the interim and N is the initial number 
of subjects planned (350).  
The adjusted odds ratio estimate prior to exponentiating and the 95% CI will be obtained 
using methodology suggested by Hung and Lawrence: 
𝛿̂ = 𝑟1𝛿̂(1) + √1 −𝑟1 √𝑁∗− 𝑟1  𝛿̂(2) 
𝑟1 + √1 −𝑟1 √𝑁∗− 𝑟1 
 
where  
r1 = n/350  


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 30 of 60 
N* = (Re-estimated total sample size)/350 
 
 
 
95% CI = 
  
Note that it is possible for ZCHW and 𝛿 to have opposite directions, particularly when close to 
zero, in which case the absolute value of the ratio will be used in the above formula.  
See Section 11 for further details on the interim analysis. 
The primary analysis and each sensitivity analysis will also be performed using the full 
combined dataset with the missing data imputed separately for interim subjects and 
post-interim subjects. No CHW adjustment will be conducted. Presentation of results will 
start with these analyses (additionally including the CHW results) and then follow with 
the results of the analysis from each individual stage. 
8.2.3 Sensitivity Analyses 
Sensitivity analyses of the primary efficacy endpoint will be conducted to evaluate the 
robustness of study results under different assumptions and imputation algorithms. For 
each of these sensitivity analyses, the final p-value will be calculated based on the CWH 
procedure, using the formula specified above. 
Sensitivity 1: Early Discontinuations as nonresponders  
Subjects who discontinue study drug early will be considered nonresponders 
(including subjects that discontinue study drug, but continue to report NRS scores 
as described in Section 8.1.1). Subjects who do not discontinue but have missing 
Week 12 data will be imputed via MI as is done in the primary analysis. The 
imputed data will be analyzed using a logistic regression model similar to the 
primary analysis.  
 
Sensitivity 2: Multiple imputation; missing not at random (MNAR) 
This sensitivity analysis is an implementation of a pattern mixture model that 
draws from different populations based on the reason for withdrawal.  
o Intermittent missing NRS scores will first be imputed using the MCMC 
method with the SAS MI procedure, which is appropriate for non-monotonic 
missing data. 
o For subjects who discontinued study drug due to adverse events, NRS scores 
missing after discontinuation will be imputed using the distribution of the 
baseline value of all subjects’ daily worst itching score assuming a trimmed 
normal (from 5 to 10).  
o For subjects who discontinue due to reasons other than adverse event, missing 
NRS scores after subjects discontinue study drug early will be multiply 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 31 of 60 
imputed using multiple calls of the SAS MI procedure using data from 
subjects within the same treatment group who have complete data at that time, 
including subjects who discontinued due to adverse event. Terms will include 
baseline values, region, the stratification values, and the weekly data through 
the time point being imputed. The same MI method will be used for subjects 
with other monotone missing data.  
o The proportion of subjects who have an improvement from baseline with 
respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS 
score ≥3 points will be calculated for each imputed dataset 
o Similar to the primary analysis, results of the logistic regression on the 
multiply imputed data sets will be summarized by the SAS MIANALYZE 
procedure.  
 
Sensitivity 3: Tipping point analysis 
Multiple imputation with mixed missing data mechanisms (MNAR for a CR845 
and MAR [missing at random] for placebo) will be used to assess the robustness 
of the MAR assumption. This sensitivity analysis is to investigate the departure 
from MAR assumption by progressively decreasing the treatment differences with 
respect to the NRS scores over the missing visits in active treatment group until 
conclusion from the primary analysis is overturned. This will be applied to only 
Week 12 values. The MI procedure includes the following steps: 
o Intermittent missing NRS scores will first be imputed using the MCMC 
method with the SAS MI procedure, which is appropriate for non-monotonic 
missing data. 
o The monotone missing NRS values will then be multiply imputed with the 
SAS MI procedure using the monotone regression method.  
o For each stage, MI will be performed within treatment group with covariates 
for baseline NRS score, region, both randomization stratification factors and 
the non-missing NRS scores for each week. Should convergence issues occur 
due to small cell size for the categorical covariates at either stage, those 
covariates will be removed from the model- with the exception of region, as 
described in the primary. 
o For subjects in the active treatment group, a shift parameter running from 0 to 
5 points in .25 point increments in PROC MI will be progressively applied to 
impute the missing data at Week 12, until the p-value is >0.05. 
o This sensitivity analysis will not be performed should the initial primary 
results fail to achieve significance 
To evaluate the potential impact of the interim analysis on the properties of statistical 
inference at the end of the trial, the primary and sensitivity analyses of the primary 
endpoint will also be presented separately for the sample of subjects enrolled into the 
study before and after the interim analysis. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 32 of 60 
8.2.4 Key Secondary Endpoints 
The key secondary endpoints are: 
 Proportion of subjects achieving ≥4-point improvement from baseline with 
respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at 
Week 12 of the Double-blind Treatment Period; 
 Proportion of patients achieving ≥3-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8 
of the Double-blind Treatment Period;  
 Proportion of patients achieving ≥3-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4 
of the Double-blind Treatment Period; 
 Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8 
of the Double-blind Treatment Period;  
 Proportion of patients achieving ≥4-point improvement from baseline with respect 
to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4 
of the Double-blind Treatment Period; 
 Change from baseline in itch-related quality of life at the end of Week 12 of the 
Double-blind Treatment Period, as assessed by the total Skindex-10 Scale score. 
 Change from baseline in itch-related quality of life at the end of Week 12 of the 
Double-blind Treatment Period, as assessed by the 5-D Itch Scale; 
 
8.2.4.1 
5-D Itch Scale  
The 5-D Itch Scale was developed as a brief but multidimensional questionnaire designed 
to be useful as an outcome measure in clinical trials. The 5 dimensions of itch being 
assessed are degree, duration, direction, disability, and distribution (see protocol 
Appendix 4).  
The duration, degree, and direction domains each include 1 item, while the disability 
domain has 4 items. All items of the first 4 domains were measured on a 5-point Likert 
scale. The distribution domain included 16 potential locations of itch, including 15 body 
part items and 1 point of contact with clothing or bandages.  
Single-item domain scores (duration, degree, and direction) are equal to the value 
indicated below the response choice (range 1–5).  The disability domain includes 4 items 
that assess the impact of itching on daily activities: sleep, leisure⁄social activities, 
housework⁄errands, and work⁄school. The score for the disability domain is achieved by 
taking the highest score on any of the 4 items. For the distribution domain, the number of 
affected body parts is tallied (potential sum 0–16), and the sum is sorted into 5 scoring 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 33 of 60 
bins: sum of 0–2 = score of 1, sum of 3–5 = score of 2, sum of 6–10 = score of 3, sum of 
11–13 = score of 4, and sum of 14–16 = score of 5. 
The scores of each of the 5 domains are achieved separately and then summed together to 
obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritus) and 
25 (most severe pruritus).  
Total 5-D Itch score = duration score (single item) + degree score (single item) + duration 
score (single item) + maximum (4 disability items) + category score based on sum of 
affected body parts. 
The scoring manual does not give specific direction regarding scoring when some 
questions are missing; therefore, each domain and the total score will be set to missing 
when any of their individual components are missing, with the exception of the disability 
domain.  The maximum of any items is present for disability will be used for that domain. 
Missing data will be handled implicitly in the MMRM model or explicitly via multiple 
imputation (see below). 
8.2.4.2 
Skindex-10 Scale  
Developed specifically for uremic pruritus, the Skindex-10 Scale (see protocol 
Appendix 3) is an instrument for measurement of quality of life. Subjects are asked the 
question “During the past week, how often have you been bothered by” and respond by 
filling in 1 of 7 circles numbered from 0 (labeled with the anchor phrase “never 
bothered”) to 6 (labeled as “always bothered”) for each of the 10 questions.  
The total score is the sum of the numeric value of each answered question. 
Additionally, the total score is subdivided into 3 domain scores, which are sums of the 
scores of the following questions: disease domain (questions 1 to 3), mood/emotional 
distress domain (questions 4 to 6), and social functioning domain (questions 7 to 10). 
The scoring manual does not give specific direction regarding scoring when some 
questions are missing; therefore, the three domains and the total score will be set to 
missing when any of their individual components are missing. Missing data will be 
handled implicitly in the MMRM model or explicitly via multiple imputation (see 
below). 
8.2.4.3 
Key Secondary Analyses 
Worst Itching Intensity ≥4-Point Improvement at Week 12 
The proportion of subjects achieving ≥4-point improvement from baseline with respect to 
the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12 of the 
Double-blind Treatment Period will be analyzed following a methodology identical to the 
one employed for the primary analysis of the primary endpoint (see section 8.2.2). The 
same dataset will be utilized; separate flags for various cut points of improvement will be 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 34 of 60 
utilized to facilitate these analyses. The analysis will be completed for both the ITT and 
PP Populations. 
Worst Itching Intensity ≥3-Point Improvement and ≥4-Point Improvement at Week 
8 and Week 4 
The proportion of subjects achieving ≥3-point improvement and ≥4-point improvement 
from baseline with respect to the weekly mean of the daily 24-hour Worst Itching 
Intensity NRS at Weeks 8 and 4 of the Double-blind Treatment Period will be analyzed 
following a methodology identical to the one employed for the primary analysis of the 
primary endpoint (see section 8.2.2). The same dataset will be utilized; separate flags for 
various cut points of improvement will be utilized to facilitate these analyses. The 
analysis will be completed for both the ITT and PP Populations.  These will be tested in 
the order described in section 8.1.3. 
5-D Itch Scale and the Skindex-10 Scale 
The 5-D Itch Scale and the Skindex-10 Scale scores will be analyzed only at Week 12 
using an analysis of covariance (ANCOVA). The model will contain treatment as fixed 
effects, with baseline score, region, and the randomization stratification variables as 
covariates. The baseline 5-D total score and the Skindex-10 total score will be defined as 
the value collected on Day 1, prior to randomization. Convergence issues with the region 
covariate will be handled as described in section 8.1.4. 
Additionally, subjects who discontinue treatment but continue on study and have 5-D and 
Skindex-10 scores recorded will have these scores censored following discontinuation of 
treatment; missing data rules will apply to these censored values as though they had 
missing values/ dropped out from the study entirely. 
For each domain in each questionnaire, missing values at Week 12 will be imputed using 
an MI approach, assuming that subjects who discontinue double-blind treatment early 
would have similar 5-D Itch and Skindex-10 scores as other subjects in their respective 
treatment arm that have complete data. All available visits will be included in the MI to 
better inform the Week 12 imputed results. The MI approach will proceed as follows, 
using all ITT subjects (that is, it will not be split into IA subjects and post- IA subjects): 
 Intermittent missing scores will first be imputed using the Markov Chain Monte 
Carlo (MCMC) method implemented with the SAS MI procedure, which is 
appropriate for non-monotonic missing data.  
 The monotone missing values will then be multiply imputed with the SAS MI 
procedure using the monotone regression method.  
 For each stage, MI will be performed within treatment group with covariates for 
baseline score, region, both randomization stratification factors, and all non-
missing visit scores for each domain of the questionnaire. Should convergence 
issues occur due to small cell size for the categorical covariates at either stage, 
they will be removed from the model- with the exception of region as described 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 35 of 60 
for the primary analysis.  Convergence issues with the region covariate will be 
handled as described in section 8.1.4. 
 Twenty imputations will be performed for each domain. 
 For each questionnaire, the total score at each visit will be computed from the 
domain scores for each imputed dataset. 
 The ANCOVA analysis described above will be implemented for each imputed 
dataset.  
 Results of the ANCOVA on the multiply imputed data sets will be summarized by 
the SAS MIANALYZE procedure.  
Since the observed change from baseline at Week 12 among the non-imputed data will be 
reported with the MMRM analyses described below, only the LS means, standard errors, 
95% CIs, and differences between treatment groups from this ANCOVA will be reported. 
The analysis will be completed for both the ITT and PP Populations. 
Sensitivity Analyses of 5-D Itch Scale and the Skindex-10 Scale  
Three additional analyses will be performed for these outcomes.  These will include 
MMRM, missing imputed using control distribution, and a missing imputed using 
baseline distribution. 
 Mixed effects model with repeated measures 
The 5-D Itch Scale and the Skindex-10 Scale scores will be analyzed using a mixed 
effects model with repeated measures (MMRM). The model will contain treatment, week, 
and treatment-by-week interaction as fixed effects, and baseline score, region, and the 
randomization stratification variables as covariates. The baseline 5-D total score and the 
Skindex-10 total score will be defined as the value collected on Day 1, prior to 
randomization. Repeated measures will include values assigned at the end of Weeks 4, 8, 
10, and 12 (end of treatment); see Section 3.1 for visit windowing.  
It is important to note that, in HD subjects, the study drug administered during the last 
dialysis of a particular week is not cleared until the first dialysis of the next week. 
Therefore, measurements that would reflect treatment effect at the end of a specific week 
(e.g., Week 4) and labelled “end of Week xx” will actually be collected during the first 
day of the next week (e.g., Week 5). 
An unstructured covariance matrix will be used to model the within-subject errors. 
Should the model fail to converge, a compound symmetric covariance matrix will be used 
instead. The Kenward-Roger approximation will be used to estimate the denominator 
degrees of freedom. Missing scores will not be imputed. Assuming that the data are 
MAR, the estimates of the treatment differences calculated from the MMRM described 
above are unbiased. 
Standard descriptive statistics will be reported for each time point on the values and 
changes from baseline along with the least squares (LS) means, standard errors, 95% CIs 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 36 of 60 
and differences between treatment groups reported with LS means, standard errors, and 
95% CIs. 
 Missing imputed using control distribution  
For this analysis, the 5-D Itch Scale and the Skindex-10 Scale scores will be analyzed 
only at Week 12 using an analysis of covariance (ANCOVA). The model will contain 
treatment as fixed effects, with baseline score, region, and the randomization 
stratification variables as covariates. The baseline 5-D total score and the Skindex-10 
total score will be defined as the value collected on Day 1, prior to randomization. 
Convergence issues with the region covariate will be handled as described in section 
8.1.4. 
As with the main MI analysis subjects who discontinue treatment but continue on study 
and have 5-D and Skindex-10 scores recorded will have these scores censored following 
discontinuation of treatment; missing data rules will apply to these censored values as 
though they had missing values/ dropped out from the study entirely. 
For each domain in each questionnaire, missing values at Week 12 will be imputed using 
values from the control arm.  This assumes that subjects (regardless of randomized arm) 
who discontinue double-blind treatment early would have similar 5-D Itch and Skindex-
10 scores as subjects in the placebo arm that have complete data.  
All available visits will be included in the MI to better inform the Week 12 imputed 
results. The MI approach will proceed as follows, using all ITT subjects (that is, it will 
not be split into IA subjects and post- IA subjects).    
 Intermittent missing scores will first be imputed within treatment group using the 
Markov Chain Monte Carlo (MCMC) method implemented with the SAS MI 
procedure, which is appropriate for non-monotonic missing data. Covariates for 
baseline score, region, both randomization stratification factors, and all non-
missing visit scores for each domain of the questionnaire will be included. 
 The monotone missing values will then be multiply imputed with the SAS MI 
procedure using the monotone regression method. Covariates for baseline score, 
region, both randomization stratification factors, and all non-missing visit scores 
for each domain of the questionnaire will be included. 
 The MNAR option in Proc MI will be used with the visit values and will 
reference the placebo group for informing the imputation. 
 For each stage, should convergence issues occur due to small cell size for the 
categorical covariates at either stage, they will be removed from the model- with 
the exception of region as described for the primary analysis.  Convergence issues 
with the region covariate will be handled as described in section 8.1.4. 
 Twenty imputations will be performed for each domain. 
 For each questionnaire, the total score at each visit will be computed from the 
domain scores for each imputed dataset. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 37 of 60 
 The ANCOVA analysis described above will be implemented for each imputed 
dataset.  
 Results of the ANCOVA on the multiply imputed data sets will be summarized by 
the SAS MIANALYZE procedure.  
The LS means, standard errors, 95% CIs, and differences between treatment groups from 
this ANCOVA will be reported. The analysis will be completed for both the ITT and PP 
Populations. 
 Missing imputed using baseline distribution 
This imputation approach will largely be identical to the Missing imputed using control 
distribution approach, but will utilize the baseline distribution to impute missing values; 
this assumes that the unobserved values for subjects that discontinue will revert to scores 
similar to the population at baseline. 
 Intermittent missing scores will first be imputed within treatment group using the 
Markov Chain Monte Carlo (MCMC) method implemented with the SAS MI 
procedure, which is appropriate for non-monotonic missing data. Covariates for 
baseline score, region, both randomization stratification factors, and all non-
missing visit scores for each domain of the questionnaire will be included. 
 For the monotonic missing scores following discontinuation, each will be imputed 
using the distribution of the baseline value of all subjects’ daily worst itching 
score assuming a trimmed normal (from 5 to 10).   
 Twenty imputations will be performed for each domain. 
An identical approach to above will be applied for analysis and combination of the MI 
repetitions.  The LS means, standard errors, 95% CIs, and differences between treatment 
groups from this ANCOVA will be reported. The analysis will be completed for both the 
ITT and PP Populations. 
8.2.5 Other Efficacy Endpoints 
The remaining efficacy analyses will present further presentations of the itch intensity 
measures, itch-related quality-of-life measures, plus the PGIC. 
8.2.5.1 
Itch Intensity Measures  
 Proportion of subjects who have an improvement from baseline at Week 12 of the 
Double-Blind Treatment Period with respect to the weekly mean of the 24-hour 
Worst Itching Intensity NRS scores >0, ≥1, ≥2, ≥3, ≥4, ≥5, and ≥6 will be 
analyzed and reported in a manner identical to that described in section 8.2.4.3  
above.  The same dataset from the primary analysis will be used, utilizing 
additional flags for these cut points of improvement. However, no adjustment for 
interim analysis will be implemented. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 38 of 60 
 Proportion of subjects who have an improvement from baseline at Week 12 of the 
double-blind treatment period with respect to the weekly mean of the 24-hour 
Worst Itching Intensity NRS scores ≥3 will be reported overall and by each of the 
randomization stratification variables using the primary analysis and model 
removing the stratification factor that’s being reported from the model. The same 
dataset from the primary analysis will be used, utilizing additional flags for these 
cut points of improvement. However, no adjustment for interim analysis will be 
implemented. 
 Proportion of subjects who have an improvement from baseline at Week 12 of the 
double-blind treatment period with respect to the weekly mean of the 24-hour 
Worst Itching Intensity NRS scores ≥3 and ≥4 will be reported by region using 
the primary analysis and model removing region from the model. The same 
dataset from the primary analysis will be used, utilizing additional flags for these 
cut points of improvement. However, no adjustment for interim analysis will be 
implemented. 
 Proportion of subjects who have an improvement from baseline at Week 12 of the 
double-blind treatment period with respect to the weekly mean of the 24-hour 
Worst Itching Intensity NRS scores ≥3 and ≥4 will be reported by dialysis type 
using the primary analysis. The same dataset from the primary analysis will be 
used, utilizing additional flags for these cut points of improvement. However, no 
adjustment for interim analysis will be implemented.  Given the possibility of low 
counts, model results may not be reported for some types of hemodialysis. 
 Proportion of subjects that are complete responders will be reported.  A subject 
that has >= 80% of the non-missing 24-hour Worst Itching Intensity NRS scores 
equal to 0 or 1 on Week 12 is considered a complete responder; subjects that have 
less than 4 NRS scores reported or drop out prior to week 12 are also considered 
non-responders.  Differences between CR845 0.5 mcg/kg and placebo will be 
compared using a logistic regression model containing terms for treatment group, 
baseline NRS score, region, use of anti-itch medication during the week prior to 
randomization, and presence of specific medical conditions. 
 Change from baseline in the weekly mean of the 24-hour Worst Itching Intensity 
NRS score at each week of the Double-blind Treatment Period (Week 1 to 
Week 12). Treatment differences between CR845 and placebo at each 
post-baseline time point will be analyzed using an MMRM. The model will 
contain treatment, week, and treatment-by-week interaction as fixed effects, and 
baseline score, region, and the randomization stratification variables as covariates.  
An unstructured covariance matrix will be used to model the within-subject 
errors. Should the model fail to converge, a compound symmetric covariance 
matrix will be used instead. The Kenward-Roger approximation will be used to 
estimate the denominator degrees of freedom. Two analyses will be conducted: in 
the first analysis; missing scores will not be imputed, and in the second analysis, 
the same dataset from the primary analysis will be used to address missing data.  
Standard descriptive statistics will be reported for each time point on the values 
and changes from baseline along with the LS means, standard errors, 95% CIs, 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 39 of 60 
and differences between treatment groups reported with LS means, standard 
errors, and 95% CIs. 
8.2.5.2 
Itch-related Quality-of-Life Measures  
In addition to the Week 12 results and treatment comparisons, all time points for the 5-D 
Itch Scale and Skindex-10 will be reported as described in Section 8.2.4.3 , with the 
exception of the ANCOVA analysis, and utilized as further efficacy endpoints. 
Additionally, the ANCOVA and MMRM analyses described in Section 8.2.4.3 for the 
Skindex-10 will be repeated for all 3 of the Skindex-10 subdomains and the 5 Itch 5-D 
domains. 
The proportion of subjects who have an improvement from baseline in Skindex-10 score 
of at least 15 points by week will be analyzed and reported along with a logistic 
regression model-based estimates of the proportions of responders, odds ratio, 95% CIs, 
and p-value. No imputation of data will be implemented.  
The proportion of subjects who have an improvement from baseline in the 5-D Itch Scale 
total score of at least 5 points by week will be analyzed and reported along with a logistic 
regression model-based estimates of the proportions of responders, odds ratio, 95% CIs, 
and p-value. No imputation of data will be implemented.  
8.2.5.3 
Patient Global Impression of Change 
The PGIC is a global PRO measure that assesses the change (improvement or worsening) 
in overall status of itch relative to the start of the study. The scale has only 1 item, with 
values ranging from 1 (Very Much Improved) to 7 (Very Much Worse) (see protocol 
Appendix 5, Section 14.5). 
Counts and percentages of subjects for each response will be reported as well as a count 
of subjects with missing values. All subjects should complete the PGIC Week 12 or early 
termination, so missing data should be minimal. 
The counts and percentages of subjects who rate their itch condition as “Very much 
improved” or “Much Improved” at the end of Week 12 of the Double-blind Treatment 
Period/end of double-blind treatment, will be reported. Treatment difference will be 
tested using the Cochran-Mantel-Haenszel exact test, adjusting for the randomization 
stratification variables.  The Mantel-Haenszel estimate of common odds ratio, exact 
95% CI for the common odds ratio, and CMH exact test p-value will be reported for this 
treatment comparison. Additionally, the exact Clopper Pearson 95% CIs for the 
proportion of subjects who rate their itch condition as “Very much improved” or “Much 
Improved” will be reported. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 40 of 60 
9. 
SAFETY EVALUATION 
9.1 
Overview of Safety Analysis Methods 
The following assessments will be used to evaluate the safety of CR845 in hemodialysis 
subjects with moderate-to-severe pruritus: 
 Adverse events 
 Clinical laboratory parameters  
 Vital signs 
 12-lead ECG 
All safety analysis will be performed based upon the treatment the subject actually 
received after randomization. All safety endpoints will be summarized by treatment 
group (and visit as appropriate) for the Double-blind Safety Population.  
 
9.2 
Adverse Events 
The period of adverse event reporting will start after the signing of the informed consent 
form (ICF) through the study Follow-up Visit or Early Termination Visit (or 7 days after 
the last dose if no Early Termination Visit was conducted). All adverse events that occur 
during this reporting period will be collected for all subjects, including subjects who are 
deemed to be screen failures. 
Treatment-emergent adverse events (TEAEs) relative to the Double-blind Treatment 
Period are identified as any adverse event with an onset date after the first dose of the 
study drug up to the study End of Treatment/Early Termination Visit or 7 days after the 
last dose if no End of Treatment/Early Termination Visit was conducted, whichever is 
later.  
All tabular adverse event summaries will be for TEAEs.  
For events with missing start dates, the following criteria will be used: 
 If the start date for a particular event is missing, then the event is considered 
treatment-emergent for the Double-blind Treatment Period, unless the end date is 
reported and prior to the Double-blind Treatment Period start date. 
 If a partial date is consistent with being in more than 1 period, then it will be 
assumed to have occurred in the Double-blind Treatment Period,  
 If the start time is missing and the start date is the same as the start of a given 
period, the adverse event will be considered to have occurred in that period. 
All adverse events will be coded to SOC and preferred term using the MedDRA version 
20.1. The MedDRA treatment dictionary will be used to map adverse events verbatim to 
SOC and preferred term for standardization and summary purposes. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 41 of 60 
The incidence of TEAEs will be summarized by treatment group and overall. If a subject 
experienced more than one episode of an adverse event, the subject is counted once for 
that preferred term. If a subject had more than 1 adverse event in a SOC, the subject is 
counted only once in that SOC. The summary tables will include incidence estimates for 
overall SOC, as well as for preferred terms within each SOC. Incidence for SOC will be 
presented by decreasing frequency overall and then alphabetically; for preferred terms, 
incidence will be presented by decreasing frequency overall within each SOC and then 
alphabetically. 
The investigator is to record the severity of each adverse event as mild, moderate, or 
severe. If the same TEAE occurs for a subject on multiple occasions, the TEAE will be 
categorized according to the highest severity rating for that TEAE in that subject. If the 
severity of the TEAE is not reported, then the severity of the TEAE will be counted as 
severe. For each treatment group and period, the incidence within each category will be 
presented.  
The investigator is to record their opinion on the relationship of each adverse event to 
study drug (not related, related). If a subject experiences the same adverse event multiple 
times, the event with the strongest relationship to study drug will be counted. For each 
treatment group, the incidence within each category will be presented. For the summary 
of TEAEs by relationship to study drug, if the relationship is missing, it will be counted 
as related. The incidence of drug-related events will be summarized for each period by 
treatment group and overall.  
Separate tables summarizing the incidence of TEAEs of special interest (AESIs), will be 
presented. Selected preferred terms shown in Appendix 16.3 are combined into the 
following categories:  
 Gait disturbance  
 Fall 
 Dizziness 
 Somnolence 
 Seizure 
 Syncope 
 Mental status changes 
 Mood changes 
 Unusual feeling, sensation 
 Tachycardia 
 Palpitation 
Incidence rate will be calculated for serious TEAEs, and TEAEs leading to death, and 
will be summarized by SOC and preferred term; and by preferred term only for AESIs.  
Incidence rate will be calculated as (1000 * the number of events)/total person-years, 
where total person-years is the sum across all subjects in the treatment group of the 
individual subject risk times, and individual subject risk time is the number of days from 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 42 of 60 
first dose to the last day of the period where an event would be deemed to be treatment 
emergent. 
The summary statistics for the time to first onset among subjects with a given AESI will 
be presented for each AESI.  Additionally, the durations will be summarized with 
descriptive statistics; if a subject has more than one AE within and AESI category, the 
longest duration will be summarized.  This will also be presented for a subset of common 
AEs. 
 
To explore the duration and temporal relationship of AESIs, a graphical representation of 
occurrences and durations of AEs within each AESI will be presented with subjects on 
the y-axis and time on the x-axis (Swimmer plot).  
The following summary tables will be presented for the Double-blind Treatment Period: 
 An overall summary showing for each treatment group, the number and 
percentage of subjects with a TEAE, serious TEAE, related TEAE, severe TEAE, 
TEAE leading to dose interruption, TEAE leading to study drug discontinuation, 
TEAE leading to study discontinuation, TEAE of special interest. This table will 
also include number of events. This display will be repeated for subgroups by 
randomization stratification variables, region and dialysis type.  
 TEAEs by SOC and preferred term 
 Serious TEAEs by SOC and preferred term 
 TEAEs by SOC, preferred term, and maximum severity 
 Related TEAEs by SOC and preferred term 
 TEAEs leading to study drug discontinuation by SOC and preferred term 
 SAEs by stratification factors, SOC, and preferred term 
 TEAEs by region, SOC, and preferred term 
 TEAEs by dialysis type, SOC, and preferred term 
 Most common TEAEs (≥2% or more of subjects in any treatment group) by 
preferred term 
 AESIs by preferred term 
 Related AESIs by preferred term 
 AESIs by stratification factors and preferred term 
 AESI incidence rate by preferred term 
 AESI time to onset and duration summary statistics 
 Serious TEAE incidence rate by SOC and preferred term 
 TEAEs leading to death incidence rate by SOC and preferred term 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 43 of 60 
 Custom MedDRA query (CMQ) events (see Section 16.2). 
In addition, all adverse events will be listed in chronological order including subject 
identifier, age, race, gender, and all related event status information (start and stop dates, 
whether the event was ongoing, study day of onset, severity, seriousness, relationship to 
study drug, action taken with study treatment, and outcome). Note: For the all adverse 
event listing only, any screen failure subject who has an adverse event after signing ICF 
will be included for completeness. Separate listings will be generated for serious adverse 
events (SAEs), deaths, and adverse events leading to treatment discontinuation. 
Additionally, a coding list of preferred terms and the verbatim text associated with them 
will be produced. 
The incidence of TEAEs in each CMQ category (see Section 16.2) will be summarized. If 
a subject experienced more than 1 episode of an adverse event, the subject is counted 
once for that preferred term; the total number of subjects reporting an event in the 
category will also be reported. 
No statistical tests will be performed on adverse events. 
9.3 
Deaths, Serious Adverse Events, and Other Significant Adverse 
Events 
An SAE is defined as any adverse event occurring at any dose and regardless of causality 
that results in death, is life-threatening, requires in-patient hospitalization or prolongation 
of existing hospitalization, results in persistent or significant disability/incapacity, is a 
congenital anomaly/birth defect, or is an important medical event.  
Serious adverse events will be collected on the electronic CRF (eCRF) from the date the 
ICF is signed up to the Follow-up Visit or 7 days following the last dose of study drug, 
whichever is later. Serious adverse events that occur after the Follow-Up Visit and up to 
30 days thereafter should also be documented on an SAE form if they are deemed by the 
investigator to be “related” to the study drug. Serious adverse events that occur after the 
Follow-up Visit and up to 30 days thereafter do not need to be documented on an SAE 
form if they are deemed by the investigator to be not related to study drug. A more 
detailed definition of SAEs is provided in Protocol Section 6.5.4. The analysis of SAEs is 
similar to that of adverse events described in Section 9.2.  
Subject deaths are captured on the Adverse Events eCRF page. Subject death listings will 
include all death data available, including date of death and cause of death. Additionally, 
SAEs and adverse events resulting in discontinuation will be listed as discussed in 
Section 9.2. 
9.4 
Clinical Laboratory Evaluation 
Summaries of actual values and the changes from baseline to each time point (when 
applicable) will be presented for quantitative laboratory parameters (e.g., white blood cell 
count, lymphocyte count). Only data from the central laboratory will be used.  


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 44 of 60 
Baseline is defined as the last measurement taken on or prior to the first day of dosing. 
Note that the Day 1 assessment can be included in the evaluation of baseline if the 
assessment is performed prior to dosing. 
All laboratory evaluation summaries will include the subjects in the Double-blind Safety 
Population who have at least 1 post-baseline time point (for criteria based on 
post-baseline assessments) and with both a baseline and at least 1 post-baseline time 
point (for criteria evaluating changes from baseline). 
Laboratory values will be reported in Système International units.  
Laboratory test results will be classified according to whether the value was below (L), 
within (N), or above (H) the laboratory parameter reference range. A summary of 
treatment-emergent shifts will compare the baseline L/N/H classification for each 
laboratory test to the highest and/or lowest L/N/H classification during the treatment 
period. Clinically important laboratory values based on pre-specified criteria appropriate 
for the study population will also be summarized. 
Additionally, alanine aminotransferase, aspartate aminotransferase, bilirubin, and alkaline 
phosphatase will be presented in a separate table, with 3× and 5× upper limit of normal 
(ULN) flagged for alanine aminotransferase and aspartate aminotransferase; 2×ULN 
flagged for bilirubin, and 1.5×ULN flagged for alkaline phosphatase. 
Additionally, clinically significant laboratory findings will be reported for hemoglobin, 
calcium, serum albumin, and phosphate. Ranges are given below. 
Test 
Low 
High 
Hemoglobin (g/dL) 
<7 
>15 
Calcium (mg/dL) 
<7 
>10.5 
Serum albumin (mg/dL) 
<3 
>5.5 
Phosphate (mg/dL) 
<2.5 
>8 
Potassium (mmol/L) 
<2.5 
>7 
 
9.5 
Vital Signs, and ECG 
9.5.1 Vital Signs 
Summary tables for vital signs will include descriptive statistics (number of subjects, 
mean, standard deviation, median, minimum, and maximum) for baseline and each 
post-baseline assessment. Descriptive statistics will be calculated on both the actual 
values and the change from baseline. Baseline is defined as the last measurement taken 
on or prior to the first day of dosing. Note that the Day 1 assessment can be included in 
the evaluation of baseline given that the assessment is performed prior to dosing.  


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 45 of 60 
All double-blind vital sign summaries will include the subjects in the Double-blind Safety 
Population who have at least 1 post-baseline assessment (for criteria based on post-
baseline assessments) and with both a baseline and at least 1 post-baseline assessment 
(for criteria evaluating changes from baseline).   
Clinically notable vital signs will be identified based on the criteria below. For each vital 
sign parameter, the number and percentage of subjects with at least 1 notable value will 
be tabulated by week and overall for the Double-blind Treatment period. 
Vital Sign Parameter 
Value 
Systolic blood pressure 
180 mm Hg 
 
90 mm Hg 
Diastolic blood pressure 
100 mm Hg 
 
60 mm Hg 
Heart rate 
 >130 bpm 
 <55 bpm 
bpm = beats per minute 
 
All vital signs will be listed in by-subject listings, including visit and collection date/time, 
and will be sorted by subject identifier and date/time of assessment.  
9.5.2 12-Lead ECGs 
Standard 12-lead ECG readings with the subject in a supine position will be performed. 
Electrocardiogram results include an overall interpretation of “normal,” “abnormal but 
not clinically significant,” or “abnormal and clinically significant.” These results will be 
tabulated by treatment group and overall at each time point. Electrocardiogram values 
will also be listed by subject.   
Clinically significant abnormalities at screening will be recorded as medical history. 
Clinically significant abnormalities or worsening of ECG findings observed after the first 
dose of study drug should be reported as adverse events. 
Electrocardiogram results will be listed for each visit, including whether ECG was 
performed (yes/no), explanation (if not performed), assessment date/time, study date, 
overall interpretation, and relevant medical history identifier or adverse event identifier if 
deemed a clinically significant abnormality. 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 46 of 60 
10. 
OTHER ANALYSES 
10.1 
Inflammatory Biomarkers 
The observed value and the change in inflammatory biomarkers (e.g., interleukin-6, 
interleukin-8, and granulocyte macrophage-colony stimulating factor) from pre-dose to 
the end of the Double-blind Treatment Period (Week 12) will be presented by treatment 
group. Univariate and multivariate analyses of the change in inflammatory biomarkers 
will be described in an analysis plan, separate from this document. 
10.2 
Incidence of Infections Related to Uremic Pruritus 
Incidence of infections related to uremic pruritus occurring during the Double-blind 
Treatment Period based on adverse events, hospitalizations, and/or use of antibiotics for 
treatment of infection related to uremic pruritus will be reported with counts and 
percentages for each treatment group.  
10.3 
Hospitalizations, Emergency Department Encounters  
The proportion of subjects who had in-patient hospitalization, and the count and 
percentage for whether dialysis was performed during hospitalization, and summary 
statistics for duration of stay will be reported by treatment for each study period.  






Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 49 of 60 
12. 
CHANGES TO THE ANALYSES PLANNED IN THE PROTOCOL 
There is no change to the analysis planned in the protocol.  
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 50 of 60 
13. 
RANDOM SEEDS FOR MULTIPLE IMPUTATION 
For MIs and other instances where random seeds are required, the values used (in order) 
are: 
9392857 
3985729 
2843255 
1086284 
6547484 
9017456 
1597295 
3252256 
5821871 
1852467 
6126715 
4232132 
1841654 
4645284 
2587345 
 
Note that not all seeds may be required in programming the MIs. If additional seeds are 
needed, they will be chosen by adding 1 to each of the values above, again using them in 
order. 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 51 of 60 
14. 
SAMPLE SAS CODE 
Below is the SAS code used to create the dataset to be used in the primary analysis. 
Weekly NRS scores will be subset on the ITT Population and the dataset will be 
transposed to create one observation per subject with separate variables for baseline (v1) 
through week 12 (v13) values. These values as well as a numeric variable for the planned 
treatment group (trt01pn) and numeric flags for region, anti-itch medication use at 
baseline (antiIn) and specific medical conditions (specmedn) will be used during the 
imputation procedures. 
 
The first stage of imputation will create monotone missing data using MCMC and the 
following code: 
proc mi data=INDATA seed=9392857 nimpute=20 MAXIMUM=10 MINIMUM=0 
out=OUTDATA1 minmaxiter=1000000 ; 
mcmc chain=multiple initial = EM(CONVERGE=0.001 maxiter=100000) NBITER=500 
NITER=100 impute = monotone displayinit ; 
var antiIn specmedn region v1 v2 v3 v4 v5 v6 v7 v8 v9 v10 v11 v12 v13; 
by trt01pn; 
run; 
 
Using the output data, imputed data following the last non-missing will be reset to 
missing so that only intermittent values are imputed in this first pass. 
 
The second stage will use this output, then fill in the monotone missing values with the 
following MI code: 
proc mi data=OUTDATA1 seed=3985729 nimpute=1 MAXIMUM=10 MINIMUM=0 
out=OUTDATA2 minmaxiter=1000000 ; 
monotone reg; 
var antiIn specmedn region v1 v2 v3 v4 v5 v6 v7 v8 v9 v10 v11 v12 v13; 
by trt01pn; 
run; 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 52 of 60 
15. 
REFERENCES 
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical 
trials. Biometrics. 1999;55(3):853-7. 
Lawrence J, Hung H.M. (2003), “Estimation and Confidence after Adjusting the 
Maximum Information”. Biometrical Journal 45, 143–152 
Mehta C and Pocock S. Adaptive increase in sample size when interim results are 
promising: A practical guide with examples. Statistics in Medicine. 2010; 30: 3267–3284. 
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental 
Disorders.  5th ed.  Arlington, VA:  American Psychiatric Association; 2013.






Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 55 of 60 
a. 
Each visit during the Double-blind Treatment Period will coincide with the patient’s normal dialysis treatments. 
b. 
The End-of-Treatment Visit in the Double-blind Phase will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 13 [Day 85]), which also corresponds to Day 1 
of the Follow-up Period (FU Day 1). Only patients not participating in the Open-label Extension Phase are required to complete the Follow-up Period. 
c.     Medical history will be updated on Day 1 with any changes since the Screening Visit, and inclusion/exclusion criteria will be confirmed prior to randomization.  Antipruritic medication will be 
updated at each dialysis visit during the Run-in Period. 
d 
Electrocardiograms must be performed prior to the start of dialysis at Screening, Day 85 (End of Treatment), or at Early Termination visit. 
e 
Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded on Days 1, 15, 29, 43, 57, 71 and 85 (End of Treatment), or at Early Termination visit only 
when the patient is in a sitting or semi-recumbent position.  Heart rate will be measured at each dialysis; if heart rate is clinically significant and outside the prespecified visits per the Schedule of 
Events, the heart rate will be recorded on the relevant CRF page.  
f 
Pre-dialysis vital signs, including body temperature, heart rate, and blood pressure, will be recorded at the Follow-up Visit (7-10 days after EoT/ET visit).  Heart rate will be measured at each 
dialysis. 
g. 
Blood samples for clinical laboratory evaluation will be taken at Screening, and on Days 1 and 85 (End of Treatment), or at Early Termination visit only.  
h. 
Training on Worst Itching Intensity NRS will be conducted prior to the first day of the Run-in Period (Day -7).   
i. 
Training on Skindex-10 Scale and 5-D Itch Scale may be performed at any time during Screening prior to randomization on Day 1 of the Double-blind Treatment Period. 
j. 
Patients will be requested to complete their Worst Itching Intensity NRS worksheets each day at a similar time (either at home on non-dialysis days around the normal start time of their dialysis or 
in the dialysis unit).  On dialysis days, the worksheets will be completed prior to or during dialysis, but must be completed prior to dosing. 
k. 
5-D Itch Scale and Skindex-10 Scale completed on Day 1 and the first visit of Weeks 5, 9 and 11 (on Days 29, 57 and 71) and Week 13 (Day 85).  The 5-D Itch Scale will preferably be completed 
first.  If the first visit of the week is missed, the patient may complete the worksheets at their next visit for the same week.  The worksheets will be completed prior to or during dialysis (preferably 
within 1 hour of the dialysis), but must be completed prior to dosing. 
l. 
Biomarker samples must be collected prior to the start of dialysis on Day 1 and Day 85.  
m. 
Concomitant medications including antipruritic medication will be updated at each dialysis visit during the Double-blind Treatment Period, and until the end of the Follow-up Period.  
n. 
A list of specific signs/symptoms will be verified with the patient by qualified site staff, preferably to be completed on Wednesday/Thursday each week during the Run-in Period, the Double-blind 
Treatment Period and the Follow-up Period.  It is not to be completed on Monday/Tuesday.  
 
 
 
 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 56 of 60 
 
 
 
16.2 
Custom MedDRA Query (CMQ) Preferred Terms 
CMQs 
 
Gait Disturbance 
Ataxia 
Balance disorder 
Coordination abnormal 
Gait disturbance 
Gait inability 
Tandem gait test abnormal 
 
Dizziness 
Dizziness 
Dizziness Postural 
Vertigo 
 
Syncope 
Presyncope 
Syncope 
 
Fall & Potentially Drug Related Injury 
Accident 
Back injury 
Contusion 
Fall 
Fracture (all preferred terms containing “fracture”) 
Head injury 
Injury 
Limb injury 
Muscle contusion 
Muscle injury 
Road traffic accident 
Skeletal injury 
Haematoma 
Subdural hematoma 
Epidural haematoma 
Traumatic haematoma 
Periorbital haematoma 
Ecchymosis 
Subdural hematoma 
Subdural haemorrhage 
 
Mood Changes & Behavioral Changes 
Abnormal behavior 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 57 of 60 
Affect lability 
Aggression 
Agitation 
Anger 
Anxiety 
Apathy 
Blunted affect 
Crying 
Depressed mood 
Disinhibition 
Dysphoria 
Emotional distress 
Emotional poverty 
Euphoric mood 
Flat affect 
 
Grandiosity 
Hostility 
Inappropriate affect 
 
Listless 
Mood altered 
Mood swings 
Morose 
Nervousness 
Patient uncooperative 
Restlessness 
Social avoidant behavior 
 
Seizures 
Autonomic seizure 
Clonic convulsion 
Drug withdrawal convulsions 
Epilepsy 
Epileptic aura 
Focal dyscognitive seizures 
Generalised tonic-clonic seizure 
Partial seizures 
Partial seizures with secondary generalisation 
 
Seizure 
Seizure cluster 
Simple partial seizures 
Status epilepticus 
Tonic convulsion 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 58 of 60 
Mental Status & Cognitive Changes 
Acute psychosis 
Delirium 
Altered state of consciousness 
Hallucination (any preferred term containing “Hallucination”) 
Bradyphrenia 
Change in sustained attention 
Cognitive disorder 
Confusional state 
Delusion (any preferred term containing “Delusion”) 
Depressed level of consciousness 
Disorientation 
Encephalopathy 
Illusion 
Judgment impaired 
Lethargy 
Mental impairment 
Mental status changes 
Stupor 
Thinking abnormal 
 
Unusual Feeling, Sensation 
Asthenia 
Depersonalisation/derealisation disorder 
Derealisation 
Dissociation 
Feeling abnormal 
Feeling cold 
Feeling despair 
Feeling drunk 
Feeling guilty 
Feeling hot 
Feeling jittery 
Feeling of body temperature change 
Feeling of despair 
Feeling of relaxation 
Feelings of worthlessness 
Malaise 
Psychiatric symptom 
Sensation of foreign body 
Suffocation feeling 
 
Palpitations & Tachychardia 
Palpitations 
Heart rate irregular 
Heart rate increased 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 59 of 60 
Tachycardia 
Atrial tachycardia 
Junctional ectopic tachycardia 
Supraventricular tachycardia 
Ventricular tachycardia 
Sinus tachycardia 
Tachycardia paroxysmal 
Tachyarrhythmia 
Ventricular tachyarrhythmia 
 
Somnolence 
Somnolence 
Sleep disorder 
Abnormal sleep related event 
Microsleep 
Sleep attacks 
Sedation 
 
 
 


Cara Therapeutics 
CONFIDENTIAL 
Statistical Analysis Plan 
Protocol No. CR845-CLIN3103 
 
09MAR2020 
Version: CARA_CR845-CLIN3103DB_final_v1_1_SAP_20200309.docx 
Page 60 of 60 
16.3 
Adverse Events of Special Interest (AESIs) and Preferred Terms 
AE of Special Interest Terms 
Preferred Terms 
Gait disturbance 
Gait disturbance            
Falls 
Fall 
Dizziness 
Dizziness 
Somnolence 
Somnolence 
Seizures 
Seizure 
Syncope 
Syncope 
Mental status changes 
Mental status changes 
Mood changes 
Mood altered 
Unusual feeling/sensation 
Feeling abnormal 
Tachycardia 
Sinus tachycardia, Tachycardia, Tachyarrhythmia 
Palpitation 
Palpitations